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Abstract. Microorganisms group themselves into assemblies 
known as communities or biofilms, which are associated with 
surfaces. A matrix of self-segregated polymeric substances 
enhances their attachment. Communication between bacterial cells 
involves the production and detection of diffusible signal 
molecules, known as quorum sensing, which is an important 
regulatory mechanism of biofilm strategies. Biofilms thrive 
everywhere; in subaerial surfaces they can be driven by sunlight, 
with photosynthesizing components. A special case is those which 
colonize works of art, forming patinas and becoming involved in 
the degradation of colonized substrata. Knowledge of three-
dimensional structure of the biofilm and the distribution of species 
concerned is crucial for managing and preventing uncontrolled 
colonization and for preserving cultural heritage sites. This paper 
describes their role in this degradation, some examples of biofilms 
and their resilience mechanisms. The methods used in their study 
when growing in monuments and caves are also discussed. 
 
Introduction 
 
 Most microorganisms live attached to a surface rather than as single, 
suspended cells [1].  The aggregation of microorganisms attached to a   surface   
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and enclosed in a matrix is called a biofilm [2,3] (Fig. 1). Biofilms constitute 
a protected mode of growth that allows microorganisms to survive in hostile 
environments [4]. Under suitable conditions, all unprotected natural and 
artificial substrata quickly become colonized by these communities. The 
characteristics of individual biofilms are extremely variable. Biofilms can 
have an effect on human health and are related to some diseases. They also 
play important roles in the context of energy and the environment.  
 Biofilm-forming microorganisms generate a matrix of hydrated 
extracellular polymeric substances (EPS), which form their immediate 
environment [5]. EPSs vary in their composition and thus in their chemical 
and physical properties. EPSs are mainly polysaccharides, proteins, nucleic 
acids and lipids. These substances provide the mechanical stability of 
biofilms, mediate their adhesion to surfaces and form a cohesive, three-
dimensional polymer network that interconnects and transiently immobilizes 
biofilm cells [6-8]. The relative amounts of different polysaccharides also 
depend on the physiological state of the biofilm and the availability of 
nutrients. Slow growth or nutrient shortage enhances the synthesis of EPSs 
[9], which are a key structuring component for nutrient absorption and 
protection against desiccation, and are part of the stress response. The 
coexistence of species in a biofilm depends on their capacity—and that of 
their competitors—to bind to the substrate.  
 
                                          a                                   b 
 
 
c                                     d 
 
Figure 1. Detail of subaerial biofilms (a,c).  a) Mayan monument (Chiapas, Mexico), 
mortar with tough green colonies of N. cf. commune, accompanied by Trentepohlia 
aurea (L.) Martius c) Collbató cave (Barcelona, Spain), speleothems with lampenflora, 
mainly Scytonema julianum (Kütz.) Meneg. and green microalgae. Schematic 
representation of biofilm structure and main species (b,d). b) from a. d) from c. 
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1. Biofilm development 
 
 Formation of a microbial biofilm is a complex multistep developmental 
process that consists of several overlapping stages. Most of our information 
comes from bacterial biofilms for which the formation of a biofilm has been 
described as a sequence of events [10,11]: i) the first event is the substratum 
conditioning with the absorption of water, organic matter or dissolved 
organic macromolecules; ii) the second event is the arrival or mass transport 
of microorganisms to the area; iii) the third event is the adhesion of the 
microorganisms, which is a prerequisite for the formation of biofilms on 
surfaces. Initial attachment to a variety of materials and early biofilm 
formation depend on the surface and type and degree of roughness of the 
substratum. Irregular surfaces are preferential starting points for attachment 
because they provide niches in which microorganisms are protected. After 
making contact with a surface, bacteria become attached in a process that was 
formerly considered reversible. This process is frequently mediated by the 
presence of extracellular materials but is also accompanied by physiological 
changes that end in irreversible surface binding [12]; iv) the fourth event is 
the expansion of the biofilm, which involves the aggregation of cells into 
microcolonies that then grow and mature. The microorganisms produce and 
release materials mediated by the microorganisms themselves. Changes in the 
gene expression and formation of exopolymeric material are regulated by 
cell-to-cell signals [13]; v) the fifth event is the return to temporary motility 
in response to nutritional cues, so that biofilm cells are released in order to 
repeat the process.  
 
2. Quorum-sensing 
 
 Quorum-sensing (QS) regulates the communication, behavior and several 
cellular processes of the microorganisms, including biofilm formation. QS is 
a form of intercellular communication between single-cell organisms that 
allows them to act coordinately like multicellular organisms. Release of the 
QS signal compounds is dependent on the density of the population [14-15] 
and leads to changes in bacterial gene expression [2] and to significant 
changes in the phenotype [17]. QS signals synchronize with the growth stage 
of a culture and accumulate to a threshold level. This controls the switch 
from the behavior typical of single-cell organisms to that of cells within a 
colony or a biofilm [11, 18]. There are a number of different QS signaling 
systems employed by Gram-negative bacteria, such as oligopeptide 
autoinducers, furanones, triclosan or mixtures of fatty acids, but the most 
characterized is the component LuxR-N-acyl homoserine lactones (AHLs) 
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[19-20]. AHLs are produced by homologues of the AHL synthase LuxI from 
S-adenosyl methionine and the intracellular pool of acyl-carrier proteins [21]. 
AHLs differ in the length, degree of saturation and substitution of the acyl 
side chains. The autoinducer molecules bind to the appropriate transcription 
regulator(s) when the bacterial population reaches the quorum level (that is, 
the signal concentration reaches a threshold concentration high enough to 
facilitate binding to the receptor) [13]. Binding of the autoinducers is 
followed by activation or repression of target genes. Thus, quorum sensing 
allows bacteria to make a unified response. This benefits the population [22] 
because it enhances access to nutrients and more favorable environmental 
niches and improves action against competing bacteria and environmental 
stresses [11, 15] (Fig. 2). The bacterial species within a consortia respond to 
different QS signals [23,16]. There are few reports of AHL activity in 
cyanobacteria [24, 15], but this could be due to the lack of studies. 
 
 
 
Figure 2. Communication between bacterial cells involves the production and 
detection of diffusible signal molecules known as quorum sensing (QS). Numbers in 
the flow chart represent different stages of the QS process. Arrows show the main 
direction of signal transport (based on Dobretsov et al. 2009). 
 
3. Methods of study 
 
 A multistep approach involving molecular, chemical and microscopy 
techniques is used to assess the composition, 3D structure and distribution of 
the biofilms.  
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 Nonculture-based molecular methods allow community compositions 
and activities to be characterized in situ. These methods include DGGE, 
clone library analysis, quantitative PCR, and stable isotope probing that can 
be used to obtain the phylogeny, relative abundance and genetic activity of 
individual members of a biofilm community [25, 26]. In particular, 
functional genomic approaches provide important clues about phototrophic 
biofilm biology [27]. 
 A number of techniques for detecting and identifying quorum sensing 
molecules or for monitoring the activity of these compounds have been 
described [15, 13, 28]. Approaches used for detecting and identifying AHLs 
include cell-based assays using AHL-specific bacterial biosensors, thin-layer 
chromatography, gas chromatography/mass spectrometry, and liquid 
chromatography. Bacterial biosensors cannot synthesize AHLs, but they can 
express specific compounds when exogenous AHL [a common one is 
Agrobacterium tumefaciens  (Smith & Townsend) Conn] is added.  
 Microscopy techniques include light microscopy (LM), scanning electron 
microscopy in back-scattered electron mode (SEM-BSE), energy dispersive X-
ray microanalysis (EDX), X-ray diffraction (XRD), transmission electron 
microscopy (TEM) and confocal laser scanning microscopy (CLSM), which 
enables non-disruptive observation of live cells.  
 Scanning electron microscopy (SEM) is useful for examining surface 
topology and the distribution of specimens as well as monitoring the 
interactions between biofilms and substrates (Fig. 3). However, conventional 
SEM requires samples to be imaged under vacuum, and biological material 
tends to be susceptible to dehydration. Sheaths and mucilaginous outer layers 
may become condensed or blur the surface of the specimens. Other types of 
SEM overcome some of these processing inconveniences. For example, 
environmental scanning electron microscopy (ESEM) allows hydrated samples 
to be observed without the need for coating them or further processing. 
Scanning microscopes can be coupled to backscattered electron imaging (BSE) 
(Figs. 3b and d) or energy dispersive spectroscopy (EDS). These two analytical 
techniques are mainly used to discriminate inorganic from biological 
substances or for the elemental analysis of a sample.  
 Confocal scanning laser microscopy (CLSM) is a tool for 3-D localization 
of fluorescent organisms or items dyed with fluorescent labels, externally or 
inside the substrata. The technique provides an efficient way of determining the 
presence, the viability, the functionality and the spatial organization of specific 
organisms. It makes non-invasive optical sectioning possible by subtracting 
out-of-focus planes of the image. The surface and the in-depth structure of the 
sample can be examined by CLSM with minimal preparation and without 
disturbing the structure [29, 30]. 
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a                                                                   b 
 
                       
 
                              c                                                               d 
 
Figure 3. SEM-BSE images. Low magnification overview of biofilms colonizing the 
surface of subaerial biofilms. a) SEM image of a biofilm formed by diatoms 
(Diadesmis gallica W. Smith) and moss protonemata (Zuheros cave, Cordoba, Spain). 
b) SEM-BSE image of endolithic coccoid growth (Chroococcidiopsis sp.) through the 
intercrystalline porosity of a speleothem (Nerja cave, Malaga, Spain). c) SEM image 
of a biofilm formed by a single-celled chlorophyta (Muriella sp.) irregularly 
distributed on a dolomite surface (Zuheros cave, Córdoba, Spain). d) SEM-BSE image 
showing coccoid cyanobacteria (grey) entrapped with inorganic granules (in a bright 
shade of gray).  
 
 The above described microscopy techniques complement each other, 
providing an efficient method for determining the presence and viability of 
biofilms, which allow designing control strategies and biofilm monitoring. 
    
4. Subaerial biofilms 
 
 Most earth-illuminated surfaces are covered by biofilms formed by 
subaerial or endolithic photosynthesis-based microbial ecosystems. Subaerial 
means at the surface, exposed to the air, and endolithic means into outer 
centimeters of rocks, close to the surface [31, 32]. Photosynthetic 
microorganisms only need light as a source of energy, and inorganic substances  
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                                 a    b 
 
       
 
Figure 4. Confocal compound images of biofilm forming microorganisms from 
aerophytic biofilms: a) Field material of Chroococcidiopsis sp.  b) General view of a 
cultured strain of Nostoc cf. commune. Color key: photosynthetic pigments 
(Chlorophyll a and/or phycobilins), magenta. EPS (labeled with ConA-Alexa 488), 
green. Chroococcidiopsis sp. sheaths, blue. Scale bar = 10 μm. 
 
to grow. Heterotrophic organisms are integral parts of the communities and use 
organic matter both as a source of energy and as a substrate to synthesize their 
own components. The EPSs and organic matter produced by phototrophs are 
often exploited by non-photosynthetic microorganisms, such as fungi or 
bacteria, which subsequently flourish. Reported examples include 
proteobacteria and actinobacteria, mainly in epilithic communities, and 
acidobacteria, actinobacteria and low GC firmicutes, mainly in endolithic 
communities [33-36].  
 Subaerial biofilms are composed of photosynthetic cyanobacteria, 
algae, lichens and mosses, and several kinds of heterotrophic bacteria are 
companions [36-40]. Sequences of bacteria and archaea on monuments 
around the world are phylogenetically related to sequences found on 
different surfaces and at different geographical locations [41]. Striking 
similarities have been observed in subsurface (hypogean) environments, 
such as caves [42, 43], mainly associated with crystal formation. The 
main biomass observed with optical and electronic examination usually 
corresponds to cyanobacteria, also known as blue-green algae, so named 
because these organisms have the characteristics of bacteria and 
photosynthetic pigments like algae, which makes them blue-green or dark 
in color. Cyanobacteria show entangled filaments or heterogeneous 
aggregates with air spaces between them.  
 Cyanobacteria in subaerial biofilms resist environmental changes (e.g. 
extended droughts, high temperatures or prolonged solar exposure). They have 
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several well-known survival strategies related to desiccation [44, 45], which 
include using water retained within the substrata and the formation of 
protective, drought-resistant compounds [46]. Their persistence and success in 
terrestrial environments has been attributed to their ability to tolerate 
desiccation and to rapidly rehydrate and recover metabolic activity once 
favorable conditions have been reestablished [44, 47, 48]. Resilient species 
such as Chroococcidiopsis spp. (Fig. 4a) and Nostoc spp. (Fig. 4b) dominate 
certain communities in both hot and cold deserts due to their heat-tolerance and 
ability to recover after desiccation [48, 49, 50]. 
 Here we report some examples of biofilms mainly made up of 
photosynthetic organisms.  
 Mexican Mayan monuments have low diversity of species due to extreme 
environmental conditions (Fig. 1a). In a habitat dictated by alternating wet and 
dry seasons, a N. cf. commune (Fig. 4b) survives by varying its developmental 
stages. Its life cycle comprises two seasonally-determined stages -growth 
during the wet season and dormancy during the dry season- and two 
transitional stages -preparation for the dry season, and rehydration and 
recovery-. To survive the driest conditions, the biofilm reduces the number of 
cells inside thick sheathed colonies and synthesizes the pigment phycoerythrin, 
which increases cell tolerance against the detrimental effects of strong light 
[50]. In addition, some photosynthetic microorganisms cope with high solar 
irradiance by synthesizing UVR screens [51, 52].  
 Subaerial biofilms can also thrive in dim environments. In cave 
habitats and catacombs the most common stress factor is light shortage, 
followed by humidity, a lack of nutrients, and to a far lesser extent, 
temperature [53, 54]. The amount of light varies depending on the cave 
type, and also within the cave according to gradients that go from the 
mouth to the interior [55, 56]. From the mouth of the cave to the sampling 
point furthest inside the cave, the organisms are organized in mosaics or 
belts according to light gradients, relative humidity and temperature. The 
diversity of microalgal and cyanobacterial species decreases with 
decreasing light [56]. Coccoid forms are more abundant in illuminated 
areas and dripping sites, and form biofilms marked by vertical 
stratification [39]. Filamentous forms tend to be more diverse in darker or 
more humid locations [55]; Scytonema julianum can withstand strong 
environmental fluctuations [38], while other filamentous cyanobacteria 
such as Loriellopsis cavernicola Hernández-Mariné & Canals require 
long-term stability [56, 57]. This heterogeneous distribution reflects the 
different adaptation strategies used by microorganisms [54], and provides 
certain advantages for some of the constituent microorganisms in the 
biofilm structure.  
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   a         b 
 
               
 
Figure 5. Confocal three-dimensional images of aerophytic biofilms: a) Projection 
showing inorganic calcareous material (white) (Nerja cave, Cordoba, Spain), plus 
spatial distribution of pigment autofluorescence (red) of single celled chlorophytes 
(Muriella sp.) distributed in a thin layer, penetrating the fissures and fractures.  b) 
Extended projection of a biofilm dominated by Asterocapsa divina J. Komárek 
(Mayan monuments, Chiapas, México). Color key: photosynthetic pigments 
(Chlorophyll a and/or phycobilins), red. EPS (labeled with ConA-Alexa 488), green. 
Reflection from inorganic materials, white. 
 
5. Biodeterioration 
 
 Cultural heritage sites made of natural or artificial materials (e.g. rocks or 
stones and concrete or plaster) are governed by similar principles to any other 
terrestrial system, and are therefore susceptible to weathering. Subaerial 
biofilms colonize both the stone surface and the porous interior. Biofilm 
colonization of buildings or artwork is considered damaging, basically due to 
their chemical and physical activity [33, 58, 59]. Moreover, detectable 
colored patinas are considered dirty [42, 60].  
 Biodeterioration of exposed stone is primarily dependent on the 
availability of water and nutrients. Specific parameters, like porosity, 
permeability and architectural conditions, exposure and environmental 
factors at the site will determine the intensity and rate of biocorrosive attacks 
[61]. In many cases, these processes have been found to deteriorate the 
stone. Alterations are associated with repeated wetting and drying cycles that 
lead the organisms, which are attached to the rocks by EPSs, to expand and 
contract. In addition, the action of organic acids or metabolic products can 
enhances the weathering reactions and decrease the integrity of the 
mechanical properties of the natural or artificial materials. In spite of this, it is 
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difficult to determine whether photosynthetic biofilms will have a 
biodeterioration or bioprotection effect on the surface they are attached to 
because biofilms can be both beneficial and detrimental depending on the 
substrate and microorganisms involved. Thin superficial biofilms can cause 
discoloration of stone surfaces and mechanical and biochemical deterioration, or 
alternatively, they can protect the surface from weathering processes [54, 62].  
 
                           a                                                              b 
 
         
 
Figure 6. Optical micrographs: a) Discoloration on a roman fresco caused by a 
ubiquous development of actinobacteria and cyanobacteria forming a subaerial 
biofilm. b) Typical subaerial biofilm that develops in an area with run-out water 
(Vittoriosa, Malta). The black stain is mainly caused by actinobacteria, cyanobacteria 
and fungi.  
 
6. Conclusion 
 
 Biofilms are the default mode-of-life for many bacterial species and 
present remarkable complexity aimed at the protection of constituent 
microorganisms. Understanding factors that control the microorganisms as 
well as the effects of environmental factors on biofilm formation and control 
strategies will require further studies. 
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Abstract. Influenza is a highly contagious, major respiratory tract 
disease affecting millions of people each year. At present, two 
classes of antivirals are available: the neuraminidase inhibitors and 
the M2 proton channel blockers amantadine and rimantadine. 
However, rapid emergence of M2 blockers resistance makes 
imperative the development of new anti-influenza drugs. In the last 
few years several groups have synthesized and evaluated several 
analogs of amantadine. While several of them are active against 
wild-type M2 channel only a few are able to inhibit the mutant ion 
channels that lead to amantadine-resistance.  
 
Introduction 
 
 Influenza is a worldwide epidemic that causes substantial morbidity and 
mortality. Of the three types of influenza viruses, A, B and C, influenza A and B  
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cause seasonal epidemics. Moreover, influenza A viruses are responsible for 
sporadic pandemics that usually cause higher mortality rates than seasonal 
influenza epidemics. The most severe pandemic, the “Spanish flu”, occurred 
in 1918, is thought to have killed more individuals than any disease outbreak 
in history, resulting in approximately 40 million deaths worldwide [1]. More 
recent pandemics in 1957 (“Asian flu”, H2N2 strain) and 1968 (“Hong Kong 
flu”, H3N2 strain) were not as deadly, yet influenza remains a grave health 
hazard [2]. For example, in the United States, according to the Center for 
Disease Control and Prevention (CDC), influenza and its complications are 
currently the leading cause of death due to any infectious disease. In fact, in 
2009, a new influenza virus (“swine flu”, H1N1 strain) originated a new 
pandemic that caused much concern, although, thankfully, was not as deadly 
as initially thought [3]. In addition, H5N1 viruses (“bird flu”), which are also 
currently worldwide circulating, are extremely virulent in humans but have 
not acquired the ability for efficient human-to-human transmission yet [4]. 
 Influenza A viruses infect a wide range of avian and mammalian hosts, 
unlike influenza B viruses, which infect only humans. Influenza A and B 
viruses are enveloped negative-strand segmented RNA viruses. The envelope 
of influenza A viruses contains two different surface glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA) [5]. Influenza A viruses are 
categorized into antigenic HA and NA subtypes: 16 HA (H1–H16) and 9 NA 
(N1–N9) antigenic subtypes have been identified so far. For example, the 
2009 “swine flu” is an H1N1 virus because it contains a H1 subtype HA and a 
N1 subtype NA. 
 The major influenza A subtypes that have infected humans during 
seasonal epidemics are H1N1, H2N2 and H3N2. Within a subtype, different 
strains arise as a result of point mutations in a process known as ‘genetic 
drift’. These new strains cause seasonal epidemics. A new pandemic can 
emergence by two different mechanisms: by direct transmission from animals, 
usually birds, to humans, as happened in 1918 with the “Spanish flu”; or 
through reassortment of an avian influenza virus with a human influenza 
virus, as occurred in 1957 with the “Asian flu” (H2N2) and, again, in 1968 
with the “Hong Kong flu” (H3N2) [6]. The H1N1 virus of the 2009 “swine 
flu” is an apparent reassortment of four endemic strains of influenza: one from 
humans, one from birds, and two from pigs, a fact that further exemplifies the 
versatility of the influenza A virus [3]. When a new pandemic starts, the HA 
of the new strain differs substantially from recent HAs of seasonal influenza A 
viruses and, consequently, most of the human population lacks immunological 
protection against this virus, resulting in a pandemic. 
 There are two different strategies for combating influenza: vaccination 
and chemotherapy. The primary defense against influenza A has been 
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vaccination with inactivated or live-attenuated virus. However, vaccination 
effectiveness is limited due to the antigenic drifts and shifts that the 
influenza virus undergoes from year to year, and new influenza vaccines 
must be designed every year by predicting the genetic drift of seasonal 
influenza A. Antivirals have also been used for both prophylactic and 
therapeutic treatments during seasonal epidemics [5b]. Additionally, 
antivirals are particularly important at the beginning of a fast-spreading 
pandemic because the timely production of sufficient amounts of an 
effective vaccine is difficult. Current antivirals are directed against the M2 
ion-channel protein of the influenza A virus (amantadine and rimantadine, 
Fig. 1) and the NA of the influenza A and B virus (zanamivir and 
oseltamivir) [8]. However, many influenza virus strains have developed 
resistance to adamantanes and/or oseltamivir (the only orally bioavailable 
NA inhibitor), highlighting a major health risk [9]. For example, after four 
decades of effective use of amantadine, resistance by influenza viruses of 
the A/H3N2 subtype currently exceeds 90% in the United States, and virus 
mutants are as fit as the wild-type (wt) virus. The situation is even worst 
with the new 2009 pandemic H1N1 influenza. In both strains, the basis for 
resistance is a single Ser to Asn amino acid replacement (S31N) in the 
matrix M2 ion channel, which interferes with the drug's ability to block M2 
ion channel activity and viral replication [10]. 
 
 
 
Figure 1. The structures of the anti-influenza A drugs amantadine and rimantadine. 
 
 Another important problem encountered in the administration of 
amantadine and rimantadine is related to the central nervous system side 
effects of both drugs. In fact, amantadine has been used in the treatment of 
Parkinson’s disease, although its antiparkinsonian effect is poorly understood 
[11]. The side effects of rimantadine are analogous, but somewhat less 
pronunced than those of amantadine [12]. 
 The appearance of pandemic H1N1 and highly pathogenic avian influenza 
viruses of the H5N1 subtype being able to infect humans, the emergence of 
resistances, and the side effects of amantadine and rimantadine reveal the 
urgent need for the development of new antiviral drugs [13]. 
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 In this review, we will focus on the design of new amantadine analogs 
targeting the matrix M2 ion channel of influenza A virus. 
 
1. The M2 protein 
 
 The influenza A virus M2 protein is a homotetrameric protein containing 
four parts: a short unstructured N-terminal extracellular domain, important for 
incorporation into the virion; a transmembrane helix that is necessary for 
tetramerization, proton conductance and drug-binding; a cytoplasmic 
amphiphilic helix, involved in cholesterol-binding, membrane localization, 
budding and scission; and a disordered tail that interacts with the matrix 
protein M1 [14]. 
 The influenza virus enters its target cells by receptor-mediated 
endocytosis, which is followed by acid-induced fusion of the viral and 
endosomal membranes. This fusion event is mediated by a conformational 
change of the influenza HA proteins, triggered by the low pH in the endosome 
lumen [15]. The transmembrane region of the M2 protein forms a pH-
activated channel that selectively conducts protons along a chain of water 
molecules and ionizable sidechains, including His37, playing an essential role 
for viral replication equilibrating the pH of the virus interior with that of the 
acidic endosome. When the endosome is acidified, His37 residues in the 
transmembrane region of M2 become protonated, leading to the opening of 
the M2 channel and to a proton influx from the endosome into the virus 
interior [16]. The acidification of the virus interior enables the release of the 
viral RNA into the host’s cytoplasm after membrane fusion has taken place. In 
addition, it has been shown that, for some strains of influenza A virus, the M2 
proton channel function is required for preventing a premature HA 
conformation transition when newly synthesized viral proteins are trafficked 
through the trans-Golgi network [17]. 
 The replication of the influenza A virus can be stopped by inhibiting the 
activity of the M2 channel, using amantadine and rimantadine. 
 Although the role of the M2 protein as the target for amantadine and 
rimantadine has been known for more than twenty years [18], only very recent 
functional, structural [19] and computational [20] studies have revealed that 
the drugs inhibit proton conduction by binding to an aqueous cavity adjacent 
to M2’s proton-selective filter, thereby blocking access of proton to the filter 
[14]. These recent works enable novel insights into the adamantanes-
resistance and provide a solid basis for structure-based drug design. 
 The number of drug-resistant variants of influenza A M2 channel is 
limited by the very conserved nature of the binding site within the channel. 
Thus, only a few amantadine-resistant mutations, namely V27A, L26F and 
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S31N, have been widely observed in transmissible strains of the virus in the 
past eight decades for which a genetic record is available [21], although other 
mutations can easily be observed in vitro [22]. The mutations that cause the 
greatest decrease in inhibition, S31N and V27A, increase the polarity of pore-
lining residues. 
 
2. 1-Substituted-adamantanes 
 
 Amantadine and rimantadine exhibit their inhibitory activity at 
micromolar concentrations. Rimantadine has a superior intrinsic antiviral 
activity compared to amantadine, but peak plasma levels of rimantadine are    
2-3 fold lower than those achieved with amantadine when given at the same 
dose [23]. Amantadine was initially licensed in USA in 1966. Interestingly, 
for many years, amantadine was mainly used in western countries, while 
rimantadine was used in the former USSR and eastern European countries 
[24]. 
 Both drugs are rather old, therefore it is not a great surprise that 
hundreds of derivatives have been synthesized and pharmacologically 
tested. In fact, soon after the publication of the antiviral activivity of 
amantadine by du Pont de Nemours’ researchers [25], several amantadine 
derivatives were synthesized and evaluated as anti-influenza agents [26]. 
Most of these analogs were alkylaminoalkyl derivatives of adamantane (Fig. 2), 
although some derivatives featuring aditional polar groups, such as alcohols, 
amines, ethers, or derivatives lacking an amino group were also synthesized 
and tested (Fig. 3). 
 
 
 
Figure 2. Alkylamantadines and related compounds. 
 
 
 
Figure 3. Amantadine analogs featuring polar groups. 
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 Although several of these compounds displayed anti-viral activities 
similar to that of amantadine, they showed cross-resistance with amantadine 
and rimantadine, so their therapeutical interest is rather low. 
 Worthy of note, while amantadine is, for the most part, excreted without 
metabolism [27], rimantadine is extensively metabolized by hydroxylation 
before excretion in the urine [23c,28]. Manchand and coworkers reported 
the synthesis of three hydroxylated metabolites of rimantadine and showed 
that 2-hydroxyrimantadine was as active against several influenza A virus       
as amantadine, while the 3- and the 4-hydroxy derivatives showed                    
only very modest inhibitory activity (Fig. 4). Unfortunately, rimantadine-
resistant strains exhibited cross-resistance to the 2-hydroxyamantadine                 
[29]. 
 
rimantadine
NH2
3-hydroxyrimantadine
NH2
HO
2-hydroxyrimantadine
NH2
OH
4-hydroxyrimantadine
NH2HO
 
 
Figure 4. Rimantadine and its hydroxylated metabolites. 
 
 The antiviral activity of 2-hydroxyrimantadine was the first example of a 
trend that has also been observed in much more recent work using amantadine 
and other polycyclic systems, that is, the introduction of polar groups in the 
polycyclic scaffold is tolerated, but does not enhance the potency of 
amantadine and related aminopolycyclic derivatives. For example, in 2011, 
Wang et al. described that the aminoalcohol 3 showed an IC50 = 16 μM 
against the wt M2 channel from influenza A virus, exactly the same value than 
that reported for amantadine [30]. Surprisingly, they found that                     
1-adamantanol, 1, and 2-methyl-2-adamantanol, 2, showed IC50 values very 
close to that of amantadine, while the 3-amino-1-adamantanol, 4, showed to 
be inactive (Fig. 5). 
 
 
 
Figure 5. Several hydroxylated analogs of amantadine. IC50 values (against wt M2 
channel): amantadine (16 μM), 1 (20 μM), 2 (14 μM), 3 (16 μM), 4 (not active). 
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 Kolocouris’ group has reported the synthesis and anti-influenza activity of a 
series of heterocyclic rimantadine analogs (Fig. 6) [31]. The aziridine and the 
azepine derivatives were much less active than amantadine, while azetidine 6 
(R1=H), pirrolidines 7a (R1=R2=H) and 7b (R1=H, R2=CH3), and piperidine 8 
(R1=H) showed to be more potent than amantadine and rimantadine against the 
influenza A2/Japan/305/57 (H2N2) strain. Compounds 6 and 7b also showed 
good inhibitory activity against the influenza A/Hong Kong/68 (H3N2) strain. 
While amantadine displayed IC50 of 42 and 6 μM against A2/Japan/305/57 and 
A/Hong Kong/68, respectively, the most potent compound within this series, 7b, 
showed IC50 of 1.6 and 1.8 μM against A2/Japan/305/57 and A/Hong Kong/68, 
respectively. The introduction of an additional alkyl group in the nitrogen atom 
caused a dramatic reduction in anti-influenza activity. 
 
 
 
Figure 6. Heterocyclic rimantadine analogs. 
 
 Later on, the same group reported analogs of rimantadine featuring a 
second nitrogen atom, the aim of this modification being the incorporation of 
additional hydrogen bonding interactions with the M2 protein [32]. Although 
the presence of this second amino group was compatible with anti-influenza 
activity, the new analogs were not more potent than rimantadine. Thus, 
compounds 10 and 11 (Fig. 7) displayed EC50 of 18.3 and 24.1 μM, 
respectively, against A/Hong Kong/68 (H3N2) strain, very similar values to 
that of rimantadine (EC50 = 19.1 μM). 
 
 
 
Figure 7. Rimantadine analogs featuring a second nitrogen atom. 
 
 As previously stated, amantadine interferes with the ion channel function of 
the M2 protein of influenza A virus at low micromolar concentrations. 
Interestingly, a second mechanism of action of amantadine, at least in some 
influenza A strains, is on the hemagglutinin, at concentrations around 100 times 
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higher. Theoretically, an amantadine derivative able to simultaneously interact 
with both targets at the same concentrations should have a reduced probability 
to develop resistance. In this case, two mutations, one in each target protein 
would be necessary at once. With this aim, Scholtissek and coworkers reported 
the synthesis and evaluation of forty adamantane derivatives and tested them 
against the influenza A/Singapore/1/57 (H2N2) strain [33]. They found several 
analogs active against this strain and also against A/Swine/1976/31 and 
A/Udorn/307/72, although all the products were inactive against A/WSN/33, 
which is amantadine-resistant. Most of the active compounds at low micromolar 
concentrations (e. g., 12-14) interacted with the M2 protein; the corresponding 
escape mutants produced with them had amino acid replacements at positions 
27, 30 or 31 of the M2 protein. Interestingly, they found two compounds, 15 and 
16 (Fig. 8), able to interact with both the ion channel and the hemagglutinin at 
about the same concentration. It was expected that in order to become resistant 
the virus should mutate both proteins. However, the resistant mutants to these 
compounds showed mutations only in the HA protein [33].  
 
 
 
Figure 8. Some of the amantadine analogs reported by Scholtissek and coworkers. 
 
 Very recently, Zarubaev and coworkers have reported the synthesis and 
the anti-influenza activity of a series of di-, tri- and tetrazole derivatives of 
amantadine. Interestingly, several compounds were active against the 
amantadine-resistant influenza A/Puerto Rico/8/34 strain, which bears the 
S31N mutation in its M2 channel. Tetrazoles such as 17, 18 and 19 (Fig. 9), 
showed micromolar values of EC50 and higher selectivity index (SI) than 
rimantadine [34]. It remains to be clarified if the target of these adamantane 
derivatives is the M2 channel of the influenza virus. 
 
 
 
Figure 9. Tetrazolo-adamantanes with anti-influenza A virus activity. 
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 Finally, Zhang et al., have reported that an L-histidine derivative of 
adamantane, 20 (Fig. 10), was able to inhibit the wt, the S31N, and the double 
mutant S31N/L26I M2 channels of avian H5N1 influenza expressed in cell 
lines of transformed HEK 293. The IC50 of 20 against the wt, the S31N mutant 
and the double mutant S31N/L26I channels were 5.84, 10.96 and 9.77 μM, 
respectively [35]. However, these data were not confirmed with viral 
inhibition assays. 
 
 
 
Figure 10. Structure of histidine derivative 20. 
 
3. 2-Substituted-adamantanes 
 
 2-Amantadine is only moderately active against influenza virus. The anti-
viral activity improved by the incorporation of a 2-ethyl or 2-n-propyl group, 
although the introduction of a methyl group in C-2 diminished the activity. 
Interestingly, 2-methyl-2-adamantanol, 2a, showed an EC50 of 3 μM against 
influenza A/Japan/305/57 (H2N2) strain, very similar to the EC50 of 
amantadine against this strain (1.1 μM) [36]. As previously stated, 2a inhibits 
the wt M2 channel of influenza A with an IC50 of 14 μM [30]. In 2010, 
Kolocouris’ group reported that several adamantanaminoalcohols such as 23 
and 24 (Fig. 11) had potent anti-influenza activity. For example, aminoalcohol 
23, displayed submicromolar activity against the influenza A /Hong 
Kong/7/87 (H3N2) strain [37].  
 
21a-c
R
NH2
2a-c
R
OH
22
NH2
OH
23
NH2
OH
 
   
Figure 11. 2,2-Disubstituted adamantanes. a, R = methyl; b, R = ethyl; c, R = n-propyl. 
 
 Although 2-amantadine is only moderately active against influenza virus, 
the 2-isomer of rimantadine, 24 (Fig. 12), was found to be 4 times more potent 
than rimantadine against the influenza A2/Japan/305/57 (H2N2) strain. This 
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finding led to Kolocouris’ and De Clercq’s groups to investigate the antiviral 
activity of several 2-alkyl and 2-cycloalkyl analogs of rimantadine [38]. They 
found that alkylation of the nitrogen atom reduced the anti-viral activity as did 
the introduction of a methyl group in the C-2 of the adamantane, as in 25. 
Unfortunately, 24 was much less potent against X-31, a reassortant influenza 
A H3N2 strain (A/Hong Kong/1/68 with A/Puerto Rico/8/34) carrying the 
S31N mutation. 
 They also investigated the activity of 2-(2-adamantyl)piperidines, 2-(2-
adamantylmethyl)piperidines and 3-(2-adamantyl)pyrrolidines. In these series 
they found that while the alkylation of the nitrogen atom reduced the activity, 
as in going from 26a to 26b, the introduction of a further nitrogen atom two 
carbon away from the heterocyclic ring, as in 27a-c or 28 led to high anti-viral 
potency. For example, compounds 27a-c showed EC50 between 3 and 7 μM, 
against the X-31 strain, much lower than amantadine (EC50 = 49 μM) or 
rimantadine (EC50 = 19 μM). Taking into account the size of the diamines, it 
seems like the M2 receptor site can accommodate cages much larger than the 
adamantane. Unfortunately, the selectivity index (SI) of these compounds was 
much lower than that of amantadine or rimantadine [39]. 
 
 
 
Figure 12. 2-Substituted analogs of rimantadine. 
 
4. Azaspiroadamantanes 
 
 A unique kind of 2-substituted adamantanes is the group of the 
azaspiroadamantanes, because several of these derivatives have very potent 
anti-influenza activity. 
 Forty years ago, researchers at N. V. Philips-Duphar synthesized a series of 
azaspiroadamantanes (Fig. 13) [40]. Several of these amantadine analogs 
showed anti-influenza activity and, in fact, one of them, DU 34796, that had an 
antiviral spectrum in vitro wider than that of amantadine and was more potent 
than amantadine against mouse influenza, entered clinical trials, although finally 
the drug was not further developed [41]. The main problem of these compounds 
was, once again, the cross-resistance with amantadine and rimantadine. 
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Figure 13. Spiro adamantane derivatives synthesized by N. V. Philips-Duphar. R is a 
lower alkyl group. 
 
 As 2-adamantanamine is only moderately active against influenza virus, 
the antiviral activity of the aforementioned derivatives points out that a carbon 
substituent in the vicinity of the 2-adamantyl carbon leads to a remarkable 
increase in antiviral activity. We will see further examples of this behaviour in 
the following paragraphs and also in different analogs that will be shown in 
the next sections. 
 In the nineties, Kolocouris’ group, successfully revisited the topic, 
synthesizing several azaspiro- and oxazaspiro-adamantanes, such as those 
shown in Fig. 14. The compounds were examined against several influenza A 
strains (H1N1, H2N2 and H3N2) by De Clercq’s group. Interestingly, against 
a H2N2 strain, the compound 32b was found to be up to 230 times more 
active than amantadine. Although 32b showed a SI of 714 in vitro, 
unfortunately, it proved rather toxic in vivo. Worthy of note, the change of a 
methylene unit by an oxygen atom was compatible with anti-influenza 
activity, although these oxa-analogs were less active than amantadine [42]. 
 
 
 
Figure 14. Azaspiro- and oxazaspiro-adamantane derivatives. a, R = H; b, R = methyl; 
c, R = ethyl; d, R = cyclopropylmethyl. 
 
 Later on, with the aim of improving the antiviral activity, Kolocouris’s 
group explored the introduction of a methyl group in the pyrrolidine ring of 
32a and 32b (Fig. 15). While the introduction of a methyl in either C-3 or C-4 
of the pyrrolidine ring of 32a and 32b led to slightly less active compounds, 
introduction of a methyl in C-5 of the pyrrolidine was optimal for biological 
activity against H2N2 strain. Unfortunately, all pyrrolidines had lower SI than 
amantadine [43]. 
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Figure 15. C-methyl derivatives of azaspiroadamantanes 32a-b. a, R = H; b, R = methyl. 
 
 More recently, Kolocouris et al. have completed this series with the 
synthesis of ring-contracted and ring-expanded analogs of 32a (Fig. 16) [44]. 
Azaspiro derivatives 38-41 were synthesized and tested against an H3N2 
strain of influenza A. Whereas aziridine derivatives 38a,b were less potent 
than amantadine, azetidines 39a,b and 40, and the piperidine derivatives 41a,b 
were more potent than amantadine. Piperidine 41a, the most potent of them, 
showed significant anti-influenza A virus activity, being 12-fold more active 
than amantadine and about 2-fold more active than rimantadine. Azetidine 
36a, while being slightly less potent than 41a showed a better SI (694 vs 106). 
Methyl substitution at the nitrogen atom of all heterocycles caused reduction 
in anti-influenza virus A potency. 
 
 
 
Figure 16. Ring-contracted and ring-expanded analogs of 32. a, R = H; b, R = methyl. 
 
 Very recently, Kolocouris’ group has reported the synthesis of several 
spiropiperazines of general structure 42 (Figure 17) [45]. These compounds 
can be regarded as analogs of 33 and 34 featuring an additional nitrogen atom. 
The main aim of this approach was to introduce a further group able to 
establish additional hydrogen bonds within the channel. However, piperazine 
derivative 42a was three times less active than spiropiperidine 33 or 
amantadine. Moreover, N-methylation of 42a to 42b and 42c further reduced 
the activity, probably by hampering the hydrogen bonding ability of the 
ligand, 42c being inactive against influenza A/HongKong/68 (H3N2). No 
significant antiviral effect was observed against the amantadine resistant 
influenza A/WSN/33 (H1N1) strain. Notwithstanding the introduction of a 
second nitrogen atom was negative in this spiroadamantanes, other series of 
adamantane derivatives increased their potency with the introduction of a 
second amino group, as we have already seen in section 2. 
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Figure 17. Spiropiperidine 33 and analogs featuring an additional heteroatom. 
 
 Finally, it should be noted that, recently, Kolocouris and coworkers have 
reported the binding constants of some spiroadamantanes against the M2 
channel of the influenza A/chicken/Germany/27 (H7N7, Weybridge strain), 
expressed in E. coli [36]. The binding affinity of spiropiperidine 33 was in the 
submicrolar range (Kd = 0.39 μM), very similar to that of amantadine (Kd = 
0.32 μM), although much higher than that of rimantadine (Kd = 0.016 μM). 
Spiropirrolidines 32a, 32b, and 37b displayed binding affinities in the 
micromolar range (1.16, 2.93, and 1.5 μM, respectively).  
 Unfortunately, sometimes it is difficult to compare the anti-viral activity 
of the different adamantane derivatives. This is, at least partly, a reflection of 
the time-span lasting more than four decades in which these compounds were 
synthesized and tested. For example, while spiropiperidines 30, published in 
1972 [40d], and 33a-c, published in 1996 [42b], were tested against the 
influenza A2/Japan, an H2N2 strain, 41a-b, described in 2007 [44], were 
tested against the influenza A/HongKong/7/87, an H3N2 strain. As the 
activity of amantadine against these strains is different, it is difficult a 
quantitative comparison between the activity of all these compounds. 
Moreover, sometimes the description of the antiviral potency is not very 
accurate. For example, van Hes and coworkers, in describing the antiviral 
activity of 30, only reported “activity comparable to that of amantadine or 
better” without stating a value for the IC50 [40d]. 
 In order to investigate the SAR for their compounds, Kolocouris and 
coworkers have reported a conformational analysis study by a combination of 
NMR spectroscopy and theoretical calculations. They found that, in general, 
for the most active compounds the amine nitrogen atom lies in a distance of 
1.5 to 2.5 Å away from the 2-adamantyl carbon [47]. 
 
5. Aminospiroadamantanes 
 
 As part of its monumental work in adamantane chemistry, Kolocouris’ 
group has also reported the synthesis of several aminospiroadamantanes such 
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as those shown in Fig. 18. These compounds retain the pharmacophore group 
of rimantadine in the C-2 position of the adamantane ring. Compounds 43b 
and 44a showed to be more than 100 times more active than amantadine when 
tested against the influenza A2/Japan/305/57 (H2N2) strain [42a] with SI of 83 
and 24, respectively. 
 
 
 
Figure 18. Aminospiroadamantanes 43 and 44. 
 
 Analogs of 43 featuring a cyclobutyl or cyclopentyl ring have also been 
synthesized and tested against A2/Japan/305/57 (H2N2) and X-31 (H3N2, 
with S31N in the M2 protein) strains [38]. Cyclobutyl derivatives 45 had 
similar potency against the H3N2 strain than rimantadine. Ring enlargement 
resulted in spirocyclopentane analogs 46 which were less potent than their 
cyclobutane analogs. When tested against the X-31 strain, all the new 
compounds showed to be less potent than rimantadine (Fig. 19). 
 Overall, in going from cyclopropyl analogs 43 to cyclopentyl 
derivatives 46, it appears as if increasing the carbon crowding around the 
spiro carbon leads to compounds with reduced antiviral potency. However, 
it must be taken into account that Philips-Duphar researchers reported, in the 
1970s, that the cyclopentyl derivative 47 had, against the A2/Japan/305/57 
(H2N2) strain, an antiviral activity of the same order of DU 34796, that, as 
we have already stated, entered clinical trials [40d]. Moreover, very 
recently, DeGrado’s group disclosed in a patent the structure of the 
cyclohexyl derivative 48, somehow related to spiropiperidine 41a. 
Compound 48, when tested against the wt M2 channel of influenza A virus 
expressed in oocytes of Xenopus laevis, showed an IC50 of 18.7 μM, very 
similar to that of amantadine (IC50 = 16 μM) and was slightly less active 
than rimantadine (IC50 = 10.8 μM). As rimantadine, 48 was inactive against 
the mutant S31N. However, compound 48 revealed to be a submicromolar 
inhibitor of the clinically important mutant V27A (IC50 = 0.31 μM) and also 
showed to be active against the mutant L26F (IC50 = 5.6 μM). To the best of 
our knowledge, 48 is the most potent compound ever reported against the 
mutant V27A [48]. Unfortunately, there is no data regarding the activity of 
compounds 43-47 against the V27A mutant M2 channel. Worthy of note, 
analog 49 has not been synthesized yet. 
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Figure 19. Aminospiroadamantanes 45-48 and unkown compound 49. a, R = H; b,            
R = methyl. 
 
 Taken together the antiviral acitivity of compounds 43 to 48, it seems that 
the distance and orientation between the nitrogen atom and the adamantyl 
cage is more important than the steric hindrance around the spiro carbon atom. 
 
6. 1,2-Annulated adamantane derivatives 
 
 In the earlier 1970s, several patents by Squibb claimed anti-influenza 
activity for a series of 1,2-annulated adamantanopyrrolidines of general 
structure 50 (Fig. 20), although no much details regarding biological activity 
were given [49]. Nearly forty years later, Kolocouris’s group synthesized 
several adamantanopyrrolidines 51-52, the related compound 53 and  1,2-
annulated adamantanopiperidines of general structures 54-56 and tested them 
against influenza A/Hong Kong/7/87 (H3N2) strain [50]. 
 
 
 
Figure 20. 1,2-Annulated adamantane derivatives 50-56. a, R = H; b, R = methyl; c,        
R = ethyl. 
 
 The compounds 52a and 56a elicited submicromolar activities (IC50 of 0.5 
and 0.6 μM, respectively) and a SI of 732 and 200, respectively, being 
equipotent to rimantadine (IC50 = 0.36 μM). Compounds 51 and 54, with the 
nitrogen atom attached directly to the C-2 position of the adamantane ring, 
showed low micromolar activities (between 2 and 8 μM), similar to that of 
amantadine (2.0 μM). 
 As previously seen in other series, these results showed that a large 
lipophilic moiety in the vicinity of adamantane skeleton is compatible with 
good anti-viral activity, that moving the amine nitrogen atom away from the 
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2-adamantyl carbon atom enhaces activity (compare 52a, IC50 = 0.6 μM, with 
51a, IC50 = 2.2 μM), and that N-alkylation reduced the potency (compare 52a, 
IC50 = 0.5 μM, with 52c, IC50 = 2.4 μM, or 56a, IC50 = 0.6 μM, with 56b,  
IC50 > 500 μM). 
 In closing sections 2 to 5, it should be mentioned that in 2009, K.-C. Chou 
published a fragment-based quantitative structure-activity relationship              
(FB-QSAR) study with 34 substituted adamantanes. His main conclusion was 
that position 2 of the adamantane was more sensitive to substitution than 
position 1 [51]. 
 
7. 2-Azaadamantanes and (2-oxaadamant-1-yl)amines 
 
 Geigy has claimed that 2-azaadamantane, 57 (Fig. 21), first described in 
1964 by Stetter et al. [52], displayed antiviral activity against three different 
influenza A H2N2 strains: A/Bethesda/10/63, A/Taiwan/1/62 and 
A/Singapore/1/57, but not further progress was published later [53]. 
 More recently, we have found that replacement of the methylene unit of 
C-2 in amantadine by an oxygen atom to obtain (2-oxaadamant-1-yl)amine, 
58, reduced the antiviral activity [54]. 
 
 
 
Figure 21. 2-azaadamantane and (2-oxaadamant-1-yl)amines. 
 
8. BL-1743 and related compounds 
 
 In 1995, Bristol-Myers Squibb’s researchers carried out a high-throughput 
screen based on the ability of inhibitors to reverse the toxicity associated with 
M2 channels expressed in the yeast Saccharomyces cerevisiae membranes. 
They found an azaspiro[5.5]undecane derivative, BL-1743, able to efficiently 
inhibit the activity of wt influenza A M2 channels (Fig. 22) [55]. The 
mechanism of action of BL-1743 was further characterized by 
electrophysiological methods. BL-1743 was also able to inhibit the AM2 
channel expressed in Xenopus oocytes, as determined using the two-electrode 
voltage clamp (TEV) technique. It was found that the majority of M2 
sequences isolated from influenza viruses resistant to amantadine were also 
resistant to BL-1743, which suggests that BL-1743 binds competitively with 
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amantadine. Interestingly, the kinetics of channel inhibition by BL-1743 were 
more rapid, showing a fast onset of inhibition as well as a reasonably rapid 
reversal of inhibition following removal of the compound [56]. This behavior 
contrasts with that of amantadine, whose second-order rate constant for the 
onset of inhibition is much slower than the diffusion-controlled rate, and 
whose off-rate is essentially irreversible on the minute to hour time scale of 
the experiment. The Hill coefficient for inhibition was 1.0, which is consistent 
with the binding ratio of one BL-1743 per AM2 tetramer [56]. 
 It should be noted that twenty years before the discovery of BL-1743, A. 
H. Robins Company Inc., in a US patent [57], claimed anti-influenza activity 
for a series of aminospiranes that were already known from older literature 
[58]. Compounds 59-61 (Fig. 22) protected chicken embryos against influenza 
A/Taiwan/1/64 (H2N2) strain better or similarly than amantadine. No 
information about the activity of these compounds against amantadine-
resistant strains was disclosed. 
 
 
 
Figure 22. BL-1743 and related aminospiro[5.5]undecanes. 
 
 Taking into account the recent determination of the 3-D structure of the 
M2 ion channel of influenza A virus [19], and the structural difference 
between BL-1743 and the amantadine class of compounds, in 2008 Pinto’s 
and DeGrado’s groups started a SAR study of this scaffold with the aim of 
discovering new inhibitors of amantadine-resistant mutants [59]. 
 Interestingly, spiropiperidine 62a (Fig. 23), an analog of BL-1743 lacking 
the imidazoline group, had an IC50 of 0.9 μM against the influenza A wt M2 
channel expressed in the Xenopus oocytes membrane, which is more than one 
order of magnitude more potent than amantadine (IC50 = 16 μM) and represents 
a more than 45-fold increase in potency relative to BL-1743 (IC50 = 45.3 μM). 
Alkylation of 62a with a methyl group to 62b reduced the potency (IC50 = 20.6 
μM), and alkylation with larger groups as in 62c led to inactive compounds. 
Several N-heteroarylmethyl derivatives of 62 were also inactive. Worthy of 
note, solid-state NMR data indicated that 62a interacts with influenza A M2 
channel differently from amantadine, affecting a longer stretch of the 
transmembrane helix and immobilizing the G34-I35 region. Ring-contracted 
analogs 63 and 64 were also active (IC50 = 8.1 and 12.0 μM, respectively) 
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although were less potent than 62a. Dithiene 65 was moderately active           
(IC50 = 37.6 μM), while ketal 66 was inactive [59a]. Finally, it should be noted 
that 62a can be seen as a simplified analog of Kolocouris’ spiroadamantane 41a 
(Figure 16), a compound that, when tested against influenza A/Hong Kong/7/87 
(H3N2) strain, was found to be 12-fold more active than amantadine [44]. 
 
 
 
Figure 23. Spiropiperidine 62 and related compounds. a, R = H; b, R = methyl; c,               
R = methylcyclopropyl; d, R = methyl-2-pyridyl; e, R = methyl-2-imidazolyl. 
 
 Moving the nitrogen atom out of the spiro-ring led to the aforementioned 
amine 59. DeGrado’s group found that 59 had an IC50 of 12.6 μM, very 
similar to amantadine. Analogs 67 and 68 were also active (IC50 = 15.7 and 
14.6 μM, respectively), while more complex derivatives, such as 69 were 
inactive (Fig. 24) [59b]. Interestingly, while 59 was less potent than 62a 
against the wt channel of influenza A, 59 was active against the amantadine-
resistant L26F and V27A mutants (IC50 = 30.6 and 84.9 μM, respectively) and 
also inhibited replication of recombinant mutant viruses bearing these 
mutations in plaque reduction assays. However, 59 was inactive against the 
S31N mutant. It is interesting to compare the structure and the activity of 59 
with the spiroadamantane 48 (Fig. 19). While 59 and 48 displayed very 
similar activities against the wt channel (IC50 = 12.6 and 18.7 μM, 
respectively), 48 is much more potent against the amantadine-resistant 
mutants (V27A, IC50 = 0.3 μM; L26F, IC50 = 5.6 μM) [48]. 
 
 
 
Figure 24. Spiro[5.5]undecan-3-amine 59 and related compounds. 
 
9. Ring-contracted adamantane analogs 
 
 For the wt M2 protein, the diameter of the hole made from four Ser31 of 
separate trans-membrane chains is about 8 Å. However, after the mutation of 
residue 31 from Ser to Asn, the diameter of this hole was reduced to 6.32 Å 
[20i]. As the X-ray structure of the M2-amantadine complex shows that 
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amantadine is located in the hole between Ser31 and Ala34, the mutation of 
Ser to Asn leaves less space for amantadine entering or being stabilized [19d]. 
 Taking into account this reduction in the space available for binding, we 
synthesized a series of ring-contracted amantadine and rimantadine analogs, 
featuring noradamantane and bisnoradamantane scaffolds (Fig. 25). Several 
derivatives showed low micromolar inhibitory activities of the wt M2 channel 
ranging from IC50 = 2.4 μM for guanidine 72 to IC50 = 17 μM for 71 and 75. 
The activity was confirmed by plaque reduction assays with influenza 
A/Udorn/72 (H3N2) strain, carrying wt M2 protein and, for 70 it was also 
confirmed in an assay of inhibitory effect on virus replication using influenza 
A/Hong Kong/7/87 (H3N2) strain [60]. However, only bisnoradamantane 
derivative 74 showed to be moderately active against the S31N channel                
(IC50 = 252 μM), being less potent than amantadine (IC50 = 200 μM) [60b]. 
Several bisnoradamantanes carrying additional rings were also studied and some 
of them showed to be slightly less potent than amantadine. For example, 
pyrrolidine derivative 76, had IC50 = 24 μM against the wt channel of influenza A.  
 
 
 
Figure 25. Ring-contracted analogs of amantadine and rimantadine. 
 
 Cubylamines also can be regarded as ring-contracted analogs of amantadine 
and rimantadine. In 1971, Du Pont de Nemours, claimed in a patent anti-
influenza activity for several cubane derivatives, such as 4-methylcubane-1-
amine, 77, and α,4-dimethylcubane-1-methylamine, 78 (Fig. 25). When mice 
infected with the influenza A/Ann Arbor/2/60 (H2N2) strain were treated with 
the rimantadine analog 78, there was a 70% survival rate as compared with 20% 
survivors in the infected, non-treated control animals [61]. 
 
10. Aminobicyclo[2.2.1]heptanes, aminobicyclo[2.2.2]octanes and 
related compounds 
 
 As early as in 1969, Smith Kline & French disclosed that 
bicyclo[2.2.1]heptanes 79-81 (Fig. 26) had anti-influenza activity. They 
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reported that compound 80, at oral and subcutaneous doses of 25-100 mg/kg, 
caused a 35-80% and a 30-75% increase in survival of mice infected with the 
influenza A/Ann Arbor/2/60 (H2N2) strain, and with a swine strain of 
influenza A, respectively [62]. Although no further details have been 
published in the western literature related to the antiviral activity of 79 or 80, 
later, Russian researchers found that an isomeric mixture of 81 and 82 
effectively inhibited replication of influenza viruses and this mixture, as its 
hydrochloride, known as deitiforin, has been in used as antiviral in the former 
USSR for several years [63]. As an anti-influenza drug, deitiforin is equal to 
rimantadine from the standpoint of the protective effect in the treatment of 
influenza infection, and it can not only efficiently supress virus-specific 
growth, but can also selectively act on virus-infected cells. It has been found 
that influenza A/Victoria/35/72 (H3N2) strain resistant to deitiforin  mutated 
the M2 protein in 3 amino acids: Met14Leu, Ala30Val and Met59Leu [64]. 
Interestingly, compound ICI 130685, which can be regarded as a derivative of 
81 with further rings, advanced into clinical trials, but was not approved for 
clinical use [65]. 
 García Martínez and coworkers have reported that several                     
1-norbornylamines were also endowed with potent anti-influenza activity. 
Secondary amines 83 and 84 were more potent than amantadine and showed 
very high SI [66]. 
 
 
  
Figure 26. Bicyclo[2.2.1]heptanes with anti-influenza activity. 
 
 In 1969, DuPont de Nemours & Co, also claimed anti-influenza activity 
for a series of bicyclo[2.2.2]octan-1-amines, 85, bicyclo[2.2.2]oct-2-en-1-
amines, 86, bicyclo[2.2.2]octane-1-methylamines, 87, and bicyclo[2.2.2]oct-
2-ene-1-methylamines, 88 [67]. They tested the compounds in mice using the 
influenza A/swine/S-15 strain and found that the unsaturated cage amines 
were similar in antiviral activity to their saturated counterparts. As seen in 
other families of polycyclic amines, substitution on the amino group with 
alkyl groups decreased the anti-viral activity. The addition of a methyl group 
in C-4 of the bicyclo[2.2.2]octane was optimal but inclusion of a larger group 
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reduced the activity. Finally, the presence of α-alkyl groups in the 
bicyclo[2.2.2]octane-1-methylamine series enhances antiviral activity. 
Overall, rimantadine analog 89 was the most active compound. 
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Figure 27. Bicyclo[2.2.2]octan-1-amine, 85, and related compounds. 
 
 Interestingly, Inamoto and co-workers reported the synthesis of several 
tricyclo[5.3.1.03,8]undecane (4-homoisotwistane) derivatives, such as amines 
90 and 91. 4-Homoisotwistanes can be seen as bicyclo[2.2.2]octane 
derivatives carrying an additional ring. Amines 90 and 91 were quite active 
against the Newcastle disease virus, which is sensitive to amantadine and is 
the causal agent of a bird disease that, when infecting humans, causes 
influenza-like symptoms. However, they did not test these compounds against 
influenza virus [68]. 
 
 
 
Figure 28. Tricyclo[5.3.1.03,8]undecane derivatives. 
 
11. Other polycycloalkanes with anti-influenza activity 
 
 Finally, in this section we will discuss several unrelated polycyclic 
structures that have shown anti-influenza activity. For example, there are 
several amines derived from the pentacyclo[5.4.0.02,6.03,10.05,9]undecane that 
have been biologically tested. In the 1970s, Smith, Kline & French, reported 
that amine 92 (Fig. 29) showed marginal activity against influenza A/Ann 
Arbor, while its isomer 93 was inactive [69]. Very recently, DeGrado and 
coworkers have found that amine 94 inhibited the activity of the wt M2 
channel of influenza A expressed in oocytes of Xenopus laevis, with an           
IC50 = 8 μM, lower than that of amantadine (IC50 = 16 μM) and rimantadine 
(IC50 = 10.8 μM). As seen in other polycyclic derivatives, the addition of a 
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hydroxyl group, as in 95, was compatible with inhibitory activity (IC50 = 24 μM), 
but not increased the potency [30]. 
 
 
 
Figure 29. Derivatives of pentacyclo[5.4.0.02,6.03,10.05,9]undecane. 
 
 In 2010, Hu et al. carried out the screening of a small primary amine 
library as M2 protein inhibitors. They reported that linear alkyl amines, 
aromatic amines and unsubstituted monocyclic amines were inactive. 
However, they found five compounds, 14, previously studied by Scholtissek 
[33], and 96-99 (Fig. 30), with similar activities to that of amantadine. 
Isopinocamphenylamine 99, the most potent inhibitor, was three times more 
active than amantadine (IC50 = 1.4 μM vs IC50 = 6.0 μM) for viral inhibition 
of the influenza A/Hong Kong/8/68 (H3N2) strain [70]. Encouraged by these 
results, the same group has very recently published a small library of 
derivatives of 99 obtained by keeping the scaffold constant and modifying the 
amino functionality. The compounds were evaluated for viral inhibiton against 
influenza A/WS/33 (H1N1), amantadine resistant, and influenza A/Hong 
Kong/8/68 (H3N2), amantadine sensitive. Although there was no inhibition of 
the amantadine resistant strain, most of the compounds exhibited antiviral 
inhibition as good as amantadine against the amantadine sensitive strain. 
Compound 100 (IC50 = 0.09 μM) was nearly 240-fold more potent than 
amantadine against wt influenza A virus [71]. 
 
 
 
Figure 30. Primary amine inhibitors of M2 channel and derivative 100. 
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 Finally, DeGrado and coworkers tested the inhibitory activity against wt 
M2 channel of a series of branched and polycyclic amines (Fig. 21) [30]. 
Surprisingly, branched alkyl amine 101 was nearly as active as amantadine 
(IC50 = 21 μM vs IC50 = 16 μM), tricyclic amine 102, showed higher activity 
than amantadine (IC50 = 9 μM) and four homoadamantane derivatives,           
103-105 and 13 showed similar activity as amantadine, suggesting that the 
M2 channel can accommodate a wide range of structural diversity and               
that is insensitive to minor scaffold modifications, so long as the shape of 
the molecule conforms to the M2 cavity. All these compounds were found    
to be less potent or inactive against V27A and/or S31N mutant               
channels, probably as a consequence of the higher polarity of the mutant 
channels [30]. 
  
 
 
Figure 31. Several inhibitors of M2 channel. 
 
12. Conclusion 
 
 Although amantadine and rimantadine have been in clinical use for 
many years and hundreds of analogs have been tested as anti-influenza 
agents, the results obtained so far are a bit disappointing. While several 
active compounds have been found, occasionally having more potency than 
amantadine and rimantadine, cross-resistance with both drugs is still an 
unresolved issue. The above notwithstanding, the recent structural, 
functional, and computational studies carried out with M2 protein have 
opened the door to the rational design of new inhibitors [72], and, very 
recently, some derivatives have shown promising activity against the V27A 
amantadine-resistant mutant [30,48,59]. The S31N mutant is still even a 
major challenge. 
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Abstract. Polyamines (PAs) are small polycationic compounds 
present in all living organisms. Compelling evidences indicate a 
role for PAs in plant protection against stress. During the recent 
years, genetic, molecular and ‘omic’ approaches have been 
undertaken to unravel the role of PAs in stress signaling. Overall, 
results point to intricate relationships between PAs, stress hormone 
pathways and ROS signaling. Such cross-regulations condition 
stress signaling through the modulation of abscisic acid (ABA) and 
ROS amplification-loops. In this chapter we compile our recent 
findings which elucidate molecular mechanisms and signaling 
pathways by which PAs contribute to stress protection in plants. 
 
1. Introduction 
 
1.1. The importance of crop protection against abiotic stress 
 
 Abiotic stresses such as cold/freezing, salinity, heat and drought 
represent serious threats to agriculture. About 70% of yield losses among 
crops are attributed to abiotic stresses. Climatic change is predicted to 
increase global temperature, alter precipitation patterns, and intensify 
drought,  increasing  the  need to  grow       crops in saline  soil [1,2].  Within  the 
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European Union, the area affected by drought has doubled in 1991-2006, 
causing an estimated loss of € 8.7 billion in 2003, and up to 25% of yield 
losses in 2006. The specific threat of drought was acknowledged by an EU 
impact assessment calling for a multi-faceted policy including the ‘use of 
more drought resistant crops’. Drought damages cannot be however viewed 
in isolation as they are often accompanied in the field by other stresses, such 
as heat, high light and increasing ozone concentrations. According to 
environmental predictions, during the 21st century global effects of 
desertification, salinization and atmospheric pollutants will produce severe 
limitations in arable lands with dramatic consequences in crop productivity.  
 In response to abiotic stress, plants initiate a plethora of biochemical and 
physiological changes. Importantly, a remarkable natural diversity exists in 
the ability of plants to cope with various stresses, ranging from highly 
sensitive plants to more tolerant ones. Thus, there is a genetic potential for 
plants to adapt to these stresses, preserving growth and/or high yield, but this 
potential has not been the main selective criteria in the domestication process, 
which yielded many crop cultivars that poorly cope with stress conditions. 
The past decade of international research characterized about 40 to 50% of 
gene functions conserved in the model plants Arabidopsis and rice, and 
sorted them into specific pathways. These efforts have created network 
models of stress and hormone regulatory pathways, as well as the definition 
of frameworks of co-regulated target genes of abiotic stress response 
pathways e.g. [3]. Except for few regulatory genes, transgenic approaches 
with individual stress-regulated candidate genes made so far little impact in 
breeding [4]. By contrast, regulation of the metabolism of compatible 
osmolytes, proline and polyamines (PAs) in particular, has emerged as more 
promising approach to practical applications. Elevated levels of PAs are one 
of the most remarkable changes that occur in plants in response to abiotic 
stress conditions [5]. The PA pathway interacts with metabolic routes of 
several signaling molecules (i.e. ethylene, NO, hydrogen peroxide) involved 
in abiotic stress responses [5]. Transcriptomic studies revealed differential 
regulation of genes in PA metabolism in response to different types of abiotic 
stress indicating that PAs are key regulatory molecules in abiotic stress 
signaling [6]. Here we focus on recent advances about the role of PAs in 
drought stress performed in the model species Arabidopsis thaliana, and 
discuss future perspectives and potential applications in crop protection.  
 
1.2. Polyamine biosynthesis, catabolism and conjugation 
 
 Polyamines (PAs) are small polycationic compounds of low molecular 
weight which are present in all living organisms [5]. Most abundant 
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polyamines are the diamine putrescine (Put), the triamine spermidine (Spd) 
and the tetramine spermine (Spm) (Fig. 1). Presence of amine groups in their 
chemical structure provide positive charges under physiological pH, which 
allows the binding of PAs to negatively charged macromolecules such as 
DNA, proteins and phospholids [5,7]. In all living organisms, the first PA 
synthesized is Put by decarboxylation of ornithine through an enzymatic 
reaction catalyzed by ornithine decarboxylase (ODC, EC 4.1.1.17; Fig. 1). 
Plants and bacteria contain an alternative route to Put production by 
decarboxylation of arginine by arginine decarboxylase (ADC, EC. 4.1.1.19; 
Fig. 1). The product of ADC activity is agmatine, which is converted into Put 
in two enzymatic steps catalyzed by agmatine iminohydrolase (AIH, EC 
3.4.3.12) and N-carbamoyl putrescine amidohydrolase (CPA, EC 3.5.1.53) 
(Fig. 1).  Higher molecular weight PAs are produced by sequential addition 
of aminopropyl moieties to the Put skeleton through enzymatic reactions 
catalyzed by spermidine and spermine synthases (SPDS, EC 2.5.1.16 and 
SPMS, EC 2.5.1.22;  Fig. 1). Donor of aminopropyl groups is decarboxylated 
S-adenosyl methionine (dcSAM), which is synthesized from decarboxylation 
of S-adenosyl methionine (SAM) by SAM decarboxylases (SAMDC, EC 
4.1.1.50; Fig. 1).  
 The levels of free PAs depend on their biosynthesis, but also catabolism, 
transport and conjugation [5]. Polyamines are catabolized through diamine 
oxidases (DAO, EC 1.4.3.6) and polyamine oxidases (PAO; EC 1.5.3.3). 
DAOs catalyze the oxidation of Put producing 4-aminobutanal, H2O2 and 
ammonia. DAOs are present in monocots and dicots, but genes encoding 
these enzymes have been documented in few species [8]. PAOs bear a non-
covalently bound molecule of flavin adenine dinucleotide (FAD) and are 
present at high levels in monocots [9]. PAOs are involved either in 
catabolism or back-conversion of PAs [5]. From the first group of PAOs, the 
maize PAO (ZmPAO) is the best characterized. ZmPAO is involved in the 
terminal catabolism of Spd and Spm producing 4-aminobutanal or (3-
aminopropyl)-4-aminobutanal, along with 1,3-diaminopropane (Dap) and 
H2O2 [8], Fig. 1. The second group of plant PAOs resembles mammalian 
Spm oxidases (SMO, EC 1.5.3.3) that catalyze the back-conversion of Spm to 
Spd with concomitant production of 3-aminopropanal and H2O2 [10].  
 As anticipated, regulation of free PA contents is also achieved through 
their conjugation to hydroxycinnamic acids. So far, caffeoylputrescine, 
coumaroylputrescine, feruloylputrescine, coumaroylagmatine, dicoumaroyls-
permidine, diferuloylspermidine, diferuloylspermine and feruloyltyramine 
have been identified in different plant species [11]. The ratios between free 
and conjugated PAs vary between plant species, being the conjugated forms 
especially abundant in Solanaceae [5]. 
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Figure 1. Polyamine metabolic pathway. Numbers refer to the following enzymes: 1, 
ornithine decarboxylase; 2, ornithine-carbamoyl transferase; 3, argininosuccinate 
synthase; 4, argininosuccinate lyase; 5, arginine decarboxylase; 6, agmatine 
iminohydrolase; 7, N-carbamoylputrescine amidohydrolase; 8, spermidine synthase; 
9, spermine synthase; 10, polyamine oxidase (also involved in back-conversion to Spd 
and Spm); thermospermine synthase ACL5; 12, diamine oxidase; 13, arginase; 14, 
putrescine hydroxycinnamoyl transferase; 15, SAM synthetase; 18, SAM 
decarboxylase; 26, polyamine oxidase. 
 
1.3. Arabidopsis thaliana: A model for polyamine research 
 
 Arabidopsis thaliana is a wild species distributed all over the world, 
mainly in the northern hemisphere. Its reduced size, easy transformation, high 
natural genetic variation and large number of molecular and genetic tools 
have made this species a model for molecular and genetic analyses. Also, 
knowledge derived from A. thaliana has successfully been applied to crop 
species. 
 The sequencing of the A. thaliana genome revealed the absence of the 
ODC pathway in this plant species [12]. Remarkably, ODC encoding genes 
are also absent in the genome of A. lyrata, ancestor of A. thaliana, thus 
suggesting that loss of ODC pathway occurred before the split between        
A. thaliana and A. lyrata lineages. AIH and CPA are found as single copy 
genes in A. thaliana [13,14]. Mutations in either AIH or CPA that disrupt 
their enzymatic activities lead to embryo lethality, thus evidencing the 
importance of keeping a minimum pool of PAs for plant survival (Alcázar et 
al., unpublished results). Whereas AIH and CPA are found as single copy 
genes, ADC and SPDS encoding genes are found as duplicates (ADC1, 
ADC2, SPDS1 and SPDS2) [7]. The finding of gene duplicates in A. thaliana 
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is frequent, due to the occurrence of large genome duplications in this 
species. However, the different gene paralogs may have evolved different cis 
elements in their promoters that provide differential transcriptional responses 
under stress [7]. This is the case for ADC1 and ADC2. Whereas the 
expression of ADC1 is highly up-regulated in response to cold [15], ADC2 is 
responsive to drought, oxidative stress, salinity and biotic stress [7]. In 
addition, ADC2 mRNA levels under non-stressed conditions are much lower 
than ADC1, which shows a more constitutive expression [16]. SPDS are also 
encoded by two genes namely SPDS1 and SPDS2, whereas only one gene is 
found to encode SPMS [7]. Before its functional characterization, the ACL5 
gene was annotated as a spermine synthase [17]. This gene was identified in 
screens for mutants showing reduced stem size [17]. However acl5 mutants 
do not show obvious reductions in Spm content (Alcázar et al., unpublished 
observations). In the recent years it has been demonstrated that ACL5 does 
not code for a spermine synthase, but for thermospermine synthase [18,19], 
thus evidencing that Spm biosynthesis also depends on a single gene (SPMS). 
Whereas depletion of Put and Spd levels in A. thaliana lead to loss of 
viability [20,21], the double acl5/spms mutant is still viable, thus evidencing 
that Spm and tSpm are not required for cell survival [22]. Nonetheless, 
acl5/spms mutants are more sensitive to stress conditions [23], although it 
remains to be clarified if this is due to pleiotropic effects of acl5 mutation 
(Alcázar et al., unpublished observations). 
 For an efficient metabolic canalization, some enzymatic pathways are 
assembled in macromolecular complexes called metabolomes. In the recent 
years our group has reported the first metabolon in plants involving 
aminopropyl transferases SPDS and SPMS [24]. Through a yeast two hybrid 
screen using one SPDS as bait, our group identified SPDS and SPMS 
interacting proteins [24]. Remarkably, ACL5 did not interact with SPDS or 
SPMS [24]. Through gel fractionation experiments from plant cell protein 
extracts, SPDS-SPMS protein assemblies were found associated to higher 
molecular weight complexes for which the molecular partners have not yet 
been identified [24]. The association between SPDS and SPMS in A. thaliana 
would provide an efficient canalization of the PA Put to Spm, something that 
has recently been observed in different species [25]. It remains to be studied 
at the proteomic level if the other components of the PA biosynthetic 
pathway (e.g. AIH, CPA, ADC and SAMDC) belong to the same 
macromolecular complex. Efforts are currently underway. 
 Arabidopsis thaliana contains five genes encoding putative PAOs [7]. 
PAO1 and PAO4 catalyze the same reaction as SMO [26,27], while PAO3 
acts in the back-conversion pathway, converting Spm to Spd and Spd to Put 
[10]. The third class of plant PAO-domain proteins are relatives of the human 
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lysine-specific demethylase 1 (LSD1) that possesses an amine oxidase 
domain similar to that of FAD-dependent PAOs [28]. LSD1 acts as a histone 
demethylase, representing an important regulator of chromatin structure and 
gene expression [29]. Arabidopsis has four LSD1-related genes, some of 
which participate in the repression of FLC, a negative regulator of flowering 
time [30,31].  
 In the recent years, increasing interest has been shown to characterize the 
function of PAs in abiotic stress tolerance. In the following sections, we 
summarize where indications are found that PAs are key molecules in abiotic 
stress signaling and protection. Due to space limitations, we have focused on 
the role of PAs in drought stress, although our research laboratory is also 
interested in cold, salinity and we plan to get insight into biotic stress as well. 
 
2. Polyamines in drought stress 
 
 The perception of water stress is rapidly sensed by plants and translated 
into a molecular signal which involves activation of mitogen-activated protein 
(MAP) kinase cascades, protein phosphatases, phospholipid signaling and 
multiple posttranslational modifications [32]. These signals induce 
transcriptional reprogramming of drought responsive genes, which are required 
to survive dehydration [32]. Eventually, stress signaling pathway activation 
leads to the accumulation of different osmolytes to cope with dehydration 
conditions. PAs accumulate to high levels in response to drought, consistent 
with their role on drought protection. In the recent years, molecular and genetic 
studies have revealed specific mechanisms of PAs in drought protection and 
signaling pathways involved. We describe in the following sections recent 
findings performed by our group evidencing PA cross-regulations with stress 
hormone pathways and metabolic canalizations of PAs in response to 
dehydration, in line with the PA-metabolon previously described [24]. 
 
2.1. ABA regulates PA-responsiveness to drought 
 
 The phytohormone abscisic acid (ABA) plays a key role in drought 
signaling and protection. Many drought-inducible genes are ABA-responsive, 
but also ABA-independent pathways are activated in response to drought 
conditions [33]. In order to determine the involvement of ABA in the 
transcriptional regulation of the PA biosynthetic pathway, Alcázar et al. [34] 
analyzed the expression of PA biosynthetic genes ADC1, ADC2, AIH, CPA, 
SPDS1, SPDS2, SPMS, ACL5, SAMDC1 and SAMDC2 in A. thaliana wild 
type plants and mutants impaired in ABA biosynthesis (aba2-3) or signaling 
(abi1-1). The ABA-deficient aba2 mutants are blocked in the conversion of 
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xanthoxin to ABA-aldehyde and contain reduced levels of ABA in seeds and 
leaves [35]. These mutants also show reduced accumulation of ABA in 
response to drought conditions [35]. The abi1 mutation affects ABA sensitivity 
in vegetative tissues  and several ABA-mediated stress responses [36].  
 Wild type plants, aba2-3 and abi1-1 mutants where exposed to severe 
dehydration conditions during 24 h, and the expression of PA biosynthetic 
genes analyzed by quantitative RT-PCR after 0, 1, 2, 4, 8 and 24 h of 
treatment.  ADC2, SPDS1 and SPMS genes were among the most responsive 
to drought treatment under the imposed drought conditions (Fig. 2).  Indeed, 
ADC2 and SPDS1 expression increased up to 32- and 25-fold respectively, 
whereas SPMS expression increased 75-fold after 24 h of treatment  [34]. These 
observations suggested a key role of ADC2, SPDS1 and SPMS conferring 
drought tolerance. Interestingly, whereas ADC2 and SPDS1 expression 
increased several fold after drought treatment, the expression of their gene 
paralogs ADC1 and SPDS2 did not change substantially [34]. These 
observations are consistent with the acquisition of certain stress-specificity 
probably due to divergent evolution of cis regulatory elements in their 
promoters. Indeed, different cis regulatory elements are found in the promoters 
of PA biosynthetic genes (Fig. 3). ABA-responsive elements (ABRE) or 
ABRE-related motifs are also found in the promoters of ADC2, SPDS1 and 
SPMS [7], highly up-regulated in response to drought stress (Fig. 3). 
 The analysis in aba2-3 and abi1-1 mutants exposed to drought conditions 
showed much more moderate increases in ADC2, SPDS1 and SPMS 
expression (Fig. 2) [34]. Hence, ADC2 increased to a maximum of 7.5-fold 
after 24 h of treatment, which represented a reduction of 78% in fold 
induction compared to the stressed wild type [34]. SDPS1 only increased up 
to 3.2-fold after 8 h (87% less increase than wild type) and SPMS increased 
3.2-fold after 24 h (96% less than wild type). These results evidence that 
transcriptional up-regulation of ADC2, SDPS1 and SPMS imposed by 
drought stress is mediated by ABA. Hence, ABA is an upstream regulator of 
PA biosynthesis in response to drought (Fig. 4). 
 To determine the effect of the transcriptional regulation of PA biosynthetic 
genes on PA levels, we analyzed the content of Put, Spd and Spm levels in 
response to drought. Wild type plants showed a progressive accumulation of Put 
in response to drought conditions, whereas this accumulation was absent in aba2-
3 and abi1 mutants (Fig. 5) [34]. Hence, the ABA-dependent up-regulation in 
ADC2 expression observed under drought conditions leads to an effective Put 
accumulation. An interesting finding from these results was the progressive 
reduction is Spm levels observed during dehydration, which was identified  later 
on as a Put to Spm metabolic canalization coupled to back-conversion which 
serves as reactive oxygen species (ROS) amplification signal [25]. 
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Figure 2. (A) Polyamine (PA)-biosynthetic pathway in Arabidopsis thaliana. (B) 
Relative transcript levels of PA-biosynthetic genes encoding arginine decarboxylase 
(ADC1, ADC2), agmatine iminohydrolase (AIH), N-carbamoylputrescine 
amidohydrolase (CPA), spermidine synthase (SPDS1, SPDS2), spermine synthase 
(SPMS, ACL5), S-adenosylmethionine decarboxylase (SAMDC1, SAMDC2) in wild-
type (wt) plants exposed to water stress after 0, 1, 2, 4, 8 and 24 h of treatment. (C) 
Relative transcript levels of ADC2, (D) SPDS1 and (E) SPMS in wt, aba2-3 and abi1-
1 plants subjected to water stress, and non-stressed wt. These results were published 
by Alcázar et al. [34]. 
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Figure 3. Cis-regulatory elements found in the promoters of PA biosynthetic genes. 
LTR, low temperature response element; DRE, dehydration responsive element; 
ABRE, ABA-responsive element. Picture adapted from Alcázar et al. [7]. 
 
 
 
Figure 4. Scheme of the transcriptional regulation of PA biosynthesis by ABA. 
Drought stress leads to an increase in ABA levels which enhances the expression of 
ABA-responsive ADC2, SPDS1 and SPMS genes. The increase in ADC2 expression 
leads to Put accumulation, whereas increases in the expression of SPDS1 and SPMS 
do not lead to accumulation of Spd or Spm. 
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Figure 5. (A) Levels of putrescine (Put) from different polyamine fractions in wild-
type, (B) aba2-3 and (C) abi1-1 plants exposed to water stress. Leaves from at least 
five plants per point of analysis were sampled after 0, 1, 2, 4, 8 and 24 h of stress 
treatment. Free, insoluble conjugated and soluble conjugated Put levels are referred as 
nmol g−1 dried weight (DW). Total levels of Put are also shown for wild-type plants. 
Values are mean ± standard error of three replicates in each one from three 
independent experiments. Published by Alcázar et al. [34]. 
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2.2. Putrescine to spermine canalization in response to drought in 
A. thaliana and resurrection plants  
 
 A number of drought tolerant species have been used to study the 
molecular basis of desiccation tolerance. Among them, the most well 
characterized example is the South African resurrection plant Craterostigma 
plantagineum.  
 In a recent article by Alcázar et al. [25] we have compared the PA 
profiles and transcriptional responses of A. thaliana wild type plants and 
PA levels of adc1-3, adc2-3, spds1-2, spds2-3 and spms-2 mutants under 
a gradual drought acclimation response to the PA profiles of the 
resurrection plant C. plantagineum exposed to desiccation treatment. This 
is the first report on PA levels in a resurrection plant that provided clue 
on the differential regulation of the PA biosynthetic pathway between 
drought tolerant (C. plantagineum) and drought sensitive (A. thaliana) 
species. 
 In this work, we exposed plants to a progressive drought acclimation 
response by withholding water for 16 days and analyzed PA levels after 0, 
2, 4, 6, 8, 10, 12, 14 and 16 days of treatment. The levels of Put 
accumulated to 1.8-fold after 2 days of treatment in wild type plants, 
which was in agreement with previous observations [34]. Interestingly, 
higher Put accumulation was observed in spds1-2 mutant compared to 
wild type after 2 and 6 days (Fig. 6) [25]. As described in the 
introduction, SPDS1 encodes one of the two SPDS gene paralogs that 
catalyze the conversion of Put to Spd. The accumulation of the precursor 
(Put) in spds1-2 mutant under drought stress indicates that SPDS1 
enzyme is involved in the Put to Spd conversion in response to 
dehydration [25]. Remarkably, peaks for Put accumulation correlate with 
higher ADC2 expression [25]. On the other hand, mutations in SPDS2 in 
the spds2-3 mutant did not lead to evident increases in Put content in 
response to drought compared to wild type plants (Fig. 6) [25]. These 
observations evidence that SPDS1 and not SPDS2 is involved in the 
conversion from Put to Spd under drought stress [25,34]. 
 An interesting finding in this work [25] was the absence of Spd 
accumulation (Fig. 6) even though a Put to Spd conversion was detected and 
mediated by SPDS1, thus suggesting that conversion to higher molecular 
weight polyamines (Spm) or degradation of Spd by PAO activity may 
contribute to Spd homeostasis. Indeed, the expression of deoxyhypusine 
synthase (DHS) followed similar kinetics to SPDS1 and other ABA-inducible 
genes (e.g. RD29A and RD22) [25].  
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Figure 6. Polyamine (PA) profiles under drought stress in PA-biosynthetic mutants 
and wild-type Arabidopsis thaliana plants. Free putrescine, spermidine and spermine 
levels were analyzed in wild-type, adc1–3, adc2–3, spds1–2, spds2–3 and spms-2 
mutants after 0, 2, 4, 6, 10 and 16 days of drought treatment. Values are the mean 
from three biological replicates ±standard deviation (SD). DW, dry weight. Results 
published by Alcázar et al. [25]. 
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 The deoxyhypusine synthase enzyme catalyzes the NAD-dependent 
formation of deoxyhypusine in the eukaryotic translation initiation factor 5A 
(eIF-5A), which requires Spd as substrate [37]. However, whether DHS 
activity significantly contributes to Spd homeostasis requires further analysis. 
 The conversion of Spd to Spm under drought stress was not observable in 
wild type plants (Fig. 6), which instead of accumulating Spm showed a 
progressive reduction is Spm levels [25]. However, loss of function of SPMS, 
involved in the enzymatic conversion of Spd and Spm, lead to evident 
increases in Spd and Put precursor in response to drought [25]. These 
observations were consistent with a Put to Spm canalization in response to 
drought that did not lead to the accumulation of the higher molecular weight 
polyamine Spm. To further determine a possible role of PAO in the oxidative 
deamination of Spm and depletion of Spm pools in response to drought, we 
measured Spm oxidase activity by detection of radiolabelled 1,5-
diazabicyclononane in protein extracts supplemented with [14C] Spm (Figure 
7) [25]. SMO activity was detectable in wild type protein extracts, but did not 
increase in response to the imposed drought conditions [25].  
 These observations indicated that depletion of Spm pools was not due to 
Spm degradation. The reason of why Spm did not accumulate regardless of a 
strong Put to Spm canalization and absence of Spm degradation could 
involve the back-conversion pathway (Fig. 8). In the recent years, PAO 
involved in the back-conversion of Spm to Spd and Put have been 
characterized [5]. In A. thaliana, PAOs AtPAO2 and AtPAO3 are involved in 
the back-conversion of Spm to Put via Spd [10]. Interestingly, the expression 
of these two PAO is induced by ABA [10],  which suggests  a     possible role in 
  
 
  
Figure 7. SMO enzymatic activities under drought. Wild type Arabidopsis plants 
exposed to drought stress were used for the analysis of spermine oxidase (SMO) 
activity at different time points of 24 h drought treatment. Values are the mean from 
three biological replicates ±SD. Results published by Alcázar et al. [25]. 
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drought stress.  Indeed, an increased expression of AtPAO2 in response to 
drought was observed in wild type plants and followed similar expression 
kinetics as ABA-inducible genes RD29A and RD22 [25]. Therefore, our 
results pointed to an active participation of the back-conversion pathway in 
the depletion of Spd and Spm pools during drought stress (Fig. 8). 
 A possible scenario for the contribution of PA back-conversion pathway 
under drought stress is the occurrence of a PA recycling loop that would serve as 
ROS signaling amplification by recurrent generation of hydrogen peroxide. 
Indeed, ROS signaling mediates many abiotic and biotic stress responses and is 
involved in activation of mitogen activated protein (MAP) kinase cascades [38]. 
 In this work [25], we also analyzed the PA levels in response to drought 
in the resurrection plant C. plantagineum. During the course of the 
dehydration treatment, the levels of Spd and Spm in C. plantagineum 
progressively increase up to 3-fold and 8-fold, respectively, during 96 h of 
treatment (Fig. 9)  [25]. Accumulation of Spd and Spm and consumption of 
the Put precursor correlated with enhanced drought tolerance. Hence, it is 
likely that Put to Spm canalization is an evolutionary conserved response 
between species, whereas the capability to accumulate high Spd and Spm 
levels discerns between drought tolerant or intolerant plants. These 
observations open a gate to manipulate PA levels for the development of 
plants with enhanced drought resistance. The modification of PA levels in 
plants can be achieved through transgenic manipulation or by exploitation of 
the natural variation in PA levels already present in nature. 
 
 
 
Figure 8. Polyamine recycling loop. Drought treatment leads to a Put to Spm 
canalization which is coupled with a Spm to Put back-conversion, releasing hydrogen 
peroxide that would serve as amplification of ROS signaling. 
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Figure 9. Free putrescine (Put), spermidine (Spd) and spermine (Spm) levels in 
Craterostigma plantagineum plants exposed to drought stress conditions for 0, 1, 2, 4, 
8, 24, 72 and 96 hours. Values are the mean from three biological replicates ±SD. 
DW, dried weight. Results were published by Alcázar et al. [25]. 
 
2.3. Drought tolerance by genetic engineering of PA levels 
 
 The expression of ADC2 is highly up-regulated in response to drought, 
and translated in an accumulation of Put. To determine a potential role of 
ADC2 in conferring drought tolerance, we transformed A. thaliana plants 
with the homologous ADC2 gene under the constitutive CaMV 35s 
promoter. The different lines analyzed (2.1, 3.6, 7.2) showed contrasting 
degrees of ADC2 expression and Put accumulation [16]. Total Put content 
was between 12- and 2-fold higher than wild type depending on the 
transgenic line (Put content line 2.1 > 3.6 > 7.2 > wild type) [16,39]. These 
lines and wild type were exposed to drought stress conditions by 
withholding watering for 14 days, and their survival rates determined (Fig. 10) 
[39]. The extent of tolerance was scored by counting the number of plants 
that resumed growth after 7 days of recovery after re-watering. 
Interestingly, plants which accumulated higher levels of Put were more 
resistant to drought stress (Fig. 10) [39]. Hence, the line 2.1 which 
accumulated 12-fold more Put showed a survival rate of 75% compared to 
the wild type (12%) (Fig. 9) [39]. The enhanced drought tolerance 
correlated with a reduced stomata aperture and transpiration rate [39]. 
These observations are consistent with a role of PAs in the regulation of 
stomata aperture through modulation of ROS and NO signaling [5]. Our 
observations indicate that enhanced drought tolerance in plants can be 
achieved by manipulation of the PA pathway. 
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Figure 10. Drought resistance phenotypes of 35s ADC2 lines 2.1, 3.6, 7.2 compared 
to wild-type. (A) Phenotype of 4-weeks-old plants dehydrated during 14 days. Wild-
type, 35s ADC2 lines 7.2, 3.6 and 2.1 have increased Put content which correlates 
with enhanced drought tolerance. (B) Survival percentages from 35s ADC2 and wild-
type plants after rehydration. Results were published by Alcázar et al. [39]. 
 
3. Genetics of natural variation for polyamine content 
 
3.1. QTL analyses for PA levels using recombinant inbred line 
populations (RILs) 
 
 In addition to genetic engineering for PA content manipulation, the study 
of natural variation for PA content provides an alternative to the achievement 
of plants with enhanced PA levels and associated stress tolerance. In this 
regard, the study of natural variation for PA content in the model species     
A. thaliana is a good starting point. In the recent months, we have undertaken 
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some experiments to determine the feasibility of cloning QTLs for PA 
content in A. thaliana.  
 A preliminary analysis for PA content at 16ºC was performed using a 
recombinant inbred line (RIL) population of 164 lines derived from the cross 
between the European accession Landsberg erecta (Ler) and the central 
Asian accession Kashmir-2 (Kas-2) [40]. These lines show a high 
transgression in different phenotypes including growth, flowering time and 
pathogen resistance [40]. We measured the Put, Spd and Spm levels after 5 
weeks of growth at 16ºC and analyzed QTLs for Put, Spd and Spm contents.  
QTL detection was performed using the software MapQTL5. We could detect 
QTLs for Put, Spd and Spm which genetically explained significant variation 
of PA levels (Alcázar et al. unpublished results). These analyses evidenced 
that (i) QTLs for PA content are detectable in A. thaliana, (ii) part of the 
phenotypic variation for PA levels can be explained genetically and (iii) the 
mapping of QTLs for Put, Spd and Spm levels should identify novel genes 
contributing to PA homeostasis. 
 The identification of genes and natural alleles contributing to the 
modulation for PA contents may reveal geographical patterns of adaptation 
thus pointing to a close relationship between PA levels and local 
environments. These studies open a new gate to implement PA content 
regulation to breeding programs dedicated to pursue enhanced drought stress 
tolerance. 
 
4. Concluding remarks and future perspectives 
 
 The genetic manipulation of PA levels enhances drought tolerance in 
different plant species. Nowadays, the mechanisms of action by which PAs 
confer enhanced drought resistance are beginning to be unraveled. Evidences 
point to the involvement of ROS signaling, possibly through PA-recycling 
loops involving PA back-conversion, as well as cross-talks with key stress 
hormone ABA. We anticipate that gaining insight into PA functions and 
exploiting natural variation for PA content regulation will provide new 
perspectives for crop protection against environmental change. 
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Abstract. There is an increasing evidence that nutritional genomics 
represents a promise to improve public health. This goal will be 
reached by highlighting the mechanisms through which diet can reduce 
the risk of common polygenic diseases. Nutritional genomics applies 
high throughput functional genomic technologies and molecular tools 
in nutrition research, allowing a more precise and accurate knowledge 
of nutrient-genome interactions in both health and disease. 
Understanding the inter-relationships among genes, genes products, 
and dietary habits is fundamental to identify those who will benefit the 
most or be placed at risk by nutritional interventions. This chapter 
provides an overview of this novel nutritional approach, including the 
most relevant results of our recent research on the nutrigenomic effects 
of food polyphenols on cancer cells. Those studies would highlight the 
molecular mechanisms underlying the chemopreventive effects of 
those bioactive food compounds. 
 
Introduction 
 
 Until recently, nutrition research concentrated on nutrient deficiencies 
and   impairment  of          health.   The   importance  of   diet   to   sustain   health,  
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prevention and treatment of diseases has been known for a long time. The 
advent of genomics –high-throughput technologies for the generation, 
processing, and application of scientific information about the composition 
and functions of genomes – has created unprecedented opportunities for 
increasing our understanding of how nutrients modulate gene and protein 
expression influencing cellular and organismal metabolism and thus, 
ultimately impacting human health and well-being. Notably, the knowledge 
of the human genome has dramatically broadened the scope of studies in 
nutrition science [1-4].  
 Nutritional genomics is a relatively new and very fast-moving field of 
research and combines molecular biology, genetics, and nutrition [3, 5]. It 
provides a genetic understanding for how diet, nutrients or other food 
components affect the balance between health and disease by altering the 
expression and/or structure of an individual’s genetic makeup. The 
conceptual basis for this new branch of genomic research is built on the 
following premises [1,6]: 
 
• Diet and dietary components can alter the risk of disease 
development by modulating multiple processes involved with the 
onset, incidence, progression, and/or severity; 
• Diet and dietary components can act on the human genome, either 
directly or indirectly, to alter the expression of genes and gene 
products. 
• Diet and dietary components could potentially compensate for or 
accentuate effects of genetic polymorphisms. 
 
 The term nutritional genomics is frequently used as an umbrella term for 
two research specialties: nutrigenomics and nutrigenetics. However, it is 
important to note the difference between the terms nutrigenomics and 
nutrigenetics because although these terms are closely related they are not 
interchangeable. Nutrigenomics focuses on the effects of nutrients on genes, 
proteins, and metabolic processes, whereas nutrigenetics involves 
determining the effect of individual genetic variation on the interaction 
between diet and disease [2,7]. Thus, those working in nutrigenomics 
investigate the role of nutrients in gene expression, and those working in 
nutrigenetics determine how genetic polymorphisms (mutations) affect 
responses to nutrients [7,8]. Moreover, when reviewing scientific literature, 
other terms appear, such as epigenetics, transcriptomics, proteomics or 
metabolomics. All of them describe processes, new tools or situations of this 
emerging field of nutrition (Table 1). The key challenge is to determine 
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whether it is possible to utilize this information meaningfully to provide 
reliable and predictable personalized dietary recommendations for specific 
health outcomes. 
 Nutrigenetics and nutrigenomics hold much promise for providing 
better nutritional advice to the general public, genetic subgroups and 
individuals [11]. In the future, the integration of nutrition and genomics 
may lead to the enhanced use of personalized diets to prevent or delay the 
onset of disease and to optimize and maintain human health. The objectives 
of this chapter are to provide an overview of this novel nutritional 
approach. Moreover, we will also include the most relevant results of our 
research on the nutrigenomic effects of food polyphenols on cancer cells. In 
addition to the essential nutrients, such as calcium, zinc, selenium or 
vitamins, there are a variety of classes of nonessential nutrients and 
bioactive components, such as polyphenols, that seem to significantly 
influence health. Those bioactive components are known to modify a 
number of cellular processes associated with health and disease prevention, 
including carcinogen metabolism, hormonal balance, cell signaling, cell 
cycle control, apoptosis, and angiogenesis. Our studies are focused in 
highlighting the molecular mechanisms underlying the chemopreventive 
effects of those bioactive food compounds. 
 
Table 1. Definitions of terms used in nutritional genomics [9,10]. 
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1. Nutrigenetics 
 
 Nutrigenetics focuses on the effects that genetic variations have on 
the binomial diet/disease or on the nutritional requirements and 
recommended intakes for individuals and populations. To achieve its 
objectives, the methodology used in nutrigenetics includes the 
identification and characterization of genetic variants that are associated 
with, or are the responsible for a different response to certain nutrients or 
food components [6,11]. These variations generically designated as 
polymorphisms, including the polymorphisms of a single nucleotide 
(SNP, single-nucleotide polypmorphisms), differences in the number of 
copies, inserts, deletions, duplications and rearrangements or 
reorganizations. Undoubtedly, SNPs are the most frequent as they appear 
every 1,000 base pairs [12]. 
 These differences may determine the susceptibility of an individual to 
have a disease related to diet or to one or some diet components, as well as to 
influence in the individual’s response to diet changes. There is certain 
parallelism between nutrigenetics and phamacogenetics, although in the field 
of nutrition is more difficult to draw conclusions, since there are important 
differences between drugs and food components, such as chemical purity, 
number of therapeutic targets and duration of the exposure, among others    
[3, 9, 11]. 
 One of the best-described examples of the effect of SNPs is the 
relationship between folate and the gene encoding for MTHFR (5,10-
methylenetetrahydrofolate reductase) [13]. MTHFR has a role in supplying 5-
methylenetetrahydrofolate, which is necessary for the re-methylation of 
homocysteine to form methionine. Methionine is essential to many metabolic 
pathways including production of neurotransmitters and regulation of gene 
expression. Folate is essential to the efficient functioning of this MTHFR. 
There is a common polymorphism in the gene for MTHFR that leads to two 
forms of protein: the wild type (C), which functions normally, and the 
thermal-labile version (T), which has a significantly reduced activity. People 
with two copies of the wild-type gene (CC) or one copy of each (CT) appear 
to have normal folate metabolism. Those with two copies of the unstable 
version (TT) and low folate accumulate homocysteine and have less 
methionine, which increases their risk of vascular disease and premature 
cognitive decline [14]. 
 Thus, in people with low folic acid intake, higher serum homocysteine 
levels would be detected in TT homozygotes compared with other genotypes, 
which would lead them to an increased risk of cardiovascular disease (Figure 1). 
However, when the intake of folic acid in diet is higher, this increased 
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amount would compensate the DNA defect in people with the TT 
polymorphism, and homocysteine serum concentrations would not reach such 
high values and consequently not show hyperhomocysteinemia. According to 
this example of gene-diet interaction, a practical application for 
cardiovascular disease prevention would be to recommend a higher daily 
consumption of folic acid-rich food to those people with the TT genotype, 
since these individuals have higher folic acid requirements than the general 
population due to their genetic susceptibility. 
 
 
 
Figure 1. Gene-diet interaction. Folic acid intake may modulate the genetic risk of 
hyperhomocysteinemia conferred by the C677T polymorphism in the MTHFR gene. 
Hyperhomocysteinemia only would happen when the mutation occurs with a low 
folate intake [Adapted from 15]. 
 
 Another of the genes on which a very active research has been developed 
is the one that encodes for the synthesis of the lipoprotein APOA1 [16]. 
APOA1 is the main component of plasmatic HDL and seems to play an 
important role in the transport of cholesterol. It has been reported that a 
polymorphism in the gene promoter the -75 A/G (substitution of guanine by 
adenine), has an influence on the individual’s response to polyunsaturated 
fatty acids (PUFA) intake. Thus, women with the A/A genotype showed 
higher HDL-cholesterol levels in plasma after ingestion of PUFA, whereas 
those with genotypes A/G and G/G (wild type) did not show HDL-cholesterol 
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changes or even a certain decrease in response to the PUFA from diet 
(Figure 2). Therefore, for the individuals with the genotype A/A the ingestion 
of PUFA could be a good diet recommendation since it increases HDL. 
Those results illustrate the complexity of polymorphism-phenotype 
associations and underscore the importance of accounting for interactions 
between genes and environmental factors in population genetic studies. 
 The examples cited here and many others that can be found in the 
literature published until now [10,11,17-20] illustrate perfectly why 
nutrigenetics is also termed personalized nutrition, since its major goal is to 
identify and characterize genes, and nucleotide variants within these, that are 
associated (or account for) the differential responses to nutrients. In addition 
to providing a more rational basis for giving personalized dietary advice, the 
knowledge gained by applying genomic information to nutrition research will 
also improve the quality of evidence used for making population-based 
dietary recommendations. The sequencing of an individual’s genome has 
fueled interest in the field of personalized medicine [21,22], but replicating 
and validating nutrigenetic studies need to remain a priority before 
personalized nutrition can be considered a worthwhile approach to improve 
human health [23]. 
 
 
  
Figure 2. Effect of polyunsaturated fatty acid intake (>4%, 4-8% and >8% of energy) 
on high-density lipoprotein (HDL) cholesterol blood levels in women.  Means were 
adjusted for age, body mass index, alcohol consumption, tobacco smoking, and 
intakes of energy, saturated fatty acids, monounsaturated fatty acids, and PUFAs 
[Adapted from 16]. 
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2. Nutrigenomics 
 
 The term nutrigenomics was coined ten years ago to describe a branch of 
nutrition and food research that applies new profiling techniques for 
transcripts, proteins and metabolites to better understand the interplay of the 
genome with its nutritional environment. In this respect, nutrigenomics is still 
in its infancy and it will need time until it really delivers what was originally 
hoped [3,6,9].  
 The field of nutrigenomics harnesses multiple disciplines and includes 
dietary effects on genome stability (DNA damage at the molecular and 
chromosome level), epigenome alterations (DNA methylation), RNA and 
micro-RNA expression (transcriptomics), protein expression (proteomics) 
and metabolite changes (metabolomics), all of which can be studied 
independently or in an integrated manner [11, 24]. In this approach, nutrients, 
other food components, and even whole diets, are considered as “dietary 
signals” that are detected by “cellular sensors”. These sensors, that are part of 
cellular signaling cascades, can affect, in turn, all the processes involved in 
cell function. Therefore, they influence the transcription, translation and 
protein expression and different metabolic pathways, which ultimately form 
the phenotype [25, 26]. 
 Using the current genomic tools that include transcriptomics, proteomics 
and metabolomics, there are two approaches in nutrigenomic research. The 
first would identify genes, proteins or metabolites that are affected by the diet 
(nutrients or bioactive compounds) and determine which are the mechanisms 
involved in this interaction and, consequently, figure out the regulation 
pathways through which the diet induces these changes. In the second 
approach, early biomarkers are sought (genes, proteins or metabolites) that 
are linked with certain dietary compounds or to the whole diet [1,24]. Those 
biomarkers could act as a “warning signals” about changes in the homeostasis 
with could have implications for the health [10,11,24]. 
 There are numerous examples [9,11,27,28] that illustrate the interaction 
between food components and the genome, from mammalian cells in culture 
to human studies. However, most applications are still of descriptive nature. 
As an example of a typical nutrigenomic approach research, we will explain 
our research which its main goal is to study mechanisms underlying the 
potential chemopreventive effects of a certain type of well-known food 
compounds called polyphenols.  
 Polyphenols are the most abundant antioxidants in the diet. Their main 
dietary sources are fruits and plant-derived beverages such as fruit juices, tea, 
coffee, and red wine. Vegetables, cereals, cocoa, chocolate, and dry legumes 
also contribute to the total polyphenol intake. Their total dietary intake could 
Carlota Oleaga et al. 56
be as high as 1g/d, which is much higher than that of all other classes of 
phytochemicals and known dietary antioxidants [29]. Despite their wide 
distribution in plants, the health effects of dietary polyphenols have come to the 
attention of nutritionists only rather recently. Current evidence strongly 
supports a contribution of polyphenols to the prevention of cardiovascular 
diseases, cancers, and osteoporosis and suggests a role in the prevention of 
neurodegenerative diseases and diabetes mellitus [30]. However, our 
knowledge still appears too limited to formulate recommendations for the 
general population or for particular populations at risk of specific diseases.  
 For many years, polyphenols and other antioxidants were thought to 
protect cell constituents against oxidative damage through scavenging of free 
radicals. However, this concept now appears to be an oversimplified view of 
their mechanism of action [31,32]. More likely, cells respond to polyphenols 
mainly through direct interactions with receptors or enzymes involved in 
signal transduction, which may result in modification of the redox status of 
the cell and may trigger a series of redox-dependent reactions [33]. Both 
antioxidant and prooxidant effects of polyphenols have been described, with 
contrasting effects on the cell’s physiologic processes. As antioxidants, 
polyphenols may improve cell survival; as prooxidants, they may induce 
apoptosis and prevent tumor growth [30, 32]. However, the biological effects 
of polyphenols may extend well beyond the modulation of oxidative stress. 
One of the best-known examples involves the interaction of soy isoflavones 
with estrogen receptors and the effects of these compounds on endocrine 
function. These effects could explain the prevention by isoflavones of bone 
resorption among postmenopausal women [30]. A detailed understanding of 
the molecular events underlying these various biological effects is essential 
for the evaluation of the overall impact on disease risk and progression.  
 
2.1. Coffee polyphenols and breast cancer: A transcriptomics approach 
 
 Coffee is one of the most popular and widely consumed beverages 
throughout the world. Recent meta-analyses demonstrate inverse associations 
between coffee intake and the risk of colon, liver, breast and endometrial 
cancer [34-37]. In prospective population-based cohort studies, the inverse 
association between coffee consumption and risk of cancer has also been 
showed. The group of Naganuma et al. [38] found that the consumption of at 
least one cup of coffee per day was associated with a 49% lower risk of upper 
gastrointestinal cancer in a Japanese population, while Wilson et al. [39] 
found that men who regularly drink coffee appeared to have a lower risk of 
developing a lethal form of prostate cancer. The lower risk was evident when 
consuming either regular or decaffeinated coffee.  
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 It has been proposed that the inverse association between coffee intake 
and colon cancer could be explained, at least in part, by the presence of 
phenolic compounds in coffee [40]. Among the different phenolic 
compounds in coffee, the most abundant are hydroxycinnamic acids, which 
exist mainly in the esterified form. The best example is chlorogenic acid (5-
caffeoylquinic acid). In fact, coffee is the major source of chlorogenic acid in 
the human diet; the daily intake in coffee drinkers ranges from 0.5 to 1 g, 
whereas coffee abstainers will usually ingest <100 mg/day. Studies have 
showed that approximately the 33% of ingested chlorogenic acid and 95% of 
caffeic acid are absorbed intestinally [41]. Thus, about two-thirds of ingested 
chlorogenic acid reaches the colon where it is probably metabolized to caffeic 
acid [42]. Bioavailability data suggest that the biological effects of 
chlorogenic acid would become apparent after its metabolism to caffeic acid, 
and hence studying the effects of this acid is necessary. 
 As mentioned before, there is enough evidence from epidemiological 
data supporting the theory that coffee seems to reduce the risk of certain 
types of cancer; however, the molecular mechanisms underlying the 
chemopreventive effects of coffee remain unknown. Using a transcriptomics 
approach, the effect at the molecular level of the main phenolic compound in 
coffee, caffeic acid, at concentrations equivalent to one cup of coffee on 
human colon cancer cells (HT29) was studied. Furthermore, the effect of 
coffee polyphenols was also evaluated in breast cancer cells. 
 Colon adenocarcinoma HT29 cells were incubated with caffeic acid at a 
concentration equivalent to one cup of coffee for 24 hours. It was previously 
determined that this concentration did not cause any cytotoxic effect in the 
cell incubations. Then, gene expression was analysed by hybridization to the 
GeneChip Human Genome U133A plus 2.0 microarrays from Affymetrix, 
containing 47,000 transcripts and variants. Quantification was carried out 
with GeneSpring GX v.11.5.1 software (Agilent Technologies), which allows 
multi-filter comparisons using data from different experiments to perform the 
normalization, generation of lists and the functional classification of the 
differentially expressed genes. 
 A list of differentially expressed genes by 1.3-fold with a p-value cut-off 
of <0.05 was generated. Upon incubation with caffeic acid, 12 genes were 
overexpressed whereas 32 genes were underexpressed. Among the 
overexpressed genes, 33% belonged to the Transcription factors category, 
25% to Cell cycle, and 17% to Biosynthetic processes or Immune response. 
Within the underexpressed genes, again the category corresponding to Cell 
cycle was the most affected (30% of the genes) followed by Biosynthetic 
processes (15%) and Transcription factors (12%). Using these data, a 
Biological Association Network (BAN) was constructed using the Pathway 
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Analysis within the GeneSpring v.11.5.1, as described in Selga et al. [43]. 
Signal transducer and activator of transcription 5B (STAT5B) and Activating 
transcription factor 2 (ATF-2) appeared as highly interconnected nodes 
(Figure 3). In fact, STAT5B was overexpressed with respect to the control by 
33,4% in cells treated with caffeic acid, whereas ATF-2 was found 
underexpressed in HT29 incubated with caffeic acid (26% decrease compared 
to the control). 
 The changes in mRNA expression of these two main (STAT5B and 
ATF-2) nodes were confirmed by RT-PCR and at protein level by      
Western blot analysis   (Figure 4).     The key function of STAT5B is to  mediate  
  
 
 
Figure 3. Biological Association Network (BAN) of differentially expressed genes 
under caffeic treatment. The BAN was constructed with the Pathway Analysis 
software within GeneSpring v11.5.1. An expanded network was constructed by 
setting an advanced filter that included the categories of binding, expression, 
metabolism, promoter binding, protein modification and regulation. Only proteins are 
represented. The BAN shows the node genes STAT5B and ATF-2 that were further 
studied. 
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Figure 4. Quantification of mRNA and protein levels for STAT5B and ATF-2 in HT29 
cells. The mRNA levels of STATB5 (A) and ATF-2 (B) were determined in control 
HT29 cells (empty bars) and cells treated with caffeic acid (CA, filled bars) by RT-
Real Time. Results are expressed in fold-changes compared to the control, and are the 
mean + SE of 3 different experiments. *p<0.05 compared with the corresponding 
control. The protein levels of STAT5B (C) and ATF-2 (D) were determined in control 
HT29 cells (empty bars) and cells treated with caffeic acid (CA, filled bars) by 
Western blot. Blots were reprobed with an antibody against β-actin or tubulin to 
normalize the results. Results represent the mean ± SE of 3 different experiments. 
*p<0.05 and **p<0.01 compared with the corresponding control. 
 
the effects of the Growth Hormone, as STAT5B-null mice failed to respond 
effectively to this hormone [44]. Modulation of STAT5 levels or transcriptional 
activity has already been described in cells treated with natural compounds 
such as nobiletin, acitrus flavonoid [45] thea flavins [46] and silibinin, a natural 
polyphenolic flavonoid which is a major bioactive component of silymarin 
isolated from Silybum marianum [47]. Activation of STAT5A/B in human 
breast cancer has been shown to positively correlate with the differentiation 
status of the tumour. STAT5 have been also shown to transcriptionally regulate 
E2-sensitive proliferative genes such as cyclin D1 and c-Myc [48] suggesting 
that STAT5 may play a role in E2-stimulated breast cancer growth. STAT5 
activation has also been linked to regulating the expression of the cell cycle 
control protein cyclin D1 both directly and indirectly [48-50]. 
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 On the other hand, ATF-2 is a member of the ATF-cAMP response element-
binding protein (CREB) family of transcription factors that can bind to the cAMP 
response element (CRE) found in many mammalian gene promoters [51]. ATF-2 
exhibits both oncogenic and tumor suppressor functions [52)] CREs are found in 
several genes involved in the control of the cell cycle, e.g., the cyclin D1 gene 
and ATF-2 binding to this sequence stimulates the transcription of cyclin D1 
[53]. ATF-2 has been correlated with proliferation, invasion, migration, and 
resistance to DNA-damaging agents in breast cancer cell lines. 
 Therefore, the two main nodes identified in our work regulate cyclin D1 
transcription. Cyclin D1 is an important regulator of G1-S phase transition, 
and its expression in breast cancer cells is sensitive to estrogens and 
antiestrogens [54]. Cyclin D1 is over expressed at the mRNA and protein 
level in over 50% of the breast cancers either in the presence or absence of 
gene amplification and it is one of the most commonly over expressed 
proteins in breast cancer [55]. In order to know the influence that caffeic acid 
could have overcyclin D1 levels, since the expression of STATB5 and ATF-2 
is modified by this phenolic compound, cyclin D1 levels in MCF-7 cells were 
analyzed upon incubation with caffeic acid by Western Blot. As shown in 
Figure 5, incubation of MCF-7 cells with caffeic acid led to a drastic decrease 
in the levels of cyclin D1 protein, together with an increase in the levels of 
STAT5B, but there was no decrease in the levels of ATF-2.  
 
 
   
Figure 5. Expression of cyclin D1 upon incubation with caffeic acid in MCF-7 cells. 
The protein levels were determined in control MCF-7 cells (CNT) and in cells treated 
with caffeic acid (CA) by Western blot. Blots were reprobed with an antibody against β-
actin to normalize the results. Results represent the mean ± SE of 3 different 
experiments. *p<0.05 and ***p<0.001 compared with the corresponding control. 
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 It is believed that compounds that modulate cyclin D1 expression could 
have a role in the prevention and treatment of human neoplasia. For instance, 
flavopiridol, a synthetic flavonoid based on an extract from an Indian plant 
used for the potential treatment of cancer, induces a rapid decline in cyclin 
D1 steady-state protein levels [54]. Taking all these results together, 
inhibition of cyclin D1 expression appears to be a good approach for cancer 
treatment. In this direction our observation that coffee and caffeic acid are 
able to drastically reduce the expression of cyclin D1 in breast cancer cells 
could suggest that some coffee components could be used as a coadjuvant 
therapeutic tool in the treatment of breast cancer. 
 
2.2. Cocoa polyphenols and changes in the CYP1A1 gene expression 
 
 Cocoa is rich in polyphenols. In fact, cocoa has the highest flavanol 
contents of all foods on a per-weight basis and is a significant contributor to 
the total dietary intake of flavonoids [56]. The main subclasses of flavonoids 
found in cocoa are flavanols, particularly the flavanol monomers catechin and 
epicatechin, and their oligomers, also known as procyanidins [57]. Many 
examples of the health benefits of cocoa consumption can be found in the 
literature [58]. 
 Epidemiologic studies of cocoa intake and cancer risk are few, and those 
assessing overall mortality provide only weak support of the benefits of cocoa. 
However, human intervention trials indicate that cocoa favours intermediary 
factors in cancer progression—specifically, markers of antioxidant status 
[59]. Moreover, there is growing evidence that polyphenols may play a role 
in regulating apoptosis [60]. Apoptosis may be triggered intrinsically, 
through the mitochondrial pathway or extrinsically by death ligands and 
receptors. It is the external pathway that may potentially be modulated by 
bioactive food components. Flavanols found in cocoa have exhibited pro-
apoptotic effects. Proanthocyanadins inhibited growth of human lung cancer 
cells in vitro and in vivo [61], and epicatechin synergistically enhanced 
apoptosis in lung cancer cells treated with epigallocatechin-3-gallate (EGCG) 
[62]. Cocoa polyphenols have also been found to inhibit the mutagenic 
activity of heterocyclic amines in vitro and ex vivo [63]. 
 It has been reported that catechins from green tea could be effective in 
modulating estrogen-induced breast carcinogenesis, either interfering with 
receptor mediated pathways or reducing the production of genotoxic estrogen 
metabolites [64,65]. In our functional genomic study, we sought to evaluate 
the effect of cocoa flavonoids in a type of breast cancer cells (MCF-7), that 
are estrogen-receptor (ER)- dependent [66]. Estrogens are implicated in the 
initiation and promotion stages of breast cancer, and lifetime estrogen 
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exposure is a major risk factor for breast cancer [67]. Estrogens exert their 
carcinogenic effects by both estrogen receptor (ER)-dependent and 
independent mechanisms [68]. Most human breast cancers are initially 
positive for ER, and their growth can be stimulated by estrogens and 
inhibited by antiestrogens such as tamoxifen. 
 For that purpose, MCF-7 cells were incubated for 24h with a purified 
polyphenol cocoa extract (PCE). PCE was used as representative of the wide 
flavonoid spectrum (monomers and oligomers) present in cocoa and the 
concentrations used were not toxic. The differential gene expression analysis 
was done using PCR arrays. In particular, the expression profile of the 84 
genes included in the Stress & Toxicity PathwayFinderTM PCR Array was 
analyzed in MCF-7 cells both control and treated with a PCE. It was 
observed that the exposure to PCE decreased the expression of serpine 1 and 
up-regulated the expression of the CYP1A1, GADD45A, GDF15, GPX1, 
RAD23A, TP53, and XRCC2 genes (Table 2).  
 Among those genes, CYP1A1 was chosen for further validation since: (a) 
it was one of the most overexpressed gene upon incubation with PCE, (b) its 
overexpression in response to polyphenols had already been described, and 
(c) it plays an important role in the oxidative metabolism of estrogens. 
CYP1A1 is a candidate gene for low-penetrance breast cancer susceptibility 
because  it      plays  an  important      role  in  the        metabolism          of  xenobiotics  or 
carcinogens as well as in the oxidative metabolism of estrogens [2004]. 
CYP1A1 encodes  aryl  hydrocarbon       hydroxylase  (AHH)  which  catalyzes  a 
 
Table 2. List of under- and overexpressed genes in MCF-7 cells upon incubation with 
PCE for 24hours1. 
 
 
1The expression of each gene was reported as the fold change obtained after each 
treatment relative to control after normalization of the data. A cut-off of 2-fold was 
chosen since small changes in gene expression may represent important changes 
downstream those differentially expressed genes. Lists of differentially expressed 
genes, with a p-value<0.05, were generated from three independent experiments. 
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hydroxylation reaction in Phase I metabolism as a first step to increase the 
polarity of different molecules. Some of these metabolites can be more active 
than the initial molecules and behave as electrophilic compounds, thus 
initiating or promoting tumorigenic processes. Additionally, other metabolites 
may behave as chemoprotectors, such as the result of 2-hydroxylation in E1 
and E2 metabolism [70]. 
 Therefore, the differential expression of CYP1A1 mRNA in control 
versus treated cells was validated by RT- Real Time PCR (Figure 6A). Next, 
we investigated whether the changes at the RNA level were translated into 
protein. PCE treatment for 24 h led to a very modest increase in CYP1A1 
protein levels (1.2-fold). A time course incubation during 24, 48, 72 and 96 h 
led to an increase in CYP1A1 protein in MCF-7 cells of 3.9-fold after 48 h 
(Figure 6B). The difference between mRNA levels and the corresponding 
protein levels  may indicate that many of          the mRNA  molecules do not  reach  
 
      
 
Figure 6. CYP1A1 overexpression in MCF-7 cells treated with PCE. (A) Determination 
of CYP1A1 mRNA levels. Results are expressed in fold changes compared to MCF-7 
control and are the mean ± SE of 3 different experiments. (B) Determination of CYP1A1 
protein levels. Results represent the mean ± SE of 3 different experiments. Significant 
differences at all time points were evaluated by ANOVA plus post hoc Bonferroni 
comparison. (C) Determination of CYP1A1 activity in MCF-7 treated cells. Results are 
expressed relative to the activity of the control and represent the mean ± SE of 3 
different experiments. Significant differences at all time points were evaluated by 
ANOVA, plus post hoc Bonferroni comparison. 
Carlota Oleaga et al. 64
the translational machinery, probably because the translation mechanism is 
saturated in these conditions. Finally, CYP1A1 activity was determined upon 
incubation with PCE. An increase in CYP1A1 activity in good correlation 
with the observed increased in CYP1A1 protein levels was determined for 
both cell lines (Figure 6C). 
 The changes in CYP1A1 expression upon incubation with PCE could 
explain the antioxidant effect of flavonoids at the molecular level since this 
gene is involved in different oxidative pathways. Additionally, CYP1A1 
overexpression might interfere with estrogen metabolism and the production 
of estrogen metabolites in breast cells. The increase in CYP1A1 activity may 
shift estrogen metabolism toward the production of 2-OHE2 (2-
hydroxyoestradiol), a relatively non-genotoxic metabolite [71]. 
 Finally, we wanted to test whether cocoa polyphenols would exert a 
synergistic effect in combination with Tamofixen (TAM) since it has been 
previously described in breast cancer cells. Thus, MCF-7 cells were 
incubated with increasing concentrations of TAM (10-6–10-3M) either alone 
or in combination with PCE (250 ng/µL). Then, cell viability was determined 
after 48 h. The presence of PCE, which did not cause significant cell death by 
itself, increased the cytotoxic effect of TAM in MCF-7 cells (Figure 7).  
 
 
 
Figure 7. Effect of tamoxifen plus PCE on MCF-7 viability. Tamoxifen (TAM) either 
alone (filled squares) or in combination with PCE (250 ng/µL for 24H, empty circles). 
Results are expressed as % of living cells compared to the control only with DMSO 
(0.22%) and represent the mean ± SE of 3 different experiments. ***p<0.001. 
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 The reduction in cell viability reached an increase of 44% when combined 
with 10-6M TAM. Thus, in our conditions, the cytotoxic effect of TAM was 
enhanced by the combination with PCE in MCF-7 cells. The presence of PCE 
caused a synergistic effect, confirmed by the Chou-Talay method,  which led to a 
decrease in cell viability of up to 40% in MCF-7 cells at tamoxifen 
concentrations that did not affect cell viability by themselves. A plausible 
explanation of the synergistic effect observed could be that the increase in 
estrogen metabolism, induced by the PCE on CYP1A1, could lead to the 
reduction in the levels of estrogens in mammary tumours, thus contributing to the 
cytotoxic effect of tamoxifen. Nevertheless, further in vivo studies are necessary 
to analyse the synergism between tamoxifen and cocoa and to establish the 
possible benefits of cocoa polyphenol consumption during breast cancer therapy. 
 
3. Conclusions 
 
 Current global trends in food consumption may have an impact on 
disease progressions observed worldwide. The impact may occur because of 
gene regulation caused by nutrients, or by other unclear means that are yet to 
be discovered. The “omics” and associated technology will surely provide a 
greater understanding of the environmental and behavioral factors that 
influence phenotype and its relationship to health and wellness. It is highly 
likely that during the next decade the nutritional supplement and functional 
food industries will experience robust growth in response to advances in 
nutritional genomics research and its applications.  
 Parallel to this growth will be impressive progress in understanding the 
specific influence of certain food components on metabolic pathways and their 
role in health and disease. It will become increasingly less expensive to generate 
genetic information about individual persons, and such data are likely to redefine 
the current concept of preventive medicine. Moreover, through nutrigenomic 
research, new nutritional regulation of gene expression will hopefully come to 
light. If specific gene regulation by nutrients is identified in genes closely related 
to disease onset and progression, new arenas for disease prevention and potential 
for treatment will come to the foreground of nutrition and preventive medicine. 
Discoveries made in the field of nutrigenomics and nutrigenetics should translate 
into more effective dietary strategies to improve overall health by identifying 
unique targets for prevention. 
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Abstract. Although bacteremic pneumococcal pneumonia is the 
most severe form of pneumonia, non-bacteremic forms are much 
more frequent. Laboratory methods for the diagnosis of non-
bacteremic pneumococcal pneumonia have a low sensitivity and 
specificity, and therefore all-cause pneumonia has been proposed 
as a suitable outcome to evaluate vaccination effectiveness.  
      This work reviews the epidemiology  of  community-acquired 
pneumonia (CAP) and evaluates the effectiveness of the 23-valent 
pneumococcal polysaccharide vaccine (PPV-23) in preventing 
CAP requiring hospitalization in people aged ≥65 years.  
      We performed a case-control study in patients aged ≥65 years 
admitted through the emergency department who presented with 
clinical signs and symptoms compatible with pneumonia. We 
included 489 cases and 1,467 controls and it was obtained a 
vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that 
PPV-23 vaccination is effective and reduces hospital admissions 
due to pneumonia in the elderly, strengthening the rationale for 
vaccination programmes in this age group. 
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Introduction 
 
 Pneumonia is an inflammation of the lung parenchyma located below the 
terminal bronchioles (respiratory bronchioles, alveolar ducts, alveolar sacs 
and alveoli) that leads to impaired gas exchange. The inflammatory reaction 
causes water density in chest X-rays, the hallmark of pulmonary 
consolidation. Pneumonia acquired outside the hospital is known as 
community-acquired pneumonia (CAP), in contrast to nosocomial 
pneumonia, which is acquired after 48 hours of admission to the hospital  or 
the first week after discharge [1].  
 Pneumonia together with influenza is the seventh leading cause of death 
in the United States of America (USA) with a high estimated monthly 
mortality rate of 19.4/100,000 inhabitants [2]. 
 On the basis of a study it was estimated roughly 915,900 cases of CAP 
could occur annually among seniors in the USA and that approximately 1 of 
every 20 persons aged ≥85 years could have a new episode of CAP each year 
[3]. Other studies estimated a number of cases of CAP requiring 
hospitalization in USA of 485,000 patients annually, and 43,000 of these 
persons died [4]. 
 Currently, an etiologic diagnosis is achieved in between 29 and 60% of 
cases of CAP requiring hospital admission, depending on the number of 
samples and techniques used [5-16]. In some studies, the rate exceeds 70%   
[17-19], although the percentage of etiologic diagnoses may be significantly 
lower in hospitals without systematic diagnostic protocols or when patients 
have received prior antibiotic treatment, with some studies finding rates of 
14% [20]  (Tables 1 and  2). 
 CAP is caused by a wide variety of bacterial species, including, in order 
of frequency, Streptococcus pneumoniae, Haemophilus influenzae, 
Chlamydophila pneumoniae, Mycoplasma pneumoniae, Staphylococcus 
aureus, Legionella pneumophila and some enterobacteria [22]. Viral 
infections result in 10-25% of CAP, but the relative frequency of the different 
microorganisms varies according to factors such as age, underlying disease 
and the diagnostic methods used [23].  
 Various studies suggest that between 30 and 50% of cases of CAP 
requiring hospitalization are caused by S. pneumoniae  [6, 8, 24, 25]. 
 Some authors have suggested that the number of cases caused by S. 
pneumoniae is underestimated. A Spanish study found that many patients 
hospitalized with CAP in whom no etiologic diagnosis is obtained using 
routine techniques are diagnosed with pneumococcal pneumonia when more-
sensitive detection techniques are used and samples are obtained by non-
routine procedures such as transthoracic puncture [18, 26].   Ruiz-González et al.  
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Table 1. Percentage of etiologic diagnostic in several studies about CAP in Spain. 
 
 
N=number of CAP studied. 
*Percentage obtained after tests on samples of lung tissue. 
 
found that 33% of cases of pneumonia labelled as of unknown etiology using 
standard methods (blood culture, sputum culture and serology) were finally 
diagnosed as pneumococcal pneumonia after tests on samples of lung tissue 
obtained by transthoracic puncture [18].  
 Studies show that the incidence of CAP varies according to several 
factors: the country where the study is carried out, the age groups included, 
whether the study includes all patients with CAP or only those requiring 
hospitalization, and sex [27, 28].  
 In Spain, the incidence of CAP in adults ranges between 2 and 10 cases 
per 1,000 persons/year, and from 2.3 to 35 per 1,000 persons/year in people 
aged ≥70 years [21, 27, 29, 30]. The incidence of CAP is always greater in 
the elderly and persons with underlying diseases, which, together with the 
ensuing mortality, is a concern for health authorities [25].  Tables 3 and 4 
show figures of incidence in diferents studies in Spain and other countries.  
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Table 2. Percentage of etiologic diagnostic in several studies about CAP in other 
countries. 
 
 
   N=number of CAP studied. 
 
Table 3. Incidence of CAP in Spain. 
 
 
*cases/1000 persons/year. **cases/1000 persons/year in specific groups: age (years) and 
gender. M: men; W: women 
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Table 4. Incidence of CAP in other countries. 
 
 
*cases/1000 persons/year. **cases/1000 persons/year in specific groups: age (years) and 
gender. M: men; W: women 
 
 Although the criteria for hospitalization are not homogeneous, it is 
estimated that between 12 and 50% of patients with pneumonia require 
hospital admission [30-32, 36]. The figures increase with age and can reach 
between 67% and 75% in cases of CAP in people aged ≥65 years [29, 34], 
although some studies have reported figures of 73.2% for all ages [28].  
 The case-fatality rate of CAP is related to the severity of the disease and 
is lower in series that include patients treated as outpatients [27, 28, 31, 33, 
34, 37] in which the rate is ≤5%, with some studies finding no fatalities [21, 
32] (Table 5). 
 The case-fatality rate is higher in patients requiring hospitalization. In 
Spain, several series have reported a rate of around 7% in patients of all ages 
hospitalized for pneumonia [28, 38] with age-related increases being 
observed. 
 The case-fatality rate is much higher in cases of CAP requiring intensive 
care unit admission [37, 39], with a mean of 36.5% [37] and a range of 20-
53% according to the study [40]. 
 Taken together, these data show that the incidence and case-fatality rate of 
CAP are high and, therefore, strategies aimed at their reduction should be sought. 
 The 23-valent pneumococcal polysaccharide vaccine (PPV-23) has been 
available in the USA for 25 years and is currently available in most 
developed countries.  
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Table 5. Hospitalization and case-fatality rate in CAP. 
 
 
N=number of CAP studied. 
 
 The effectiveness of the 13-valent polysaccharide vaccine, the forerunner 
of the current PPV-23 was demonstrated in randomized controlled trials in 
young adults in the 1970s [41-43]. 
 Since 1984, vaccination has been recommended for persons aged ≥65 
years and people aged ≥2 years with risk factors [25, 44, 45]. 
 The current consensus is that observational studies have shown that the 
PPV-23 is effective in preventing invasive pneumococcal disease [42, 46, 
47]. However, vaccination coverages are not high in some countries due to 
doubts about the effectiveness of the PPV-23 in preventing non-bacteremic 
pneumococcal pneumonia [42, 46, 47].  
 Although bacteremic pneumococcal pneumonia is the most severe form, 
non-bacteremic forms are much more frequent [25], with only 10-20% of cases 
of pneumococcal pneumonia in adults being bacteremic. Since laboratory 
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methods for the diagnosis of bacteremic pneumococcal pneumonia have a low 
sensitivity and specificity, all-cause pneumonia has been proposed as a suitable 
outcome to evaluate the effectiveness of vaccination [42]. If a significant 
proportion of cases of CAP admitted to hospital are of pneumococcal origin, 
and vaccination is effective against bacteremic and non-bacteremic forms, this 
should result in a reduction in hospitalizations for all-cause CAP. 
 In 1999, various Spanish regions introduced PPV-23 vaccination for 
patients aged ≥65 years into the vaccination schedule [45], in accordance 
with international recommendations [44]. 
 Vaccine coverage in some regions reached 35% in 2001, and 40% 
thereafter [48]. This coverage and the large number of hospitalizations for 
CAP in Spain made it possible to establish the objective of this study: To 
evaluate the effectiveness of PPV-23 in preventing cases of CAP requiring 
hospitalization in people aged ≥65 years. 
 
1. Methods    
 
Study design   
 
 A matched case-control study in patients with CAP admitted to five 
hospitals in three Spanish regions between 1 May 2005 to 31 January 2007 
was carried out [49].  
 A case was defined as a person aged ≥65 years admitted to hospital 
through the emergency department who presented with an infiltrate on chest 
X-ray compatible with pneumonia and one or more of the following 
symptoms or signs of acute lower respiratory tract infection: cough, pleuritic 
chest pain, fever >38ºC, hypothermia <35ºC or dyspnea within the past 24 
hours [25, 50].   Exclusion criteria were institutionalized patients, patients 
with nosocomial pneumonia (onset ≥2 days after hospital admission), patients 
whose initial diagnosis of pneumonia was not confirmed during the hospital 
stay and cases of CAP in whom the pneumococcal and influenza vaccination 
status could not be determined 
 Three hospital controls were selected for each case. Controls were 
admitted through the emergency department with a diagnosis other than 
pneumonia, selected from the admission lists of each participating hospital. 
On selection, the vaccination status of controls was not known and, if the 
status could not be determined later, they were excluded. 
 For each case and control  information on age, sex, dates of 
hospitalization and discharge (alive or dead), history of pneumonia, visit to 
the doctor in the past year, smoking, risk-consumption of alcohol and the 
presence or absence of underlying conditions was obtained. The 
pneumococcal and influenza vaccination status was also collected. 
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 Each case was classified according to the level of risk and the degree of 
immunosuppression associated with the underlying disease: Stratum I (high 
risk) included all patients with conditions associated with 
immunocompromise, stratum II (moderate risk) included immunocompetent 
patients with one or more high-risk medical conditions and stratum III 
included patients not included in strata I or II (Table 6). 
 Each case was matched with three control subjects by sex, age (+/- 5 years), 
date of hospitalization (+/-30 days) and underlying disease and/or stratum. 
 Patient information was obtained through two sources: a) Review of 
written hospital medical records (underlying diseases, alcohol consumption, 
and history of pneumonia and vaccination status) and b) Interview of the 
patient or  close  relatives  (spouse      or     offspring) for visits  to the doctor in the 
past year,  alcohol consumption  and vaccination        status using a  questionnaire 
 
Table 6. Distribution of cases and controls by stratum. 
 
 
*COPD: Chronic obstructive pulmonary disease. 
** AIDS: Acquired immunodeficiency syndrome. 
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completed by qualified staff. Vaccination status was also obtained from the 
vaccination card and health care centre vaccination registers. 
 The vaccination status was ascertained by staff blinded as to whether the 
patient was a case or control. 
 Patients were considered vaccinated when the vaccine had been given ≥15 
days before the onset of pneumonia for cases or ≥15 days before the date of 
hospitalization for controls.  The same criteria were used to determine prior 
influenza vaccination (IV) status. 
 We calculated the minimum required sample size according to 
Schlesselman criteria [51]. 
 We assumed a prevalence of vaccination in the control group of 0.35 [52] 
and vaccine effectiveness (VE) against all-cause pneumonia of 35 %. With an 
alpha error of 0.05 (two-tailed), a beta error of 0.20 and three controls per case, 
we calculated that 269 cases and 807 controls would be needed. Because 
vaccination coverage was estimated to be lower in some of the participating 
regions, we increased the number of cases to 405 and controls to 1,215.  The 
study was approved by the ethic committee of each hospital. 
 
Statistical Analysis 
 
 The differences observed between cases and controls according to the study 
variables were analysed using paired tests. The McNemar chi square test or 
binomial distribution test, when appropriate, was used for categorical variables 
and the paired t-test for continuous variables. A two-tailed distribution for all p 
values and considered p<0.05 to be statistically significant was assumed.  
 Conditional logistic regression (CLR) to account for the effects of 
confounding variables was used. The variables introduced in the CLR 
analysis were influenza vaccine status, variables potentially related to the 
vaccination response and those with a p value <0.1 in the univariate analysis. 
In the final analysis, variables with a significance of p<0.05 were included in 
the model. Adjusted odds ratios (ORs) for immunosuppressed (stratum I) and 
immunocompetent patients (stratum II and III) separately and for all three 
strata combined were calculated. 
 VE was estimated using the formula VE = (1-OR) x 100. 
 The statistical analysis was performed using the SPSS v15.0 statistical 
program.  
 
2. Results  
 
  489 cases and 1,467 controls were included in the analysis; of 489 sets: 
200 (41%) in stratum I, 190 (39%) in stratum II and 99 (20%) in stratum III. 
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 The distribution of study variables was similar in the two groups, 
although more cases than controls had had a previous episode of pneumonia 
[119 (25.3%) vs 192 (13.7); p<0.001]. The only significant differences in the 
distribution of underlying diseases between cases and the three controls were 
in the proportions with solid organ neoplasia [51 (10.4%) in cases vs 304 
(20.7%) in controls; p<0.001], hematologic neoplasia [43 (8.8%) vs 53 
(3.6%); p<0.001],  chronic obstructive pulmonary disease (COPD) [180 
(36.8%) vs 442 (30.1%); p=0.006]; diabetes mellitus [108 (22.1%)  vs 393 
(26.8%); p=0.04] and corticosteroid therapy [24 (4.9%) vs 37 (2.5%); 
p=0.009] showed significant differences between cases and controls.  
 Of 489 sets, 200 were immunosuppressed and 289 immunocompetent.  
 
Vaccination effectiveness  
  
 The unadjusted and adjusted VE according to immune status are shown 
in Table 7. The overall adjusted VE for all three strata combined was 23.6% 
(95% CI: 0.9 to 41.0). For overall VE the significant variables included finally 
in the model were history of pneumonia, solid organ neoplasia, hematologic 
neoplasia, chronic obstructive pulmonary disease and diabetes mellitus.  
  
Table 7. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in 
preventing hospitalization for pneumonia [49]. 
 
 
Data are presented as n, n(%) or % unless otherwise stated.  
OR: Odds ratio. VE: vaccination effectiveness. CI: confidence interval  
*Strata II and III combined. 
#For overall effectiveness, we adjusted for history of pneumonia, solid organ neoplasia, 
hematologic neoplasia, chronic obstructive pulmonary disease and diabetes mellitus.   
For immunosuppressed patients, we adjusted for history of pneumonia, solid organ 
neoplasia, hematologic neoplasia, and chronic obstructive pulmonary disease.  
For immunocompetent patients, we adjusted for history of pneumonia, diabetes mellitus and 
tobacco use. 
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 The adjusted VE for immunosuppressed cases was 21.0% (95% CI: -18.7 
to 47.5). For immunosuppressed patients, the significant variables included in 
the model were history of pneumonia, solid organ neoplasia, hematologic 
neoplasia, and chronic obstructive pulmonary disease. 
 When strata II and III were combined into one group of 
immunocompetent patients, the adjusted VE was 23.6% (95% CI: -7.2 to 
45.6). For immunocompetent patients, the significant variables included in 
the model were a history of pneumonia, diabetes mellitus and smoking. 
 
3. Discussion of results 
 
 We studied the effectiveness of the PPV-23 in preventing CAP requiring 
hospitalization and found an effectiveness of 23.6% (95% CI: 0.9% to 41.0%). 
 Before a vaccine is licensed, its clinical efficacy is evaluated in 
randomized clinical trials [52]. Once licensed for general use, the vaccination 
effectiveness can be assessed in observational studies, which are necessary 
when clinical trials have not provided conclusive results or have not been 
made in the population group for which the vaccine is recommended. 
 The 13-valent pneumococcal polysaccharide vaccine, the forerunner of 
the PPV-23 was evaluated in randomized clinical trials including young adult 
South-African miners [41], and the results encouraged research on its 
effectiveness in the population groups for which it was recommended: people 
aged ≥65 years and those with underlying disease of risk. The results of 
clinical trials in these groups were mostly inconclusive [53-57], suggesting 
that people susceptible to infection may not have an adequate immune 
response to the pneumococcal vaccine evaluated. 
 However, Fedson et al. showed that these studies did not have a sample size 
large enough to obtain conclusive results [42], and pointed out that the outcomes 
assessed in these studies were not always the correct ones. They recommended 
that two outcomes should be assessed in evaluations of the effectiveness of the 
PPV-23: invasive pneumococcal disease (pneumococcal bacteremia) or all-cause 
pneumonia, while other outcomes that have been studied, such as pneumococcal 
pneumonia, lower respiratory tract infections, pneumonia-related deaths and all-
cause mortality not being acceptable [42]. This approach is based on the lack of 
diagnostic methods with sufficient sensitivity and specificity to correctly identify 
non-bacteremic pneumococcal pneumonia. 
 The current consensus is that observational studies have demonstrated 
the effectiveness of the PPV-23 in preventing invasive pneumococcal disease 
[42, 46, 47]. However, vaccination coverages in some countries are not high, 
partly due to doubts about the efficacy of the PPV-23 and its effectiveness in 
preventing non-bacteremic pneumococcal pneumonia [42, 46, 47, 58]. 
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 Our results show that the effectiveness of the PPV-23 in preventing 
hospitalization for pneumonia was 23.6% (95% CI: 0.9% to 41.0%).  
 Although the evidence is limited, some observational studies have shown 
some protective effect of the PPV-23 against hospitalization for CAP (Table 
8). Nichol et al.  [59, 60] and Wagner et al. [61] found that vaccination 
reduced hospital admissions due to all-cause CAP, and reduced the all-cause 
pneumonia case-fatality rate. Nichol et al. carried out a retrospective cohort 
study [59] which included 1,898 patients aged ≥65 years with COPD, and 
found that patients vaccinated with PPV-23 had a lower associated risk of 
hospitalization for CAP [relative risk (RR)= 0.57 (95% CI: 0.38 to 0.84)] and 
a lower risk of death from all causes [RR=0.71 (95% CI: 0.56 to 0.91)]. 
Wagner et al. [61] performed a case-control study of 1,077 residents in a 
geriatric hospital and found a significant reduction in the risk of pneumonia 
in people who received the PPV-23 [OR = 0.28, p <0.001] and a significant 
reduction in the risk of death from all causes [OR = 0.27, p <0.001] and death 
due to pneumonia [OR = 0.33, p <0.001]. Vila-Córcoles et al. [62]  in a 
prospective cohort study of 11,241 subjects, confirmed the protection 
obtained by vaccination with PPV-23 against hospitalization for all-cause 
pneumonia [HR: 0.74 (95% CI: 0.59 to 0.92)] and against death from 
pneumonia [HR: 0.41 (95% CI: 0.23 to 0.72)]. 
 However, Jackson et al. [63] in a retrospective cohort study of 47,365 
people aged ≥65 years between 1998 and 2001, found no reduction in 
hospitalizations due to all-cause CAP [VE= -14% (95% CI:  -28% to -2%)] 
despite finding a significant reduction in pneumococcal bacteremia [VE= 
54% (95% CI: 13% to 76%)] and all-cause mortality [VE= 12% (95% CI: 5% 
to 17%)] in the 38,207 immunocompetent patients. 
 Likewise, neither Ansaldi et al. [64] or Skull et al. [65] found a 
reduction in hospitalizations due to CAP in patients vaccinated with the 
PPV-23. Ansaldi et al. [64] retrospectively studied 9,170 subjects of all 
ages (85.4% aged ≥64 years) for a period of 547,139 person-months, of 
which 71.7% were before and 28.3% after vaccination. They found that, 
in unvaccinated patients, the risk of hospitalization for asthma or otitis 
media was significantly higher, but that although risk of hospitalization 
for pneumonia was somewhat higher in people not vaccinated with PPV-
23 (8.8 % in unvaccinated versus 7.8% in vaccinated subjects), the 
differences were not statistically significant [RR=1.12 (95% CI:0.91       
to 1.38)].  
 Skull et al. [65] evaluated the effectiveness of the PPV-23 in preventing 
hospitalization for CAP in a case-cohort study of patients with a mean age of 
78.4 years, but did not find that vaccination provided any benefits [RR= 0.99 
(95% CI: 0.82 to 1.19]. 
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 In our study, the effectiveness of PPV-23 in preventing hospitalization 
for pneumonia [23.6% (95% CI: 0.9% to 41.0%)] was close to that found by 
Vila-Córcoles et al. [26% (95% CI: 8% to 41%)] [62] and Nichol et al. [27% 
(CI: 95% -13% to 52%)], although in the latter study, the results were not 
statistically significant [60]. The VE in our study was lower than that found 
by Wagner et al. (72.1%) [61]. 
 
Table 8. Observational studies about PPV-23 effectiveness. 
 
 
*Chronic obstructive pulmonary disease. 
 
 A recently published meta-analysis of randomized clinical studies in 
older people failed to demonstrate protection of PPV-23 vaccination against 
all- cause pneumonia [66].  The study evaluated the efficacy of the PPV-23 in 
the prevention of certain clinical outcomes, including all-cause pneumonia. It 
also assessed the methodological quality of the trials analyzed. This meta-
analysis included 22 trials of which the current PPV-23 was only evaluated in 
8. Prevention of all-cause pneumonia was investigated in 19 trials, reducing 
to 11 who were studied in elderly patients or with chronic lung disease. The 
meta-analysis results for these 11 trials showed a  RR = 0.89 (95% CI: 0.69 to 
1.14), but these trials did not specify in which assessed the PPV-23, (and only 
in 8 of the 22 trials analyzed was the PPV-23 used in the study). According to 
information provided, it appears that only 5 of the 11 evaluated the PPV-23. 
Conchita Izquierdo et al. 82
 A 2008 systematic Cochrane review [67] of English-language studies 
evaluating the efficacy and effectiveness of the PPV-23 included 15 
randomized trials and 7 observational studies. The observational studies 
provided evidence of protection against invasive pneumococcal disease in 
populations where the PPV-23 is usually used [OR= 0.48 (95% CI: 0.37 to 
0.61)]. The meta-analysis of the clinical trials also showed the PPV-23 
provided protection against invasive pneumococcal disease [OR= 0.26 (95% 
CI: 0.15 to 0.46)]. The effectiveness of the PPV-23 against all-cause 
pneumonia was not proven because, although the OR was significant [OR = 
0.71 (95% CI: 0.52 to 0.97)] with a VE of 29% [95% CI: 3% to 48%], the 
meta-analysis had substantial statistical heterogeneity. The PPV-23 was 
associated with a not significant reduction in all-cause mortality [OR = 0.87 
(95% CI: 0.69 to 1.10)]. 
 Our study found an effectiveness of the PPV-23 in preventing 
hospitalization for all-cause CAP of 23.6%. It is estimated that only 30-50% 
of cases of CAP are due to S. pneumoniae [25] and therefore the 
effectiveness of the PPV-23 against pneumococcal pneumonia (bacteremic 
and non-bacteremic) would be expected to be higher. In the study by Austrian 
et al. [41] carried out in South African miners with the 13-valent 
pneumococcal polysaccharide vaccine, the VE was 82% against bacteremic 
pneumococcal pneumonia and 78.5% against pneumococcal pneumonia 
(diagnosed by sputum and blood cultures). Observational studies have shown 
that the PPV-23 prevents 50-70% of cases of invasive pneumococcal disease 
(due to all serotypes)  [25, 42]. If 30-50% of all cases of CAP in our 
population are caused by S. pneumoniae, our findings suggest that if the level 
of protection against all-cause CAP was 23.6%, the level of protection 
against pneumococcal pneumonia would be near the level of protection (50-
70%) found in observational studies of invasive pneumococcal disease [46]. 
 Our study, like other observational studies, has strengths and limitations. 
One strength was the size of the sample (489 cases and 1,467 controls), 
which yielded statistically significant results for the overall study population. 
The adjusted overall VE was 23.6% (95% CI: 0.9% to 41.0%). The lack of 
statistical significance in immunocompetent patients may be due to a sample 
size that was not sufficient to study the effectiveness of groups according to 
the immune status. 
 In case-control studies of vaccination there is always a possibility of bias 
that distorts the results and reduces the validity of the findings [68]. One 
source of bias is the assessment of vaccination status in patients. However, in 
our study, information on the vaccination status was obtained retrospectively 
by investigators who were unaware of whether the patient was a case or a 
control, using the records of the same primary care centres for cases and 
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controls, and therefore this point is moot. Moreover, the vaccination status 
was investigated in all primary care centres to which the patient was assigned 
since the PPV-23 was introduced in the vaccination programme (2000). 
 To control for confounding variables, controls were matched with cases 
by date of hospitalization, age, sex and underlying diseases that could 
influence the disease incidence. Even so, statistically significant differences 
between cases and controls were observed for some variables: history of 
pneumonia, solid organ malignancy, hematologic malignancy, corticosteroid 
treatment, diabetes mellitus and COPD. The explanation is that pairing was 
carried out taking into account the disease with greater immunosuppression 
or the longest evolution, but many patients had more than one disease. To 
avoid the possible confounding effect of these variables, we adjusted the 
results using conditional logistic regression. Influenza vaccination could have 
a confounding effect when assessing the protective effect of the vaccine. 
However, we believe that this possibility was minimized as the variable was 
always introduced into the conditional logistic regression analysis.  
 
4. Conclusion 
 
 The incidence of CAP is always greater in the elderly and persons with 
underlying diseases, and between 30 and 50% of cases of CAP requiring 
hospitalization are caused by S. pneumoniae. Therefore the reduction of 
pneumonia-related morbidity partially will depend on the improved use of 
preventive strategies such as immunization against S. pneumoniae.  
 In our study, the overall effectiveness of the PPV-23 in preventing 
hospitalization for pneumonia is estimated at 23.6% (95% CI: 0.9% to 
41.0%). Current recommendations on PPV-23 vaccination are based on 
studies of vaccine effectiveness against invasive pneumococcal disease. Our 
results suggest that the PPV-23 is effective and reduces hospital admissions 
due to pneumonia in the elderly, thereby reinforcing the application of 
vaccination programmes in this age group. 
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Abstract. Green chemistry plays a very important role in the 
sustainable development, seeking to reduce and prevent pollution 
at its source, minimizing the hazard and maximizing the efficiency 
of the chemical processes. Ionic liquids (ILs) are a new generation 
of chemicals that have a great potential for contributing to the 
greenness of chemical processes and developing new applications, 
both being of interest for the pharmaceutical industry. This work 
deals with the development of ILs as greener alternatives for some 
of the processes within the frame of green chemistry. It focuses on 
the environmental impact of the ILs, their ecotoxicity and potential 
biodegradability, compiling results of different ecotoxicological 
studies. ILs have the reputation of being “green” chemicals, but not 
all of them can pass favourably the tests evaluating their 
environmental effects. 
 
Introduction 
 
 Green chemistry can be defined as the design of chemical products and 
processes that reduce or eliminate the use and generation of hazardous 
substances,   along           with   the   minimization   of   waste   production.   Green      
 
Correspondence/Reprint request: Brezana Peric, Laboratori d’Edafologia, Facultat de Farmàcia  Universitat de 
Barcelona. Avda. Joan XXIII, s/n. 08028 Barcelona, Spain. E-mail: brezana@hotmail.com 
Brezana Peric et al.  90
chemistry can be applied across the life cycle of a chemical product, 
including its design, manufacture, and use. Chemical and pharmaceutical 
industries are among the main sources of pollution and hazardous waste 
generation, but they are also responsible for the prevention of any potential 
danger to the environment.  
 P.T. Anastas and J. C. Warner are considered to be the promoters of 
green chemistry. In their book “Green Chemistry Theory and Practice” 
published in 1998 [1], they formulated the 12 basic principles of green 
chemistry. The main ideas underlying the principles are to use less chemicals 
and energy, more secure raw materials, solvents and processes, to achieve 
energy efficient processes, to minimize waste production and reduce 
derivatization steps. Green chemistry promotes the use of safe, environment-
benign substances, including solvents, whenever possible, the control of 
waste in real time and the increase of the amount of raw material present in 
the final product. 
 Most of the processes that involve the use of chemicals have the potential 
to cause a negative impact on the environment. For this reason it is essential 
to eliminate or at least reduce the involved risk to an acceptable level. The 
simplest form to express the risk is by multiplying hazard and exposure. The 
traditional way to minimize the risk of chemical processes has been to limit 
exposure by controlling the so-called circumstantial factors, such as the use, 
handling, treatment and disposal of chemicals. In contrast, green chemistry 
seeks to minimize risk by minimizing hazard. It means that the green 
chemistry shifts control from circumstantial to intrinsic factors, such as the 
design or selection of chemicals with reduced toxicity and of reaction 
pathways that eliminate by-products or ensure that they are benign. Green 
chemistry has become a major component of the science and of the 
sustainable development in general. Academic interest in green chemistry 
involves worldwide research aimed at cleaner processing and it has increased 
significantly in the past few decades. 
 
1. Green chemistry metrics and pharmaceutical industry 
 
 A key question is how one can judge whether new processes do indeed 
have a reduced environmental impact. A series of green chemistry metrics of 
different categories (mass, energy, safety, ecotoxicity, etc.) can be used in 
order to evaluate the efficiency and potential environmental impact of the 
chemical processes [2]. The first one formulated was the Sheldon’s 
Environmental factor (E-factor) [3]. It represents the weight of waste per unit 
weight of product and has been widely used by chemists. This metric is very 
simple to understand and use. It emphasizes the waste produced in the 
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process, instead of in a reaction, thus helping those who try to fulfill one of 
the twelve principles of green chemistry, namely, to avoid waste production. 
The E-factor incorporates yield, stoichiometry and solvent utilization and can 
be used to assess multi-step reactions (step by step or in one calculation).  
 Another green chemistry metric used is Atom Economy (AE) which 
gives an idea of how much of the reactants remain in the final product [4, 5]. 
It is expressed by the ratio (percentage) between the molecular weight of the 
final product and the molecular weights of the reactants. Its drawback is that, 
for example, catalysts and solvents are ignored, as they are not incorporated 
into the final product. AE is focused on the molecular weights and not on the 
mass or stoichiometric yield.  
 Glaxo Smithkline (GSK) developed two other metrics [6] one of them 
being carbon efficiency, which can be calculated by the percentage of total 
carbon amount in the product compared to that in the reactants. The other one 
is the reaction mass efficiency, which compares the mass of the final product 
with the mass of the reactants (in percentage). It takes into account atom 
economy, the amount of product obtained in a chemical reaction and 
stoichiometry. Like carbon efficiency, this measure shows the “greenness” of 
a reaction but not of a process. They do not take into account the global 
amount of waste produced. These two metrics could describe a process as 
“very green”, but they would not be taking into account any of the solvents 
used, nor the energy issues. 
 Another metric is Process Mass Intensity (PMI) [7] that is defined as the 
ratio between total mass of materials used and mass of product. PMI is 
similar to the E-factor and it is easy to calculate. It includes all materials used 
in the synthesis of 1 kg of product (e.g. reagents, solvents, water, etc) not 
only the waste, as it happens in the E-factor. It is important to take into 
account that in the life cycle analysis of a pharmaceutical process the waste’s 
contribution is much lower than all the materials used in the process. The 
pharmaceutical industry, through the American Chemical Society Green 
Chemistry Institute Pharmaceutical Roundtable, has selected PMI as the key 
mass-based green metric to know the greenness of processes and uses it to 
obtain greater efficiency and innovation in the pharmaceutical and fine 
chemicals industries. 
 The EcoScale is a recently developed metric tool for evaluation of the 
effectiveness of a synthesis reaction [8]. It is characterized by its simplicity 
and general applicability. The EcoScale evaluates the quality of the organic 
preparation based on yield, cost, safety, conditions and ease of 
workup/purification. It uses a scale from 0 to 100 with 100 representing the 
ideal reaction (100% yield and minimal risk for the operator and 
environmental impact). The EcoScale score is then calculated by lowering the 
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maximum value of 100 by any applicable penalty points, which take into 
account both the advantages and disadvantages of specific reagents, set-ups 
and technologies. By calculating the EcoScale score, a quick assessment of 
the "greenness" of reaction protocol is obtained, and the areas that need 
further attention are clearly indicated, which finally can lead to the 
improvement of reaction conditions. The considered penalty points and its 
quantification are described by Van Aken et al. [8].  
 Among all the mentioned metrics, E-factor or PMI seem to be the most 
adequate to evaluate the “greenness” in the pharmaceutical industry, because 
they include solvents, catalysts, reaction media and any other substance 
involved in the processes. E-factor is useful in highlighting the fine chemicals 
and pharmaceutical industries (Table 1) as the areas in which green chemistry 
is likely to have its most immediate impact.  
 It is important to emphasize that these green chemistry metrics are an 
oversimplification and do not allow to know some environmentally 
important properties, such as the toxicity, the biodegradability, the 
bioaccumulation and the fate of the chemicals used. However, these 
factors are often used by chemical and pharmaceutical industries because 
they are easy to use and provide information that allows the comparison 
between different processes.   
 The pharmaceutical industry's constant drive to lower the spending is 
helping to speed up the adoption of green chemistry because it can also offer 
significant cost advantages. The savings involve more efficient syntheses that 
avoid exotic reagents, minimizing energy use, replacing organic solvents, etc. 
Many pharmaceutical companies are finding innovative ways to reduce their 
impact on the environment during drug manufacturing. Pfizer [9] is applying 
the principles of green chemistry in the production of Viagra®, Lyrica®, 
Lipitor®  and      Vfend®.  For example,  in the process of synthesis of Viagra®,  
 
Table 1. Environmental impact as measured by the E-factor [3]. 
 
Industry    Product tons        per year 
               E-factor  
    (waste/product ratio  
            by weight) 
Oil refining 106 - 108 ~ 0.1 
Bulk chemicals 104 - 106 < 1-5 
Fine chemicals 102 - 103 5-50 
Pharmaceuticals 100 - 103 25->100 
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the number and  quantity of solvents    involved has been reduced [10].  
The Eli Lilly Company has redesigned the synthesis of one anticonvulsive 
drug, LY300164. Aventis has developed a new synthesis of 
hydrocortisone using microorganisms. BHC Company (BASF 
Corporation) developed an improved efficient method to make ibuprofen 
using only three steps instead of the former six. In this case, all starting 
materials are converted to product, reclaimed as by-product or completely 
recycled in the process. Thus, the generation of wastes has been 
practically eliminated [11]. 
 All of these examples can be cited as industry models of environmental 
excellence in chemical processing technology and are implementing the basic 
principles of green chemistry. 
 
2. Ionic liquids: Properties and applications 
 
 In the pharmaceutical industry, organic solvents are a major source of 
waste because they are used as reaction media or in separation operations and 
their efficient control can produce a substantial improvement in the 
environmental impact of a process [2]. The best way to avoid problems with 
solvents is not to use them, an approach that has been widely exploited in the 
paints and coatings industries. Most reactions do, however, require a solvent, 
and a green chemical process must necessarily involve solvents that are 
environmentally acceptable. One of the new classes of solvents that offer 
opportunities to move away from traditional chemical processes to new, 
clean, green technologies are the ionic liquids [12]. BASF designed a new 
process for scavenging acids in the chemical synthesis of phosphorus 
compounds using ionic liquids: BasilTM (Biphasic Acid Scavenging Utilizing 
Ionic Liquids), which offers significant advantages over the conventional 
system. This is the first large-scale industrial process worldwide that uses 
ionic liquids, and their developers received the "Innovation Award" of the 
"European Chemical News" trade journal and the BASF Innovation Award in 
October 2004.  
 An ionic liquid (IL) is generally defined as a salt in which the ions are 
poorly coordinated, with a melting point below 100 °C [13]. Some ILs can be 
liquid even at room temperature [14] and then they are called room 
temperature ionic liquids (RTILs). Most of the ILs used up to date have a 
bulky organic cation (imidazoliuma, pyridiniumb, pyrrolidiniumc, 
piperidiniumd, ammoniume, phosphoniumf, etc.), substituted with alkyl chains 
of different length (from C1 to C22) and inorganic anions such as halogen 
(Cl¯, Br¯, I¯), [N(CN)2]¯, [BF4]¯, [PF6]¯, etc. (Fig. 1). New ionic liquids, with 
linear aliphatic anions are currently being developed [15]. 
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Figure 1. Principal ions present in most ILs. 
 
 Ionic liquids (ILs) are not newly discovered compounds, they have been 
known for almost a century. The first documented observation of ionic 
liquids by chemists was the so-called ‘red oil’ formed during Friedel–Crafts 
reactions in the mid-nineteenth century. The structure of the red oil was later 
identified by NMR as a stable intermediate composed of a carbocation and a 
tetrachloroaluminate anion [16, 17]. The earliest example of a room 
temperature ionic liquid was ethylammonium nitrate (EtNH3+[NO3]¯) with a 
melting point of 12 ºC. It was described by Paul Walden in 1914 and 
obtained by the neutralization of ethylamine with concentrated nitric acid. 
One of the first 1,3-dialkylimidazolium RTILs was reported in the early 
1980s by Wilkes and co-workers. It was obtained through the mixing of 1-
ethyl-3-methylimidazolium chloride with aluminum trichloride [16]. Organo-
aluminate ILs have a limited range of applications due to the high reactivity 
of the chloroaluminate anion towards water [18]. In the early 1990s, Wilkes 
reported two new ILs such as 1-butyl-3-methylimidazolium tetrafluoroborate 
and 1-butyl-3-methylimidazolium hexafluorophosphate [16]. The cation 1-
ethyl-3-methylimidazolium has been the most widely studied until 2001, and 
nowadays, 1,3-dialkylimidazolium salts are one of the most popularly used 
and investigated class of ILs [19]. Research into synthesis and possible 
applications of new ILs is growing in exponential form. The 20 papers 
published in 1994 have become more than 2,500 in 2008 [20]. 
 The physicochemical properties of the ILs, like all other materials, 
depend upon the intermolecular and intramolecular forces and, subsequently, 
upon the structure of the cation and the anion. A significant number of 
investigations have been conducted for ILs on the relationship between their 
physicochemical properties and the structure of their cation and anion. [21-
24]. In general, ILs have a negligible vapor pressure so they are not volatile 
and no atmospheric pollution can be expected due to their use. ILs are also 
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thermally stable so they can be used in chemical processes that require heat 
input. These and other characteristics (Table 2) such as nonflammability 
make them useful for many applications, and make that they meet up to the 
criteria of green chemistry.  
 There are literally millions of different structures that may be formed by 
combining different cations and anions and the number of possible 
combinations is estimated to be as high as 1018 [28, 29]. This enormous 
quantity of possible ILs would permit, based on physicochemical 
characteristics, to select the most appropriate for a particular purpose. In 
particular, RTILs are often called “designer solvents” because it is possible to 
create an IL with a required property. RTILs have been used for several other 
applications, and their development continues at a considerable rate owing to 
their peculiar physical and chemical properties such as high thermal and 
chemical stability, lack of inflammability, low volatility, and tunable 
solubility in several organic compounds [30]. Due to their low volatility, 
many of the RTILs have been used as greener alternatives to conventional 
toxic and volatile organic solvents by taking advantage of their unique 
properties [31]. This set of properties allows the design of very attractive 
reaction systems that can solve some of the main drawbacks of currently used 
methods of synthesis or to obtain new procedures for making various 
products [32, 33]. Polarity, hydrophilicity/hydrophobicity and other 
properties of ILs can be adjusted by an appropriate combination of cations 
and anions [34].  
 As the unique properties of the ILs were being discovered, there was a 
rising interest in applying them as a reaction medium in a wide variety of 
chemical transformations that until recently could only be carried out in 
organic solvents. The literature describes numerous uses of ILs, some of them 
being:       reaction  media for many  organic transformations [35],  in separations 
 
Table 2. Some physico-chemical characteristics of ionic liquids [25-27]. 
 
Decomposition point 150 – 500 ºC 
Dielectric constant Implied ≤ 30 
Electrical conductivity at 25 ºC < 0.6 S m-1 (maximum value 11.9) 
Flammability Non-flammables 
Melting point < 100ºC (maximum value 239 ºC) 
Temperature range liquid phase From  - 96 to 300 ºC 
Thermal conductivity 0.117 – 0.199 W/m/K 
Vapor pressure Negligible 
Viscosity Usually  0.013 – 0.22 Pa.s  (maximum value 1.02) 
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and extractions [36], as electrolytes for electrochemistry [37], in 
nanotechnology [38], in biotechnology [39], and in engineering processes 
[40], absorption of gases (CO2) [13], as catalysts in organic synthesis [41], 
aldol condensation [42] and organometallic and radical polymerization [43]. 
Other authors have described ILs specific applications for extraction of active 
ingredients from medicinal plants [44-46]. Some of the ILs applications are 
presented in Fig. 2.  
 The great number of potential ionic liquids and the possible applications 
makes their classification a very difficult task because different criteria can 
be used (physical, chemical or structural characteristics, industrial 
applications, etc.). So, according to the chemical properties, ILs can be 
divided into protic (PILs) and aprotic (AILs). The distinguishing feature 
between both is that all PILs have a proton available for hydrogen bonding 
[47], whereas AILs have not.  
 However, for some authors, the most useful way of grouping them is 
based on the properties that have conditioned the evolution of their use. 
According to Hough et al. [48] the first generation includes ILs for which the 
accessible physical properties such as decreased vapor pressure and high 
thermal stability are often unique. Second generation ILs have potential use 
as functional materials (energetic materials, lubricants, metal ion complexing 
agents, etc.) which utilize novel tunable physical and chemical property sets. 
The third and most recent generation of ILs involves biological properties 
combined with chosen physical and chemical properties. This third 
generation of ILs with biological properties may be a breakthrough for the 
pharmaceutical  industry  because it    opens up many  possibilities  to  generate  
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Figure 2. Possible applications of ionic liquids [51]. 
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active pharmaceutical ingredients (APIs) in the form of ionic liquids         
(IL-APIs). Most of APIs are crystalline salts that present some problems 
related to dissolution, transport, bioavailability and polymorphism control, 
which can reduce the pharmacological activity [49, 50].  A possible way to 
overcome the drawbacks of a drug with an ionic active group is to change the 
complementary ion for another one able to bring IL physico-chemical 
properties to the new substance and thus modify its initial pharmacokinetic 
properties. 
 The design of IL-APIs with dual biological activity is a step beyond drug 
development. This can be achieved by the combination of a cation and an 
anion (both being APIs) to generate an IL that maintain the pharmacological 
activities of each drug while improving their pharmacokinetic properties [50, 
52]. Hough et al. [48] have synthesized dual IL-APIs, like ranitidine docusate 
and didecyldimethylammonium ibuprofenate from ranitidine hydrochloride 
(histamine H2-receptor antagonist) and sodium docusate (emollient), and 
didecyldimethylammonium bromide (antibacterial) and sodium ibuprofenate 
(anti-inflammatory), respectively. The same authors have described 
synergistic effects in the case of lidocainium docusate, an IL-API prepared by 
the combination of an analgesic (lidocaine hydrochloride) and an emolient 
(sodium docusate). Bica et al. [53] have paired salycilate and acetyl salycilate 
with a set of cations with variable biological activity covering analgesic, local 
anesthetic, antiarrhythmic, antimicrobial or antibacterial activity to obtain 
dual functional liquids salts. However although such ILs with aspirin could 
be prepared, they suffer from limited stability and slowly decompose into the 
corresponding salycilate ILs when exposed to moisture. 
 Recently, MEDRx Co. Ltd. (a Japanese pharmaceuticals company) and 
IL Pharma Inc. (a subsidiary of MEDRx Co., Ltd.) are developing Etodolac 
Patch (MRX-7EAT) for treatment of pain and inflammation using ILTS® 
(Ionic Liquid Transdermal System). MRX-7EAT is a pharmaceutical topical 
patch containing etodolac, a non-steroidal anti-inflammatory drug [54]. The 
oral etodolac products have been widely known and used to relieve pain and 
inflammation. However, MRX-7EAT will be the first topical etodolac patch 
in the world. The results of non-clinical studies in some animals have shown 
the safety and efficacy of MRX-7EAT, and the results of clinical trials in 
human have also shown the safety and tolerability. 
 On the other hand, some considerations should be taken into account 
when trying to bring new substances to market. The current  legislation on 
chemicals in  the European Union [55] called Registration, Evaluation, 
Authorization, and Restriction of Chemical Substances (REACH) regulates 
the safety of chemical products, their manufacturing, toxicity, 
biodegradability, transport and use in the industrial sectors. Even though ILs 
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have potentially “green” profile, they are basically chemical products, and as 
such, have to fulfill the REACH criteria, taking into account their possible 
commercial use. In this sense, a very important aspect that has to be studied 
in sufficient depth is the potential negative impact of ILs, both on the 
environment and humans. The findings for the toxicity of ILs must comply 
with the requests of the REACH.  
 
3. Ecotoxicity of ionic liquids 
 
 Even though the ILs are considered as non-volatile and thus cannot 
contribute to the air pollution, the water solubility of many ionic liquids is not 
negligible. The potential release of ionic liquids into aquatic and terrestrial 
environment may lead to water and soil pollution, and related risks.  So, it is 
important to evaluate ecotoxicity, biodegradability, bioaccumulation and 
environmental fate of these chemicals. Taking into account the possible use 
and commercialization of ILs, they should pass the REACH evaluation, 
which recommends that the tests used for the assessment of the potential 
toxicity of chemicals have to be done in accordance with OECD guidelines. 
These tests can be divided into three groups: effects on biotic systems, health 
effects, and degradation and accumulation. 
 There is a wide range of OECD tests that can be implemented in order to 
assess the potential ecotoxicity of ILs on biotic systems. Some of the most 
frequently used up to date are:  Freshwater Alga and Cyanobacteria, Growth 
Inhibition Test [56], Daphnia sp. Acute Immobilisation Test [57], Daphnia 
magna Reproduction Test [58], Lemna sp. Growth Inhibition Test [59], 
Earthworm Acute Toxicity Tests [60], Terrestrial Plant Test: Seedling 
Emergence and Seedling Growth Test [61], Soil Microorganisms: Nitrogen 
Transformation Test [62], Soil Microorganisms: Carbon Transformation Test 
[63], Collembolan Reproduction Test in Soil [64]. There are other non OECD 
methods that are also commonly used to evaluate the ecotoxicity on aquatic 
organisms: Bioluminiscence inhibition assay in Vibrio fischeri [65], snails 
[66], and zebra mussel [67]. 
 Several properties of ionic liquids and their effects on aquatic organisms 
have been investigated in different works. Toxicological research studies 
concerning ionic liquids have been undertaken in the past decade and some of 
these findings will be summarized below. 
 Green algae are ecologically relevant organisms that are at the base of the 
food chain. The algal test has an advantage over tests done with e. g. fish or 
invertebrates because it measures a population-level response. Algae have 
short life cycle which makes them ideal for toxicological studies, as they can 
respond quickly to environmental change [68]. Cho and co-workers [69] have 
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found that the toxicity of 1-butyl-3-methylimidazolium, 1-butyl-3-
methylpyridinium, 1-butyl-1-methylpyrrolidinium, tetrabutylammonium and 
tetrabutylphosphonium bromides was between two and four orders of 
magnitude greater than those of the organic solvents examined (methanol, 
dimethylformamide and 2-propanol). This group was investigating other 
series of imidazolium based ILs and the conclusion was that the toxicity of 
ILs increased with the increase in side chain length [70]. Other authors [71] 
indicate that ILs derived from imidazolium present an acute toxicity to 
Daphnia magna higher than benzene and some organochlorine solvents (tri- 
and tetra-chloromethane). Latała et al. [72] have examined the effect of 
imidazolium based ILs on other species of Baltic algae (Oocystis submarina 
and Cyclotella meneghiniana). They found that the response of the two 
species differed dramatically being Oocystis submarina more resistant to the 
toxicity of ILs than the other one, and that the toxicity was reduced in more 
saline waters. Matzke et al. [73] investigated the effect of imidazolium based 
ILs with C4 and C8 side chains on Scenedesmus vacuolatus species. Their 
findings confirmed other authors conclusions, i.e. that the toxicity strongly 
depends on the side chain effect. 
 Ecotoxicological literature on ILs toxicity to invertebrates mainly focuses 
on the use of Daphnia magna as a test organism because it is an important 
link between microbial and higher trophic levels. The results of all studies 
noted the link between toxicity and alkyl chain length of the tested ILs 
containing   imidazolium,  pyridinium   or  quaternary  ammonium  as       cations  
 
   
 
Figure 3. Morphology of Pseudokirchneriella subcapitata (photo from National 
Institute for Environmental Studies of Japan) [74] and growth algae inhibition curves 
showing the ecotoxicity of 100 mgL-1 of 1-butyl-3-methyl imidazolium (blue and 
yellow lines) in comparison with a control (red and green lines). Unpublished results 
from the authors. 
Particle diameter (μm) 
LC = 2.055 μm  UC = 8.106 μm [15650]
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[71,75-78]. Similar results were obtained in other studies on the snail 
Physa acuta with imidazolium and pyridinium based ILs [79] and also on 
Dreissena polymorpha (zebra mussel) [80]. In these tests a positive 
relationship between alkyl chain length and toxicity of ILs was also 
demonstrated, as well as the lower sensitiveness of Physa acuta than 
Daphnia magna to ILs. 
 Zebrafish (Danio rerio) plays an important role in ecotoxicology as an 
important model vertebrate. Concerning toxicity of ILs to the zebrafish, Pretti 
et al. [81] evaluated the toxicity of commonly used (imidazolium and 
pyridinium ILs) and new AMMOENG® ILs (quaternary ammonium 
derivates). The results of this study revealed that ILs may cause a completely 
different effect on fish than expected according to their chemical structures. 
Imidazolium, pyridinium and pyrrolidinium could be regarded as non-highly 
lethal towards zebrafish. On the other hand, some ammonium salts showed 
LC50 remarkably lower than that of organic solvents and tertiary amines. 
They also demonstrated that fish species are less sensitive to ILs toxicity 
compared to other species belonging to lower trophic levels. 
 The duckweed, Lemna minor, is a common aquatic plant that has been 
frequently a focus of the investigation of phytotoxicity of ILs [73, 82-84]. In 
general, 1-alkyl-3-methylimidazolium compounds with longer alkyl chains 
were more toxic to Lemna minor than those with short alkyl chain lengths. 
Imidazolium and pyridinium cations with butyl groups had similar EC50 (the 
concentrations that produced a 50% reduction in root growth) while the 
equivalent ammonium cation had a much higher EC50 and thus proved to be 
less toxic.  
 Microtox® is a standardised toxicity test system which is based on the 
reduction of the bioluminescence of the marine bacteria Vibrio fischeri when 
exposed to a range of concentrations of the tested chemical. This is a rapid, 
sensitive, reproducible, ecologically relevant and cost effective test. It is 
recognised and used throughout the world as a standard test for aquatic 
toxicity testing. Docherty and Kulpa [85] investigated the toxicity of 
imidazolium and pyridinium ILs and found that the hydrophobicity, which 
corresponds to the increasing alkyl chain length of the IL cation induces 
rising toxicity. These findings are consistent with those from other authors 
[73, 86]. Couling and co-workers [75] have expanded the range of 
investigated ILs and noted that the quaternary ammonium compounds were 
less toxic than the imidazolium and pyridinium analogues. In comparison to 
some commonly used industrial solvents such as phenol, toluene and 
benzene, long chain (> C4) ILs are more toxic. The values of EC50 for the 
most frequently used organic solvents for the Microtox® test are presented in 
the Table 3.  
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Table 3. Acute toxicity of organic solvents to Vibrio fischeri [87]. 
 
Solvent log EC50 (µM) 
Methanol 3.50 
Acetonitrile 2.77 
Acetone 2.52 
Benzene 2.03 
Phenol 1.49 
 
 Generally speaking, all of the aquatic toxicity tests showed that the head 
group (cationic part of the molecule) was responsible for the toxicity of the ILs. 
In most cases there was no influence of the anionic part of the ILs molecule to the 
toxicity. Only the anion bis[(trifluoromethyl)sulfonyl]imide [(CF3SO2)2N]¯  
showed higher toxicity than others. The side chains on the head groups were 
proven to have a very strong influence on the toxicity. The longer and more 
branched the side chain is, the more toxic is the ionic liquid. Most toxic ionic 
liquids have an alkyl chain with more than eight carbons. These results point to 
the fact that some ILs may be more toxic than the commonly used organic 
solvents, and not as green as expected. 
 In Table 4 the toxicity of ILs to different levels of biological complexity 
is presented.  
 
Table 4. Toxicity of different ILs expressed as logEC50 (µM): 1-butyl-3-
methylimidazolium (C4mim), 1-hexyl-3-methylimidazolium (C6mim), 1-octyl-3-
methylimidazolium (C8mim), 1-butylpyridinium (C4py), 1-butyl-3-methylpyridinium 
(C4mpy), 1-butyl-3-methylpyrrolidinium (C4mpyr),  1-butyl -3-methylpiperidinium 
(C4mpip). N.A. non available. 
  
Ionic liquid Vibrio fischeri P. subcapitata Lemna 
 minor 
Daphnia 
magna 
[C4mim]Cl 2.95 [85] 2.34 [73] 2.82 [73] 1.93 [75] 
[C4mim]Br 3.07 [86] 3.46  [88] N.A. 1.57 [75] 
[C4mim][BF4] 3.55 [86] N.A. 2.49 [82] 1.68 [75] 
[C4mim][PF6] 3.07 [89] 2.20 [78] N.A. 1.85 [75] 
[C6mim]Br 1.42 [75] 2.57  [70] N.A. 0.78 [75] 
[C6mim][BF4] 3.18 [86] N.A. N.A. N.A. 
[C8mim]Cl 1.19 [89] 1.46 [78] N.A N.A 
[C8mim][BF4] 1.41 [86] N.A. N.A N.A 
[C4py]Cl 3.18 [84] N.A. 2.32 [84] N.A. 
[C4mpy]Br 2.12 [85] 3.46 [88]  N.A. 1.76 [75] 
[C4mpyr]Cl >4.30 [84] 3.67 [88] N.A. N.A. 
[C4mpip]Br 4.27 [84] 3.27 [84] 0.47 [84] N.A. 
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  Peric et al. (unpublished results) have studied the toxic effect on aquatic 
organisms of a new family of water soluble PILs which are composed of 
ammonium substituted organic salts. The cationic moiety is mono-, di- or tri- 
hydroxiethylammonium while the anionic moiety is an alkylcarboxylate      
(≤ C5). The results show no toxicity to aquatic organisms, with EC50 values 
being between 460 and 2600 mg L-1 for the tests of aquatic toxicity 
(Microtox® test and green algae growth inhibition test). According to the EU 
regulation [90] they have no toxic effects on aquatic organisms (all of the 
EC50 are above the limit value of 100 mg L-1). Within this group of PILs the 
toxicity increases with the increase of complexity of the molecule. 
Comparing the EC50 values obtained for the aprotic ILs it can be seen that the 
new PILs are less toxic than the AILs studied up to date.  
 Studies on the effects of the ILs on soil and sediment organisms are very 
limited or still missing so far. Terrestrial organisms such as the spring tail 
Folsomia candida, a soil invertebrate [73], the earthworm Eisenia foetida 
[91] or Caenorhabditis elegans (a soil roundworm) [92] have been tested. In 
this last case, the authors suggest the use of Caenorhabditis elegans as a 
model organism for inexpensively and quickly exploring toxicological effects 
of 1-alkyl-3-methylimidazolium chloride ILs.  
 Concerning higher plants, Matzke et al. [73] investigated the toxicity of 
ILs derived from imidazolium with different anions to wheat (Triticum 
aestivum) and cress (Lepidium sativum). The side chain effect was once again 
confirmed, with slightly diverse patterns of toxicity depending on the anion 
used. Matzke et al. [93] investigated the influence of different clay minerals 
and clay concentrations on the toxicity of the anionic moieties of 
imidazolium based ILs towards wheat plants. The obtained data showed that 
1-butyl-3-methylimidazolium bis[(trifluoromethyl)sulfonyl]imide appeared to 
be the most toxic, independently of the type of clay added to a reference soil. 
The toxicity of different ILs with the same cationic moiety (1-butyl-3-
methylimidazolium chloride, tetrafluoroborate and hydrogen sulfate) was 
mainly dependent on the cation and the observed effects varied according to 
the added clay type and clay concentration to the reference soil. An increase 
of smectite clay content resulted in less inhibitory effects of these ILs. 
Studzinska and Buszewski [94] have proved that hazardous effects of 
imidazolium ILs are closely connected with organic matter content in soil. 
Soil with more organic carbon was observed to sorb IL cations more 
extensively than soil with little or no organic matter; hence, the more fertile 
the soil, the lower probability of hazardous effect of ILs to plants.  
 Wang and co-workers [95] conducted a study on the effect of 1-butyl-3-
methylimidazolium tetrafluoroborate on wheat seedlings. The increase of this 
IL concentration in soil showed a significant negative effect both on 
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germination and roots and shoot length of the wheat plants. At low 
concentrations, 1-butyl-3-methylimidazolium tetrafluoroborate did not 
inhibit, and even promoted wheat seedling growth. At high concentrations, 
this IL inhibited wheat seedling growth significantly and decreased 
chlorophyll content, thereby reducing photosynthesis and plant growth. In 
another research, the phytotoxicity  tests of chiral ILs  containing (-)-nopyl 
derivatives were carried out in a plant house using spring barley (Hordeum 
vulgare) which is a monocotyledonous plant, and a common radish 
(Raphanus sativus L. subvar. radicula Pers.) which is a dicotyledonous plant 
[96]. According to the obtained results, increasing the concentration of ILs 
resulted in a systematic decrease in the crop fresh weight of total sprouts and 
the crop fresh weight per plant, both for spring barley and for common 
radish. It could also be noted that barley was more resistant than the radish 
and tolerated higher concentrations of ILs in soil. 
 A study conducted by Peric et al. [97] evaluated the toxicity of three 
protic ionic liquids: hydroxyethylammonium formate, 
dihydroxyethylammonium propionate and trihydroxyethylammonium 
pentanoate to terrestrial organisms by performing different bioassays with 
plants (onion, grass, and radish) and soil microorganisms involved in the 
most important biogeochemical cycles (carbon and nitrogen mineralization). 
The PILs analyzed in the study showed no toxicity, with EC50s above 1000 
mg kg-1 in all assays except for Raphanus sativus plant test with 
trihydroxyethylammonium pentanoate (EC50 = 826 mg kg-1) (Fig. 4). Within 
the group of terrestrial organisms, the higher plants (the three plant species 
tested) have shown to be more sensitive to the presence of PILs than the soil 
microbiota, with Raphanus sativus being the most sensitive to the presence of 
PILs. From the results it can be deduced that, in general, the compounds with 
more complex molecular structure have a greater tendency to cause inhibition 
in the organisms tested than the compounds with the smaller molecule and 
simpler structure.  The three analyzed        PILs seem to be non toxic in the  terms  
 
 
 
Figure 4. Effect of trihydroxyethylammonium pentanoate on germination and growth 
of Raphanus sativus plants [97]. 
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of chronic toxicity for plants and C and N cycles. Comparing the results from 
this test with those obtained by other authors for the group of aprotic 
imidazolium based ionic liquids [73, 95, 98], it was observed that the 
analyzed PILs are less toxic than the AILs. Even though the plant species 
used in the test were not the same as those used by other authors, the values 
of EC50 for the AILs were generally one order of magnitude lower than EC50 
for the tested PILs. 
 Although the investigation of the phytotoxicity of ILs and their effect on 
soil has not been intensive, the available data can give a boost for the 
environmental scientists to start dealing more with the potential impact of ILs 
towards plants and soil.  
 
4. Biodegradability of ionic liquids 
 
 Some methods for the determination of biodegradability in water and soil 
are described in the Section 3 (Degradation and accumulation) of the OECD 
guidelines for the testing of chemicals. The most widely used, that permit the 
screening of chemicals for ready biodegradability in an aerobic aqueous 
medium, are included in the Test No. 301: Ready Biodegradability [99]. The 
methods are: the dissolved organic carbon (DOC) Die-Away test, the CO2 
Evolution test (Modified Sturm Test), the MITI (Ministry of International 
Trade and Industry, Japan) test, the Closed Bottle test, the Modified OECD 
Screening Test and the Manometric Respirometry Test. One of the most 
frequently used parameters for the assessment of biodegradation in aqueous 
medium is biodegradation percentage, which represents the ratio beetwen the 
biological oxygen demand (BOD) and the Theoretical Oxygen Demand 
(ThOD) calculated from the chemical formula of the compound. The pass 
level for ready biodegradability is 60% of ThOD for respirometric methods, 
reached within 28 days. Compounds reaching or exceeding the pass level 
after more than 28 days (the usual duration of the tests) are not to be 
considered as readily biodegradable. The biodegradability in soil can be 
assessed by means of the test No. 307 Aerobic and anaerobic transformation 
in soil [100] and it is also expressed as the biodegradation percentage. Other 
methods as test No. 217, Soil microorganisms: carbon transformation test 
[63] and ASTM D 5988-96 have been used by different authors to evaluate 
indirectly the biodegradation process [101]. 
 The biodegradation potential of ILs in aqueous media has been addressed 
in some works. Wells and Coombe [78] investigated the biodegradability of 
ammonium, imidazolium, phosphonium and pyridinium compounds by 
measuring BOD. They observed that the cations with short side chains (C4) 
were not biodegradable. A strong inhibitory potential to the inoculum used in 
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the test was observed for series with longer side chains (C12, C16 and C18), 
indicating the toxicity of these ILs towards the microorganisms used. 
Docherty and co-workers [102] examined the biodegradability of                
N-methylimidazolium and 3-methylpyridinium compounds substituted with 
butyl, hexyl and octyl side chains and bromide as the anion. A dependency 
between biodegradability and the side chain length was found in the DOC 
Die-Away tests and in tests monitoring the changes in the total dissolved 
nitrogen concentration. Another IL, 1-octylpyridinium bromide, met the 
OECD criterion for being classified as readily biodegradable, whereas          
1-hexylpyridinium bromide exhibited a decreased degradation rate. 
Compared to the pyridinium ILs the mineralisation of the imidazolium ILs 
was lower. The 1-methyl-3-octylimidazolium cation showed significant 
degradation rates, but those were not high enough for a classification as 
readily biodegradable. For the pyridinium and imidazolium head groups 
carrying a butyl side chain no significant biodegradation was observable. In 
another study, Gathergood et al. [103] found that the influence of anion was 
important only in a case of the octyl sulfate anion, which proved to be 
considerably more biodegradable than the other commonly used anions. The 
introduction of an ester group in the side chain of the 1,3-dialkylimidazolium 
cation led to biodegradation values very close to the pass level of the Closed 
Bottle test. 
 Stolte et al. [104] investigated the biodegradation of different N-
substituted imidazoles, imidazolium, pyridinium and 4-
dimethylaminopyridinium compounds bearing various alkyl side chains. 
They found a significant biodegradation for ecotoxicologically unfavourable 
compounds carrying long alkyl side chains (C6 and C8). In contrast for 
ecotoxicologically more recommendable imidazolium ILs with short alkyl 
(≤C6) and short functionalised side chains, no biological    degradation could be 
 
                                      
 
Figure 5. Manometric respirometers used to determine carbon mineralization and 
indirectly the biodegradation of chemicals in water and soil (Photo from the authors). 
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found. The introduction of different functional groups into the side chain moiety, 
thus offering a higher chemical reactivity, did not lead to the expected 
improvement of the biological degradation potential. After an incubation period 
of 24 days for the 1-methyl-3-octylimidazolium cation different biological 
transformation products carrying hydroxyl, carbonyl and carboxyl groups were 
identified. Furthermore, shortened side chain moieties were identified indicating 
the degradation of the octyl side chain via β-oxidation.  
 Gathergood and co-workers [105] intended to design, synthesize and 
evaluate biodegradable ILs containing ester or amide groups in the alkyl side 
chain. The introduction of a group susceptible to enzymatic hydrolysis greatly 
improves the biodegradation, compared with the commonly used 
dialkylimidazolium ILs, 1-butyl-3-methylimidazolium tetrafluoroborate and 
hexafluorophosphate. For the 3-methyl-1-alkyloxycarbonylmethylimidazolium 
bromide series, the greatest biodegradation was observed when alkyl side 
chain had 4 or more carbons. The corresponding amide analogs proved to be 
poorly biodegradable. In the next phase of their investigation [106] they tried 
to establish the influence of the anionic moiety on the biodegradability of ILs. 
Different C4mim cations combined with Br¯, [BF4] ¯, [PF6] ¯, [N(CN)2] ¯, 
[(CF3SO2)2N] ¯ and octylsulfate as the counter ion were analyzed using the 
Sturm and Closed-Bottle test protocols. No compound showed significant 
degree of biodegradation with the exception of the IL containing octylsulfate 
anion which had higher levels of biodegradability. The same group did a 
further research toward the discovery of biodegradable ILs [103]. The aims of 
the study were to incorporate additional structural modifications in order to 
improve biodegradability. They incorporated 2-methyl group into the 
molecule of imidazolium ILs to provide an additional site for metabolism, 
parting from a fact that 2-methylimidazole is significantly more 
biodegradable than imidazole. The incorporation of a methyl group in the 2-
position of imidazolium cation had no significant effect on biodegradability. 
The commonly used 1-butyl-3-methylimidazolium core showed negligible 
levels of degradation. Part of this team continued their research by trying to 
design, synthesize and evaluate biodegradable pyridinium ILs. Harjani et al. 
[107] prepared ILs bearing an ester side chain moiety, using either pyridine 
or nicotinic acid. These ILs showed high levels of biodegradation under 
aerobic conditions and can be classified as ‘readily biodegradable’. In 
contrast, pyridinium ILs with alkyl side chains showed significantly lower 
levels of biodegradability in the same test. 
 The fact that only the long side chains in ionic liquids improved 
biodegradability creates a conflict of aims between minimizing the toxicity 
and maximizing the biodegradability. The issue of biodegradability seems to 
be a problem in the development of environmentally safer ionic liquids.  
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 Peric et al. (unpublished results) have studied the biodegradability in 
water of three ILs from the new family of PILs, derived from substituted 
ammonium salts (hydroxyethylammonium formate, diydroxyethylammonium 
propionate, and trihydroxyethylammonium pentanoate). Almost all of the 
analyzed PILs showed to be readily biodegradable with biodegradation rates 
of 57 to 86% (expressed in terms of theoretical oxygen demand) in a 28 days 
period. These results can be due to the fact that these PILs do not show 
toxicity towards microorganisms and also to their non cyclic simple structure. 
Even though they have cations and anions composed of short alkyl chains 
(≤C5), these chains have hydroxyl and carboxyl functional groups which can 
increase the biodegradability rate, in accordance with the findings of other 
authors related to ester and amide functional groups [105].  
 Like in the case of the terrestrial ecotoxicity, the data on the 
biodegradability in soil is scarce. Kumar et al. [108] investigated the fate of 
1-butyl-3-methylimidazolium tetrafluoroborate when in contact with soil-
microorganisms, wastewater microorganisms, Pseudomonas putida and E. coli. 
Although 1-butyl-3-methylimidazolium tetrafluoroborate was indicated to be 
recalcitrant in Sturm and Closed-Bottle test assays as mentioned above, it 
was observed in this study that P. putida was able to break down 1-butyl-3-
methylimidazolium tetrafluoroborate after 15 days of incubation.  
 The aerobic biodegradation processes of ionic liquids in soil were 
monitored for the first time by Modelli et al. [101] , working with four ionic 
liquids obtained from the 1-butyl-3-methylimidazolium and 1-methoxyethyl-
3-methylimidazolium cations combined with the tetrafluoroborate and 
dicyanamide counter anions, by measuring the total production of CO2 over 
six months, according to ASTM D 5988-96. The results indicate that the 
biodegradability rate ranges between 17 and 52% for 1-butyl-3-
methylimidazolium and between 0.1 and 3.6% for 1-methoxyethyl-3-
methylimidazolium, with dicyanamide and tetrafluoroborate anions 
respectively. In both cases the biodegradation rate did not exceed 10% in 28 
days of the test duration.   
 Peric et al. (unpublished results) have performed other type of studies of 
biodegradability of ILs in soil, according to test No. 217, Soil microorganisms: 
Carbon transformation [63], using three ILs of the new family of PILs, 
(hydroxyethylammonium formate, dihydroxyethylammonium propionate, 
and trihydroxyethylammonium pentanoate). The results indicate that the 
biodegradation rate ranges between 60 and 90%, with the most complex ILs 
showing the lowest biodegradation rate. The ILs from the new family of PILs 
are clearly less toxic than the ILs derived from imidazolium, pyridinium, 
pyrrolidium, etc.; and also less toxic than the conventional solvents, with a 
notable rate of biodegradation in  water and soil.  This can be a      path to follow  
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Figure 6. Cumulative consumed oxygen of different concentrations of 
trihydroxyethylammonium pentanoate (2-HTEAPe) compared to the control soil, 
according to OCDE test 217 [63], to observe inhibitory effect (10,000 mg kg-1) and 
the biodegradation (1,000/5,000 mg kg-1) of IL. Data from the authors. 
 
regarding a synthesis of really green ILs, formed by a pair of organic ions, 
with simple (short and lineal) structure and functional groups which facilitate 
biodegradation. 
 
5. Conclusion 
 
 The large number of possible ILs structures and their unique physical, 
chemical and biological properties make it feasible to consider them as an 
opportunity to contribute to the greenness in the various fields in which they 
can be applied. Recent studies show that not all ILs synthesized to date are as 
green as expected. Some of the cyclic AILs, especially the ones derived from 
imidazolium and pyridinium with long side chain substituents, have proven to 
be even more toxic for aquatic organisms than the classical organic solvents 
that they are aiming to replace. However, the constant synthesis of new ILs 
presents an opportunity for the design of compounds which can comply with 
the most demanding technical requisites while presenting low levels of 
ecotoxicity and high biodegradability. A good example of this is the new 
familiy of PILs based on ammonium substituted organic salts. 
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Abstract. The preparation of enantiomerically pure compounds 
(EPC) is a continuous social demand due to the clinical advantages 
that enantiopure drugs offer over the racemic forms. Here, the best 
well-established synthetic strategies to access to single-enantiomer 
compounds are briefly described and compared. In particular, the 
enantioselective catalysis is introduced paying special attention to 
the organocatalysis, an emerging and fruitful area in the EPC-
synthesis. Of particular interest is the use of small organic 
molecules as catalysts in cascade reactions. Organocascade 
reactions involve the formation of several chemical bonds and 
often generate stereogenic centers with excellent stereoselectivity. 
Such one-pot reactions avoid time-consuming and costly step-by-
step processes and are environmentally friendly as they occur in 
the absence of metals. Additionally, the chemical waste of the 
organocatytic cascade reactions is drastically reduced since the 
intermediates are not isolated and purified. 
 
Introduction 
 
 In the pharmaceutical field, stereochemistry is placed in an extremely 
relevant position. The tridimensional structure of a compound is very 
important  when  interacting  with  a chiral     medium  as the  human  body,  the      
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biological effect directly depending on the stereochemistry of the exogenous 
compound and the receptor. Thus, a single-enantiomer drug can be 
pharmacologically interesting whereas its mirror image can be inactive or 
display a different desirable or non-desirable activity. Therefore, the 
administration of enantiopure drugs brings benefits in terms of improved 
efficacy, more predictable pharmacokinetics and reduced toxicity [1]. These 
advantages forced pharmaceutical companies [2] and health authorities [3] to 
place stereochemically pure substances in a privileged position. 
Consequently, it is not strange that 7 out of the top 10 most selling-drugs 
worldwide in 2010 are commercialized as enantiopure forms. Among them, 
the top three positions are for Nexium® (esomeprazole), Lipitor® 
(atorvastatin), and Plavix® (clopidogrel), with a whole invoicing of 15 billion 
dollars [4].  
 The large demand of enantiopure products has broken out the progress of 
the asymmetric synthesis, considered in the last years as one of the most 
important areas of research in both industry and academia. Nowadays, the 
number of synthetic methods available for the preparation of chiral molecules 
has permitted to efficiently gain access to a myriad of enantiomerically pure 
compounds. 
 
1. Strategies for the elaboration of enantiopure compounds 
 
 In 1980 Prof. Seebach [5] introduced the term "EPC-synthesis" (synthesis 
of enantiomerically pure compounds) to include all the processes for the 
preparation of chiral enantiopure compounds. The three main synthetic 
approaches in EPC-synthesis are listed below (Fig. 1) [6]: 
 
? Resolution of racemates. 
? Synthetic transformations from an enantiomerically pure starting 
compound. In the particular case of an easily available natural 
compound it is called synthesis from the chiral pool. 
? Stereoselective reactions that involve an enantiopure reagent as a 
source of chirality, in stoichiometric (auxiliary) or catalytic amounts, 
which is not included in the final product.  
 
 Next, the three main strategies to obtain enantiopure compounds are 
outlined.   
 The first optical resolution of a racemic mixture was performed by Prof. 
Pasteur in 1848, who was able to manually separate the two kinds of 
hemihedral crystals of racemic tartaric acid salts [7]. This fact represented the 
discovery    of the molecular  chirality and of the spontaneous resolution [8].  In 
Strategies for the synthesis of enantiopure compounds focused on organocatalysis  117 
 
 
Figure 1. Strategies for the synthesis of enantiopure compounds. 
 
spite of the simplicity of this separation technique it is limited to 
conglomerates, since both enantiomers of the substance deposit in equal 
quantities as enantiomorphous crystals [9]. It is worthy of note that only 
between 5 to 10% of the total chiral organic solids reveals as conglomerates. 
Notably, the vast majority of resolutions involve the conversion of a 
racemate, by treatment with an enantiomer of a chiral substance, into 
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diastereomeric salts (Eq.1, Fig. 1). The different solubility properties of the 
diastereomeric salts allow the separation of both products and the subsequent 
treatment with a base or an acid give access to both enantiomers.  
 Apart from the aforementioned resolution process based on physical 
properties like solubility, there are other resolution processes as the kinetic 
resolution. The kinetic resolution relies on the unequal reaction rates of the 
enantiomers with a chiral nonracemic reagent (Eq. 2, Fig. 1). In that case, the 
reaction rates should be different enough to recover the less reactive or non-
reactive enantiomer. The maximum theoretical yield for a kinetic resolution 
is 50% for each enantiomer and one of them is chemically modified. Of 
particular interest is the dynamic kinetic resolution that permits the total 
conversion of a racemic mixture into a single enantiopure product (Eq. 3,  
Fig. 1). This strategy involves a standard kinetic resolution and an in situ 
racemization process of the less reactive enantiomer (unchanged enantiomer), 
which must be a labile chiral substrate for the easy conversion into the 
racemic mixture again [10].  
 In the chiral pool synthesis the chiral source is a natural enantiopure 
compound that will remain included in the structure of the final product (Eq. 4, 
Fig. 1). This methodology is therefore more useful when the desired final product 
and the chiral compound used are structurally similar. The chiral pool arsenal is 
integrated by carbohydrates, amino acids, hydroxy acids and terpenes.  
 The stereoselective synthesis from prochiral substrates is a potent tool 
that allows the preparation of a broad variety of enantiopure compounds. This 
methodology involves chemical reactions that introduce one or more 
elements of chirality in a substrate molecule producing stereoisomeric 
products (enantio- or diastereoisomers) in unequal amounts [11]. A chiral 
auxiliary or a catalyst is responsible for the asymmetric induction. 
 The use of auxiliaries is based on the temporarily incorporation of a 
chiral moiety in a prochiral substrate (Eq. 5, Fig. 1) generating new elements 
of chirality selectively. The process involves: 1) the introduction of the 
auxiliary; 2) high diastereoselectivity in the process of generation of the new 
elements of chirality, 3) separation of the formed diastereoisomers and finally 
4) recovery of the chiral auxiliary. As chiral auxiliaries are required in 
stoichiometric quantities, their preparation has to be easy and inexpensive. 
 Nowadays, different well-known chiral auxiliaries allow to selectively 
perform a great number of reactions [12]. Among them the Evans' 
oxazolidinones [13] or the Oppolzer's sultames [14] constitute robust 
examples. Remarkably, the use of chiral amino alcohols pioneered by A. I. 
Meyers [15], and extended for other research groups [16], played an important 
role as chiral auxiliary strategy and nitrogen source for the efficient synthesis 
of alkaloids and nitrogen-containing bioactive compounds. 
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 Chiral auxiliaries become very popular 30 years ago due to their 
efficiency in the generation of stereoselectivity, affording 100% pure 
enantiomers after the separation of the diastereoisomers. However, the need 
for using stoichiometric quantities of the chiral auxiliary and the 
disadvantage of requiring two additional synthetic steps, introduction and 
removal of the auxiliary, prompted synthetic chemists to divert their attention 
to the asymmetric or enantioselective catalysis. 
 In the enantioselective catalysis the chiral information is transferred by 
an enantiopure catalyst, which means that substoichiometric quantities of a 
chiral molecule activate the substrate in a reversible manner to accelerate the 
reaction (Eq. 6, Fig. 1). As the interaction between the catalyst and the 
substrate is reversible the catalyst is not consumed during the process and can 
be introduced in a new catalytic cycle. The atom economy of the process is 
optimal, minimizing the waste generated [17]. An additional advantage of this 
methodology is the multiplication of the chirality [18], since stoichiometric 
quantities of enantioenriched product are obtained from substoichiometric 
quantities of catalyst.  
 In contrast to the use of chiral auxiliaries that affords enantiopure compounds 
through diasteromeric intermediates, asymmetric catalysis furnishes directly 
enantiomers from prochiral compounds allowing the preparation of a broad 
variety of chiral compounds with high enantiomeric excess.  
 A relevant datum of the importance of asymmetric catalysis in Chemistry 
is that Profs. W. S. Knowles, R. Noyori and K. B. Sharpless were awarded 
with the Nobel Prize in 2001 due to their research on the field (Fig. 2).  
 Enantioselective catalysis can be divided in three main areas, 
biocatalysis, organometallic catalysis and organocatalysis, depending on the 
nature of the chiral catalysts employed. 
 In the biocatalysis an enzyme is responsible for the acceleration of the 
process [19]. Due to their complex tridimensional structure of L-amino acids, 
the biocatalysts are involved in highly chemo-, regio-, diastereo- and 
enantioselective processes. Moreover, these reactions are carried out under 
mild conditions to avoid side products and the processes are environmentally 
harmless.   
 The organometallic catalysis is responsible for the most part of the 
enantioselective catalysis published in the last years [20]. The success of this 
area is mostly due to the particular affinity of metals to complex with 
functional groups and to the structurally well defined metal-organic ligand 
complexes which is translated into an efficient asymmetric induction.  
 An important contribution in the field dates from the seventies when 
Prof. W. S. Knowles and co-workers [21] demonstrated that complexes of 
rhodium   and  phosphine ligands  with C2 symmetry catalysed the  addition  of 
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Figure 2. Nobel Prize in Chemistry (2001) shared by W. S. Knowles, R. Noyori and 
K. B. Sharpless. (http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2001/) 
 
hydrogen to one of the faces of a prochiral olefin to generate a stereogenic  
C-H center with high enantioselectivity (Fig. 3). Apart from giving a boost to 
the development of ligands with a C2 symmetry axis, the main application of 
this reaction was the industrial preparation of L-dopa [22]. 
 Nowadays, the organometallic catalysis enjoys an elevate grade of 
development including participation in a great variety of oxidations, 
reductions, insertions to σ bonds, activations of π bonds and reactions 
catalysed by Lewis acids. In spite of this advantage, some organometallic 
complexes are expensive, demanding on strict reaction conditions, and metals 
are toxic which is negative from both the environment and the contamination 
of the final product point of view.  
 
 
 
Figure 3. Enantioselective hydrogenation catalysed by rhodium-DiPAMP complex. 
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 Environmental and health regulations gave strong support to cleaner and 
non-toxic chemical processes avoiding the use of toxic reagents. Chemical 
companies consider that get rid of transition metals in catalytic reactions is 
highly desirable. In fact Nature, our source of inspiration, does not use metals 
for the most part of biocatalytic processes. In this sense, the efforts made for 
the scientific community to get synthetic sequences free of metals have 
driven to the configuration of a new area within the enantioselective 
synthesis: the organocatalysis. 
 The organocatalysis is defined as the acceleration of chemical reactions by 
small organic molecules in the absence of metals [23]. Although the 
organocatalysis is a field that has been incredibly developed in the last decade, 
the use of organic molecules to catalise chemical reactions has been known for 
more than a century [24]. In 1896, Emil Knoevenagel used a secondary amine 
(piperidine) to accelerate the condensations that received his name (Fig. 4) [25].  
 The first example of an asymmetric organocatalysis was described by 
Mackwald in 1904 using the brucine alkaloid in a decarboxylation process 
[26]. In 1912, Bredig and Fiske described the asymmetric addition of HCN to 
benzaldehyde catalysed by cinchona alkaloids [27]. However, those examples 
occurred with a low enantiomeric excess, below 10%. Later on, in 1960 
Pracejus published the organocatalytic methanolysis of a ketene with higher 
enantioselectivity levels (76% ee) [28]. In the seventies a remarkable hit in 
the organocatalysis was achieved when the first asymmetric aldolization 
(Hajos-Parrish-Eder-Sauer-Wiechert reaction) catalysed by L-proline was 
described (Fig. 5) [29].  
 In the following decades (1980-2000), two new fields in the catalysis 
with organic molecules started with the publication of the two first examples 
in the phase transfer catalysis [30] and the activation through hydrogen-
bonding interactions [31].  
 
 
 
Figure 4. Prof. Emil Knoevenagel (1865-1921). Piperidine catalysed the reaction of 
diethyl malonate with benzaldehyde.  
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Figure 5. Hajos-Parrish-Eder-Sauer-Wiechert reaction. 
 
 In 2000, a study carried out by List, Lerner and Barbas III demonstrated 
the ability of small molecules to catalyse reactions that until then were 
promoted by bigger organic molecules or enzymes through similar 
mechanisms [32]. The same year, MacMillan and co-workers developed the 
first highly enantioselective organocatalytic Diels-Alder reaction catalysed by 
a secondary chiral amine, an imidazolidinone [33].  
 This new application and the conceptualization of the word 
"organocatalysis" by MacMillan, represented the revival of the secondary 
amines and other organic molecules as catalysts. The strong support of the 
scientific community to this field was due to the numerous advantages that 
the small molecules represent for catalysis. Some of them are listed below: 
 
? The organocatalysts usually are non-sensitive to the humidity and 
the atmospheric oxygen. This stability makes catalysts easy to 
handle because it is not necessary the use of dry boxes, inert 
atmosphere or anhydrous solvents, improving the reproducibility of 
the results. 
? Nature provides enantiopure compounds that can be used directly as 
organocatalysts. Thus, these molecules are easily available in 
considerable quantities and in both enantiomeric series. 
? The organocatalysts are low or non-toxic substances, respectful with 
the environment. Moreover, they can be easily isolated from the 
reaction mixtures avoiding the contamination of the final product. It 
is noteworthy that the most part of the organocatalytic reactions are 
performed in high concentration or in the absence of solvent 
minimizing the expenses of solvent and the formation of additional 
residues. These properties increase the level of safety and reduce the 
cost of research either in the academic or industrial areas. 
  
 Nowadays, the organocatalysis is a potent synthetic tool situated in a 
privileged position between the two main catalytic strategies (the bio and 
metal catalysis) and complements them. 
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 The interest in catalysis with organic molecules is indicated in the 
increasing number of publications related to this subject in the last decade. 
The number of publications containing the concept of "organocatalysis" rose 
steadily from 2000 to 2007 (Fig. 6) rising to 821 publications in the year 
2010. Prior to 2000 the number of articles containing the indicated keyword 
was almost negligible.  
 
 
 
Figure 6. Number of publications including the term "organocatalysis" in the title or in the 
abstract from the year 2000 (4) to 2010 (821) in the SciFinder Scholar (2007) database. 
 
 This tremendous advance in the organocatalysis has given access to a 
great number of enantiomerically pure compounds with an added value from 
the biological and structural point of view including drugs and natural 
complex products [34]. 
 The development of novel activation methods is responsible for the rapid and 
continuous progress on the organocatalytic area gaining applicability to wide 
organic reactions. In a first level, the different activation methods can be 
classified taking into account if the reversible interaction between the catalyst and 
the substrate is non covalent (1) or covalent (2). The former is also divided 
depending on the implication of ionic pairs or hydrogen bonds. The latter is 
classified into N-heterocycles carbene catalysis or amine catalysis, also known as 
aminocatalysis. The reactive species that is formed when the catalyst interacts 
with the substrate determines the kind of aminocatalysis involved. Next, this 
classification is underlined and the different headings are briefly described. 
 
1. Non covalent interactions: 
 a. Formation of ionic pairs: 
  i. Phase transfer catalysis 
  ii. BrØnsted base catalysis 
 b. Formation of hydrogen bonds 
2. Covalent interactions: 
 a. Catalysis with N-heterocyclic carbenes 
 b. Catalysis with amines (via iminium ion, enamine,   
  dienamine, radical cation or ammonium ion) 
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 The enantioselective phase transfer catalysis (PTC) (1.a.i) is performed in a 
heterogeneous medium and uses quaternary ammonium salts to facilitate the 
migration of the reagent from one phase to the other. The asymmetric induction 
is based in the formation of a chiral ionic pair soluble in the organic phase that 
is where the stereoselective reaction occurs. The most used ammonium salts are 
the cinchona alkaloids derivatives and binaphthylamine derivatives [35]. The 
BrØnsted base catalysis (1.a.ii) [36] is based on the use of a chiral base able to 
deprotonate a (pro)nucleophile (chiral ionic pair) increasing the reactivity in 
front of eletrophiles. The most employed BrØnsted bases as chiral catalysts are 
the cinchona alkaloids and derivatives, due to their availability and their 
catalytic and inductive efficiency. This family of compounds is found in Nature 
as two pseudoenantiomeric forms (Fig. 7) and each of them furnishes one of 
the two possible enantiomers of the reaction product. 
 
 
 
Figure 7. Pseudoenantiomeric cinchona alkaloids. 
 
 Cinchona alkaloids have been considered as one of the most privileged 
chiral inductors in organic synthesis [37]. Different structural features of 
cinchona alkaloids are responsible for the efficient activation and 
transmission of the chiral information to the substrate [38]: 1) the presence of 
a basic nitrogen atom included in a bulky quinuclidine nucleus and a 
secondary alcohol that can activate the substrate establishing hydrogen- 
bonding interactions; and 2) the presence of a quinoline ring that can adopt 
different conformations in the reaction media acting as a "molecular wall" for 
the preferential approach of the reagent. When the basic nitrogen of the 
quinuclidine activates the (pro)nucleophile and the hydroxyl group interacts 
with the electrophile through hydrogen-bonding interactions, cinchona 
alkaloids are considered to be bifunctional catalysts as a double simultaneous 
activation occurs in the process [39]. 
 The formation of hydrogen bonds is very important in biological systems 
and in metabolic terms such interaction between enzymes and substrates 
means the acceleration of a wide variety of reactions. This biological strategy 
of activation is mimicked by different catalysts (1.b) [40]. Among them, 
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phosphoric acids and thioureas stand out due to their efficiency in the 
formation of highly organized transition states, a very important factor for the 
discrimination of the enantiotopic faces of a substrate. 
 In the catalysis through covalent interactions between a catalyst and a 
substrate is highlighted the use of N-heterocyclic carbenes (2.a) [41] and the 
catalysis using amines (2.b) [42]. The aminocatalysis is based on the use of 
amines as catalysts and represents an important part of the organocatalysis. 
There are different activation modes in aminocatalysis that allow to establish 
a classification depending on the reactive species that is generated in the 
interaction between the substrate and the catalyst.  
 In the iminium ion catalysis [43] the reactive species is an iminium salt 
formed by the reversible reaction between a primary or secondary amine 
(catalyst) and a carbonyl compound (substrate). Thus, a lowering in the 
energetic potential of the lowest unoccupied molecular orbital (LUMO) is 
observed facilitating the reaction with nucleophiles. The Knoevenagel 
condensation and the Michael addition are two examples of reaction in which 
this activation strategy has been successfully applied. When the substrate is 
an α,β-unsaturated ketone or aldehyde, the iminium ion catalysis favors the 
β-functionalization of the carbonyl compound (Fig. 8). 
 The catalysis via enamine [44] involves the generation of an enamine that 
results from the tautomerization of an iminium ion intermediate. In that case, 
a primary or secondary amine activates the substrate increasing the energetic 
potential of the highest occupied molecular orbital (HOMO). The HOMO-
raising activation facilitates the reactivity of the α-carbonyl position with 
electrophiles. This strategy has been frequently used in aldol and Mannich 
reactions (Fig. 9). 
 
 
 
Figure 8. Activation via iminium ion (Nu = nucleophile). 
 
 
 
Figure 9. Activation via enamine (E = electrophile). 
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 The catalysis via dienamine, introduced in 2006 by JØrgensen and co-
workers [45], can be considered as a kind of catalysis via enamine and it has 
been used for the functionalization of the γ position of α,β-unsaturated 
aldehydes with electrophiles.  
 In the last years, a new class of catalysis via radical cation has been 
developed [46]. In this case, SOMO (single electron occupied molecular 
orbital) activation is produced allowing the introduction of different 
substituents in the α carbonyl position. This new methodology has expanded 
the field of organocatalysis merging aminocatalysis with radical chemistry. 
 Finally, the catalysis via ammonium ion implies tertiary amines [47] as 
catalysts. The formation of ammonium enolates [48] typically with cinchona 
alkaloids, and the formation of acyl-ammonium with DMAP analogues [49] 
are representative examples. 
 The transmission of the chiral information from the catalyst to the final 
product must be very efficient in order to achieve stereoselective chemical 
processes. In the particular case of the aminocatalysis, the stereoelectronic 
properties of the catalyst (amine) are responsible for the asymmetric 
induction. Thus, the stereocontrol of a reaction can be determined by steric 
factors, electronic factors or a combination of both. Chiral catalysts bearing 
bulky groups can prevent an arbitrary approach of the reagent to the substrate 
forcing an oriented bond formation that avoids the steric hindrance. In an 
opposite way but complementary, catalysts with hydrogen-bond donating 
groups can establish interactions of electronic affinity with hydrogen-bond 
accepting groups present in the reagent, thus facilitating the reaction between 
the two reacting partners in a well-defined manner. 
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Figure 10. Stereoelectronic control of the reaction by the catalyst. 
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 Figure 10 depicts how different substituted chiral pirrolidines (A and B) 
can orientate and control the addition of aldehydes to electrophiles through an 
enamine like intermediate. The presence of bulky substituents in the 
organocatalyst (A) can shield the enamine Re face forcing the electrophile to 
a Si face approach. However, the use of pirrolidines with hydrogen-bond 
donor groups (B) would facilitate the approach of the electrophile 
preferentially for Re face of the enamine. Thus, both strategies would drive to 
opposite enantiomers. 
 
2. Cascade reactions 
 
 Evolution provided living organisms with biosynthetic processes that 
convert efficiently simple molecules into complex molecular systems. One of 
the key features of the biosynthetic routes in Nature is the achievement of 
cascade reactions. As an example, the pharmacologically and structurally 
very interesting diterpene taxol is proposed to be biosynthetically prepared in 
just five steps involving few enzymes [50] (Fig. 11). However, the most 
efficient synthesis of taxol achieved in the laboratory by Wender´s group 
involved 37 steps from verbenone with 0.44% overall yield [51]. 
  
 
 
Figure 11. Proposed biosynthesis of taxol. 
 
 In the laboratory, the preparation of complex chiral molecules requires 
several synthetic steps and involves the isolation and purification of 
intermediates. This operational strategy prevents, in most cases, a low-cost 
fast access to enough quantities of interesting natural products and bioactive 
compounds for the benefit of the community.  
 The attempts to mimic Nature for avoiding these limitations led to the 
development of new one-pot strategies. The one-pot reactions are carried out 
in a simple vessel allowing the formation of various chemical bonds and 
stereogenic centers without the isolation or purification of intermediates. 
Thus, the efficiency of the synthesis increases since the number of synthetic 
steps is reduced. As a consequence, there is a minimum consumption of 
chemicals and a minimization of waste, reducing environmental 
contamination. Therefore, chemical companies concerned about economic 
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and ecological profitability are really interested in one-pot reactions. Merck 
Research Laboratories described an impressive synthetic sequence for the 
preparation of the anti-migraine drug telcagepant (Fig. 12) [52]. A symbiosis 
between one-pot reactions and organocatalysis using Jørgensen's catalyst is 
the key feature of a brilliant synthesis with the isolation of only three 
intermediates and without chromatographic purification. This example 
illustrates the preparation on an industrial scale drug by an environmentally 
friendly process with the high quality standards that the pharmaceutical 
production demands. 
 
 
  
Figure 12. Synthesis of telcagepant potassium salt from 1,2-difluorobenzene by 
Merck Research Laboratories. 
  
 Recently, different terms to describe one-pot processes have been 
considered. Tietze [53] described a domino reaction as the process involving 
two or more sequential bond-forming transformations which take place under 
the same reaction conditions. In a tandem process the transformations occur 
simultaneously sometimes using two or more different catalytic processes 
[54]. However, the term cascade reaction is used to include the above 
mentioned one-pot reactions [55].  
 The advantages and continuous development of this bio-inspired strategy 
has converted cascade reactions in a useful tool for the rapid access to 
molecular complexity [56].  
 The combination of enantioselective catalysis, one of the most efficient 
methods in EPC-synthesis, with cascade reactions is one of the most 
powerful approaches for the preparation of chiral complex molecules, and it 
is known as organocascades or organocatalytic cascades (Fig. 13) [57]. 
 The organocatalytic approach in cascade reactions frequently involves 
only one catalyst that usually interacts with carbonyl substrates. The 
organocascades are based on the easy tautomeric iminium ion-enamine 
conversion and the different reactivity of the resulting tautomers to furnish 
consecutive reactions. The catalysis via iminium ion allows the addition of 
nucleophiles in the β-position of α,β-unsaturated carbonyl compounds. This 
addition generates an enamine-like intermediate that can react with the 
electrophiles present in the reaction media (Fig. 14).  
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Figure 13. Organocatalytic cascades. 
  
 
 
Figure 14. Domino reaction via activation iminium ion-enamine. 
 
 The combination of sequential activations via iminium ion-enamine has 
provided numerous organocatalytic cascade syntheses of enantiomerically 
pure molecules. It is noteworthy the triple cascade reaction via activation 
enamine-iminium-enamine reported by Enders and co-workers for the 
synthesis of pentasubstituted cyclohexanones (Fig. 15) [58]. 
 
 
 
Figure 15. Synthesis of pentasubstituted cyclohexanones by Enders et al. 
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3. Cooperative catalysis 
 
 The structural diversity present in the biosynthetic molecules is due to 
the combination of catalytic cascades that involve different enzymes, which 
activate different substrates. For the success of this catalytic combination, it 
is essential the capability of different enzymes to coexist in the same media 
without undesirable interactions. Moreover, some reactions need the 
participation of coenzymes and metallic cofactors as further substrate 
activators. For this reason, the efficient combination of organocatalysts with 
other catalysts, which are able to activate different functional groups, is 
highly desirable to increase the molecular diversity of the synthetic products. 
Cooperative catalysis between organic and metal catalysts has evolved 
rapidly in recent years and its improvement offers to the synthesis of 
enantiomerically pure compounds levels of reactivity, selectivity and 
diversity that are very difficult to get using other methodologies [59].  
 Remarkably, this innovative strategy not only promotes single reactions 
but also enables multiple transformations in a one-pot process for the 
generation of previously unattainable compounds.  
 
4. Conclusion 
 
 Therefore, the design and development of new catalytic strategies is a 
continuing challenge at the forefront of synthetic chemistry. Stereoselective 
organocatalytic reactions have proved to be a powerful tool for the synthesis 
of enantiomerically pure molecules. In addition, catalytic cascade sequences 
allow the minimization of time, cost, effort and waste of synthetic processes, 
thus becoming ideal biomimetic approaches to gain molecular complexity 
efficiently and ecologically. 
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Abstract. Bicellar systems are lipid nanostructures formed by 
long- and short-chained phospholipids dispersed in aqueous 
solution. Because of their attractive combination of lipid 
composition, small size and morphological versatility, bicelles 
became new targets for skin research. Bicelles modify the skin 
biophysical parameters and modulate the skin barrier function 
acting as enhancers for drug penetration. Moreover, these 
aggregates have the ability to penetrate through the narrow 
intercellular spaces of the skin stratum corneum and to reinforce its 
lipid lamellae. Their structures allows for the incorporation of 
different molecules that can be carried through the skin layers. The 
remarkable versatility of bicelles is their most important 
characteristic, which makes it possible their use in different fields. 
These aggregates represent new nanosystems for skin applications. 
In this work we provide an overview of the main properties of 
bicelles and their effects on the skin. 
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Introduction 
 
 Bicelles consist in nanostructures formed by long and short chain 
phospholipid molecules dispersed in aqueous solution [1, 2]. These structures 
represent a fascinating category of versatile and robust lipid assemblies 
whose uses are expanding in several research fields. Bicelles have been 
described as discoidal nanostructures in which a long chain phospholipid, 
usually dimyristoyl-phosphatidylcholine (DMPC), forms a flat bilayer and a 
short chain phospholipid, normally dihexanoyl-phosphatidylcholine (DHPC), 
stabilizes the rim of the structure (Fig. 1). Although this description has been 
observed in several bicellar systems, currently it is known that bicelles may 
display different morphologies depending on the sample preparation and 
experimental conditions.  
 The bicellar structure was developed by Sanders and Schwonek in 
1992 to solve experimental problems of lipid vesicles and micelles as 
membrane models for NMR studies of protein characterization [3]. 
However, the interesting combination of lipid composition, small size and 
morphological versatility made bicelles new targets for skin related 
studies. The lipid bilayered structure of this system, with diameters in the 
range of 15–50 nm and thickness about 4–6 nm, presents optimal 
conditions as potential platforms for applications related to skin research. 
This is because of the structural resemblance of bicelles and lipid layers 
of the skin stratum corneum (SC), the absence of surfactants in the 
composition of  bicelles and the possibility of encapsulating different 
molecules in the their structures.  
 
 
 
Figure 1. Schematic representation of a bicelle showing the flat bilayer region 
composed of long chain phospholipid, surrounded by a rim of short chain 
phospholipid.  
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 The SC is a bilayered lipid-rich matrix structure with embedded 
keratinocytes that builds the upper strata of skin [4]. One of the SC key 
functions is to control permeability being the main target and the main barrier 
for transdermal drug delivery [5-7]. Perturbations in the structure and lipid 
composition of SC are associated to different diseases [8-10].  In order to 
replace the SC lipids or to provide drugs and other substances needed to 
restore skin functionality, several systems have been designed as skin 
carriers, delivery systems, penetration enhancers, etc. Micelles and liposomes 
are perhaps some of the most used systems for these purposes. However, 
despite their demonstrated beneficial effects, their use has some limitations 
[11, 12]. In fact, the large size of liposomes (usually in the range of 200-500 
nm) makes their penetration in the skin improbable since the approximated 
thickness of the SC intercellular spaces are around 6 - 10 nm [13, 14]. In case 
of micelles, their surfactant components normally produce skin irritation   
[15, 16]. The use of bicelles presents advantages over these two classical 
systems because bicelles exhibit dimensions small enough to pass through the 
narrow SC lipid lamellae, they contain a bilayer for  molecules encapsulation 
and they are formed exclusively by lipids [17, 18].  
 These interesting features of bicelles have been the basis for the new 
research line that is being developed with bicelles. In the last years bicelles 
have been investigated as regard to their structure, function and interaction 
with the skin tissue. The potential of this nanostructures for skin research is 
outstanding since their applications would range from model membranes to 
study the SC lipid behavior to applications such as SC lipids regenerators, 
skin carriers, penetration enhancers or retarders and drug delivery systems 
[19]. These studies gave rise to a consistent basis for considering bicelles as 
new nanosystems for skin applications. 
 In this work, we review the main properties of bicelles and the effects of 
their interaction with the skin in vitro and in vivo. To this aim we focus on two 
systems: the classic one formed by dimyristoylphosphatidylcholine  (DMPC) 
and dihexanoylphosphatidylcholine (DHPC) and another more compatible with 
the skin characteristics formed by dipalmitoylphosphatidylcholine (DPPC) and 
dihexanoylphosphatidylcholine (DHPC).  
 
1. Preparation and morphological characteristics of bicelles  
 
 A typical preparation of bicelles involves hydrating the desired mixture of 
long- and short-chain phospholipids, followed by a series of cycles of freezing, 
thawing, and gentle vortexing until a clear solution is obtained. The archetypal 
model of bicelles is formed by dimyristoyl-phosphatidylcholine (DMPC) as large 
chain phospholipid, and dihexanoyl-phosphatidylcholine (DHPC) as short-chain 
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one. However, in order to imitate better the environment of biological membranes 
or to adapt the systems for an specific effect, bicelles with different lipid 
compositions have been prepared. In this way, DMPC can be doped with 
phospholipids that have identical chain lengths but different headgroups (e.g., 
dimyristoyl-phosphatidylglycerol (DMPG), dimyristoyl-phosphatidylserine 
(DMPS), dimyristoylphosphati-dylethanolamine (DMPE) [20, 21], palmitoyl-
stearoyl-phosphatidylcholine (PSPC) [22] or with cellular lipids such as 
cholesterol and cardiolipin) [23]. Bicelles can also be prepared with dipalmitoyl-
phosphatidylcholine (DPPC) or dilauryl-phosphatidylcholine (DLPC) to vary the 
total bilayer thickness, or with an unsaturated lipid, palmitoyl-oleoyl-
phosphatidylcholine (POPC) to obtain bicelles capable of forming micrometre-
scale lipid domains [24]. Apart from DHPC, the rim of bicelles can be formed by 
a bile-salt derivative such as 3-(cholamidopropyl) dimethylammonio-2-hydroxy-
1-propanesulfonate (CHAPSO) [25]. The so-called ideal bicelle model supposes 
a strict segregation between the two main phospholipids [26]. 
 Depending on the composition, lipid concentration (cL) and the 
long/short chain phospholipid molar ratio (q), bicelles display different 
morphologies. In general, the bigger is the q value, the bigger is the size. 
Inversely, the bigger is cL, the smaller is the size. Temperature also exerts 
important effects on bicelles. In temperatures higher than the melting or 
transition temperature (Tm) of the long chain phospholipid, bicelles undergo 
some morphological transitions and may align in magnetic fields.  
 The spontaneous alignment of bicelles is their most important 
characteristic regarding protein characterization by NMR techniques. It is 
generally accepted that bicelles with q values between 2.8 and 6.5 and lipid 
concentration in the range of 3 – 40% w/w spontaneously align in magnetic 
fields in such a way that the bilayer plane is parallel to the magnetic field, 
giving rise to a 31P NMR spectrum showing two well-resolved resonances. 
The high field resonance corresponds to the long chain phospholipid 
localized in the planar surface of the aggregate, whereas the low field 
resonance is attributed to the short chain phospholipid distributed in the torus 
[3, 27, 28]. The 31P NMR spectra of bicelles are therefore used to diagnose 
the formation of bicelles and to verify the quality of the sample orientation. 
Also these spectra give information on the morphology of the aggregates.  
 Although the classic description of DMPC/DHPC bicelles as disk-shaped 
objects formed by a DMPC bilayer and closed on the edges by DHPC 
molecules is well accepted for bicelles with q < 2.8 at temperatures below the 
Tm of the DMPC, in the last decade, this characterization has been extensively 
debated for bicelles with q > 2.8 and temperatures above DMPC Tm [27-29]. 
 The disk-shaped model is not consistent with the mechanism of bicellar 
alignment as a function of temperature in the magnetic field. According to 
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Ottiger and Bax, disk fusion would be necessary to reach an appropriate size 
for cooperative alignment [30]. The changes in viscosity and sample 
transparency that occur under temperature variations corroborate this 
hypothesis. Rowe and Neal added that the classical model does not explain 
the increase of viscosity at temperatures where alignment begins, which 
suggests the formation of large aggregates [31]. 
 Based on their observations, Nieh et al. proposed a model for bicelles 
with q = 3.2, both with and without lanthanide cations (Ln 3+) [29, 32, 33].  
At temperatures below the Tm of DMPC, the bicelles were disk shaped. As the 
temperature rose and the systems changed from the gel to the liquid crystalline 
phase in the presence of Ln3+, the bicelles fused together in an end-to-end 
manner to form lamellar sheets with perforated holes that were lined with 
DHPC. Further increases in temperature caused phase separation, with the 
formation of DHPC-rich mixed micelles and DMPC-rich oriented lamellae that 
incorporated the DHPC-rich mixed micelles, even at higher temperatures [34]. 
In the absence of Ln3+, bicelles were disk-shaped in the gel phase and chiral 
nematic or “wormlike micelles” in the liquid crystalline phase. These bicelles 
became multilamellar vesicles at higher temperatures.  
 While some authors have proposed that the aligned samples correspond to 
elongated aggregates, which are present when samples become viscous [35], 
others claim that the aligned bicelles are perforated lamellar sheets, which are 
present when the sample viscosity drops and its appearance becomes milky [28, 
30, 36]. This latter model is known as the “Swiss cheese model” (Fig. 2). In a 
comprehensive study, Triba et al. [27] found that both elongated and perforated 
lamellar structures are compatible with the NMR aligned spectra, although they 
did not disprove the possibility of discoidal structure in the aligned phase. 
 
 
 
Figure 2. Representation of the Swiss cheese model consisting of flat bilayer sheets of 
long chain phospholipid perforated with surrounding short chain phospholipid.  
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 Recently, a comparative study related the morphologies of alignable (q = 
3.5) and non-alignable (q = 2) bicellar systems, cL =20%, with temperature 
changes [37]. 31P-NMR spectra indicated that the q = 2 bicelles exhibited 
isotropic behavior at all temperatures (20-60 ºC), while the q = 3.5 bicelles 
varied considerably with temperature. Even at 20 ºC, a low field resonance 
peak and a broad higher field signal suggested partial orientation of the 
sample with the magnetic field. Just above the DMPC Tm, at 25 ºC, the 
spectrum showed two broad resonances near the positions of those observed 
at 20 ºC. At higher temperatures, the lines became more intense, indicating 
increased magnetic alignment that reached a maximum at 40 ºC. These peaks 
disappeared at higher temperatures and were replaced by a broad signal at 
higher field resonances, which are characteristic of a phase transition from 
bicellar aggregates to larger, slow-moving structures, such as vesicles. There 
was also a gradual up field shift of both peaks with increasing temperature, 
which represents an increase in DMPC bilayer order and the gradual 
incorporation of DHPC molecules into this bilayer. This study suggested that 
increasing temperatures promote the migration of DHPC molecules from the 
edges of the structures to the bilayer area of the alignable bicelles. Depletion 
of DHPC molecules at the edges leads to bilayer fusion, which increases the 
bicellar diameters and improves the alignment up to a certain point at which 
bigger and/or non-flat structures are formed and the alignment is lost.  
 Electron microscopy techniques have proven to be very useful as 
complementary techniques to determine samples’ morphology.  The study of 
these samples by Cryo-SEM and TEM found round aggregates of 
approximately 20 nm for bicelles with q = 2 below Tm and elongated 
aggregates of approximately 2000 nm above Tm. These larger aggregates do 
not align in magnetic fields, although their size and morphology explain the 
increase in viscosity with temperature. At q = 3.5, discoidal bicelles of 
approximately 40 nm were observed below Tm, and extended areas of stacked 
lamellar sheets were observed above Tm. The authors considered these 
aggregates to be the most ordered phase because the best alignments in the 
31P-NMR experiments were obtained at the same temperatures.  
 Van Dam et al. applied Cryo-TEM technique to characterize 
DMPC/DHPC q = 3.2 and cL=5% w/w doped with DMPG and CTAB [28]. 
Through this technique they observed disk shaped structures viewed face-on 
and edge on, threadlike cylindrical micelles and branched toroidal structures 
at 20 ºC, 25 ºC and 30 ºC, respectively. In another study, these authors used 
this technique to investigate the morphology of DMPC/DHPC samples over a 
wide range of cL and q, covering isotropically tumbling bicelles and larger 
aggregates [38]. They concluded that temperature and the ratio q are the 
dominating variables for changing sample morphology, while cL to a lesser 
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extent affects the aggregate structure. They observed at q = 0.5, small, 
possibly disc-shaped aggregates with a diameter of approximately 6 nm. At 
higher q-values, they observed distorted discoidal micelles that tend to sort 
cylindrical micelles similar to those reported by Barbosa-Barros et al. [37].  
 Extensive and comprehensive studies have been reported on bicelle 
morphology and phase behavior [34, 39-42]. Throughout this work, 
researchers have reported that (a) bicelles are disk-shaped nanoaggregates 
at temperatures below the Tm of the long-chain phospholipid; (b) increases 
in temperature cause an initial increase and subsequent drop in viscosity; 
and (c) when the temperature is raised above the long-chain phospholipid 
Tm, bicelles with q > 2.8 undergo morphological transitions from disks to 
elongated micelles, perforated lamellar sheets and mixed multilamellar 
vesicles. 
 However, the studies disagree on the exact morphology of the structures 
when T ≥ Tm and the sample exhibit magnetic alignment. Works describing 
the morphology of bicelles with q < 2.8 at temperatures above the long-chain 
phospholipid Tm are scarce. For these reasons, most recent reports use the 
term “bicelle” to refer only to the sample composition and not the disk-
shaped morphology.  
 
2. Effects of bicelles on the skin 
 
 The motivation for using bicelles in the skin arises from the resemblance 
of these structures to micelles and liposomes. Bicelles combine some of the 
most attractive characteristics of these systems and therefore present several 
advantages for skin applications compared to either micelles or liposomes. 
Bicelle structures contain a bilayer that allows for the incorporation of 
different molecules but are much smaller (approximately 15-40 nm) than a 
regular liposome (≅200 nm). This is due the presence of DHPC molecules on 
the edges of the structures, which control the diameter of the assembly. These 
molecules are responsible for discoidal-shaped bicelles and the formation of 
other structures, such as small vesicles. In fact, systems formed by long alkyl 
chain phospholipids and DHPC have been reported to produce reasonably 
monodisperse unilamellar vesicles that are thermodynamically stable, with 
radii ranging between 10 and 40 nm [43-46]. Several kinetic studies have 
shown that discoidal bicelle morphology is a precursor to small vesicle 
morphology [46, 47]. DHPC molecules solubilize the DMPC bilayer similar 
to a surfactant; however, DHPC is a phospholipid with the same polar head 
group as DMPC. These two lipids differ only in the lengths of their 
hydrophobic chains. The use of systems composed only of lipids avoids 
damage to the skin barrier function caused by surfactants, which is 
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characterized by breaking of the corneocyte envelopes and disorganization of 
the intercellular lipid structures.  
 As already mentioned, above the long chain phospholipid Tm 
(approximately 23 °C for DMPC), DMPC/DHPC bicelles undergo phase 
transitions, changing from small aggregates of approximately 15-20 nm to 
structures bigger than 500 nm. Because skin intercellular spaces lie in the 
range of 6-10 nm and physiological skin temperatures are near 37 ºC, this 
phase transition would present a handicap for skin penetration. DMPC/DHPC 
bicelles are likely not able to penetrate into SC intercellular spaces, and their 
effects are limited to the skin’s surface.  
 A different scenario is obtained if the long chain phospholipid DMPC is 
substituted by another phospholipid with higher Tm, such as DPPC. This 
phospholipid has two additional carbons in its hydrophobic chain and a Tm of 41 
°C. At physiological temperatures, bicelles composed of DPPC and DHPC are 
still small aggregates. Some studies have found that at 37 °C, DMPC/DHPC 
bicelles these structures have dimensions of approximately 15 nm in diameter and 
5.4 nm in thickness. These structures have been shown to penetrate through the 
intercellular spaces of the skin SC and achieve deeper internal layers [48]. 
 
In vitro studies  
 
 Experiments using human and pig SC samples treated with bicelles to 
study the effects of these systems on the SC microstructure have been 
reported. In one of these studies, fresh human SC samples were incubated 
with DMPC/DHPC bicelles with cL = 20% and q = 2 for 18 h at 25 °C. Treated 
and untreated SC samples were cryofixed, cryosubstituted and visualized by 
TEM. No differences, including microstructural alterations and/or apparent 
damage, were observed in images of the treated SC compared with untreated 
samples (Fig. 3A and 3B).  
 Given the small sizes of bicelles (20 nm in diameter and 4.5 nm in 
thickness) and their bilayered structures, the lipid dispersion through the SC 
lamellae and the reinforcement of the SC bilayer area would be expected. 
However, this was not observed, suggesting that these bicelles were not able 
to penetrate or disperse through the SC lipid area [19]. This result was 
clarified by Rodriguez et al. [49] using ATR-FTIR. Th authors reported that 
the application of DMPC/DHPC q = 2 bicelles caused phase transitions in the 
SC lipid conformation from the gel state to the liquid crystalline state. This 
transition would be promoted by the incorporation of phospholipids from 
bicelles in the SC lipid lamellar structure. This process involves an increase 
in the fluidity and/or disorder of the lipids. An analysis of phosphate 
vibrations    only  detected     effects from  DMPC/DHPC  bicelles on lipids at the 
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Figure 3. FSTEM micrograph of (A) native SC and (B) SC treated with 
DMPC/DHPC bicelles. Both images show regular areas of corneocytes, (C), lipid 
intercellular spaces (L) and corneodesmosomes (CD) [19]. 
 
outer layer of the SC, suggesting that the majority of DMPC/DHPC bicelles 
remained in the outermost part of the tissue. This is likely why Barbosa-
Barros et al. [19] did not visualize microstructural differences between 
untreated and treated SC; transitions occurring mainly on the SC surface do 
not imply structural modifications that can be visualized in EM experiments. 
 In another study, DPPC/DHPC bicelles with cL = 10% and q = 3.5 were 
incubated with fresh pig skin SC samples for 18 h at 37 ºC. This 
DPPC/DHPC system was specially developed to obtain improved effects on 
the SC microstructure and better skin penetration at physiological conditions. 
Because the DPPC Tm is 41 ºC, the structures do not undergo phase 
transitions at physiological temperatures (approximately 37 ºC), and small 
bicelle structures are favored during the incubation process. After incubation, 
both treated and untreated SC samples were high pressure frozen (HPF) from 
an initial temperature of 37 ºC, freeze fractured and observed using Cryo-
SEM [48]. These bicelles produced quite different results in the SC than the 
DMPC/DHPC q = 2 system. The DPPC/DHPC system could penetrate and 
interact with the SC, forming lipid vesicles and new lamellar-like structures 
observed by Cryo-SEM (Fig. 4). To study this phenomenon, Rodriguez et al. 
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[50] studied the effects of DPPC/DHPC on SC lipids using ATR-FTIR 
spectroscopy coupled to a tape-stripping methodology. Analysis of the lipid 
organization in terms of chain conformational order and lateral packing 
showed that bicelles hampered the temperature-dependent fluidization of SC 
lipids in the most superficial layers of the SC and led to a lateral packing 
corresponding to a stable hexagonal phase. CH2 stretching and phosphate 
vibrations in the ATR-FTIR spectra of subsequent stripping indicated that 
DPPC/DHPC bicelles penetrated into and were widely distributed in deep 
layers of the SC. These results corroborate the presence of different 
DPPC/DHPC structures inside the SC layers, and bicellar reinforcement of 
the SC structures was observed.  
 Various authors have reported studies of bicellar state-transitions from 
disks to vesicles that were induced by dilution or temperature changes. There 
is a general consensus that these transitions occur in progressive steps, 
implying the coexistence of different aggregates in the medium [28, 39, 51]. 
To study the bicelle-to-vesicle transition, DLS studies were performed by 
Barbosa-Barros et al. 2008 [48]. A DPPC/DHPC sample with q = 3.5 and cL 
= 10% was sequentially diluted with water in seven steps, and each diluted 
sample was measured using DLS at 37 °C to imitate physiological conditions. 
The DLS curves indicated that the hydrodynamic diameter (HD) of the 
structures increased upon dilution from 11.3 nm (assigned to bicelle disks) to 
aggregates larger than 1 μm. The morphologies of the aggregates were 
analyzed using EM, which confirmed the DLS results, indicating a dilution-
induced transition from disks to vesicles. 
 
 
 
Figure 4. Cryo-SEM micrograph of SC treated with DPPC/DHPC bicelles. The white 
arrow shows vesicle structures with sizes around 200 nm and the arrowhead points to 
the lamellar-like structures in the intercellular lipid areas. The black arrow shows a 
corneocytes area [48].  
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 In bicellar systems, the DHPC molecules are found mainly on the edges 
of the disk structures and in the water (as monomers). With increasing 
dilutions, the DHPC concentration in water decreases, and DHPC is 
transferred from the bicelle edges into solution, maintaining monomeric 
equilibrium. Hence, disk diameters increase, and high dilutions lead to the 
fusion and closure of large bilayered disks, forming vesicles. This bicelle-to-
vesicle transition explains the presence of vesicles in the SC intercellular 
spaces treated with DPPC/DHPC [48]. This process would have been 
promoted by the dilution of aggregates because the SC pieces were washed 
with water after incubation. Bicelles that have been transformed into vesicles 
presumably follow a process similar to that observed in the DLS observations 
of diluted bicellar solutions outside of the skin.  
 Regarding the ability of bicelles to encapsulate drugs, Rubio et al. [52] 
performed percutaneous penetration studies with DMPC/DHPC and 
DPPC/DHPC systems with cL = 10% and  q = 2 to evaluate their effects on 
the skin penetration of dichlofenac diethylamide (DDEA). The authors 
reported that the incorporation of DDEA in the bicelles led to markedly 
decreased bicelle sizes, indicating that DDEA tends to be located at the 
bicelle edges, similar to DHPC. Fig. 5 shows Cryo-TEM images of 
DPPC/DHPC bicelles with and without DDEA. Both systems decreased the 
percutaneous absorption of the DDEA compared to an aqueous solution of 
DDEA, suggesting a retarded effect after treatment with bicelles. This effect 
was more marked for the DMPC/DHPC bicelles. This could be related to the 
different Tm values for the two systems. At 37 ºC, DMPC/DHPC (Tm ≈ 23 ºC) 
bicelles were in the liquid crystalline phase, in contrast to the gel phase SC 
lipids (Tm ≈ 60 ºC). However, DPPC/DHPC bicelles (Tm ≈ 41 ºC), were in gel 
phase, similar to the SC lipids. Different mixing behaviour of lipids from 
bicelles with SC lipids could induce different effect on the retention of 
DDEA in the upper layers of the skin. This retarder effect was ascribed in 
part to rigidity in the head groups of bicelle phospholipids caused by the 
carboxyl groups of DDEA. This rigidity would hinder the penetration of 
DDEA through the skin. However, DDEA was likely unable to diffuse out of 
the bicellar systems because of its high affinity for its vehicle.  
 A second percutaneous penetration assay was also performed by these 
authors to evaluate the potential of bicelles as penetration enhancers. In this 
experiment, the skin was pretreated with the bicellar systems (DMPC/DHPC 
and DPPC/DHPC systems with cL = 10% and q = 2) before the application of 
an aqueous DDEA solution. The global results obtained showed that 
pretreatment of the skin with bicelles promotes an increase in the 
percutaneous absorption of DDEA, with no significant differences between 
DMPC/DHPC or DPPC/DHPC systems. These studies suggest that treatment 
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with these bicelle systems prior to drug treatment can enhance drug 
absorption. This enhancement is ascribed to an initial interaction of bicelles 
with the SC that causes some disorganization of the intercellular lipids, which 
are responsible for the SC barrier functionality. These results suggest a route 
to aid the absorption of DDEA through the skin.  
  
In vivo studies  
 
 Non-invasive biophysical studies performed with healthy volunteers have 
evaluated the effects of bicelles on skin in vivo.  These studies report mainly 
on measurements of skin hydration, elasticity, erythema and transepidermal 
water loss (TEWL). Skin hydration and elasticity are useful measures of skin 
water content, distensibility, extensibility and tonicity [53, 54]. Erythema 
indicates skin tolerance [55], while TEWL indicates barrier function integrity 
[56, 57].  
 The application of DMPC/DHPC bicelles with cL = 20% and q = 2 to the 
skin of healthy volunteers has been reported [19]. In this experiment, intra-
individual comparisons of three test areas on the volar forearms of 6 healthy 
Caucasian female (ages 25–38) volunteers with no visible skin abnormalities 
were performed. In the test areas, bicelles, deionized water and control (non-
treated) areas were randomized regarding the test sites on each subject. The 
solutions were applied daily over a period of 10 days, and the skin properties 
were measured each day before application.   
 Successive bicelle applications led to an increase in TEWL from days 0 
to 11. This increase was moderate and did not reach pathological levels, 
which are from 25 to 40 g/m2/h [58, 59]. Decreasing of the skin hydration 
was also observed. Elasticity, in turn, showed improvement with the 
application of bicelles. The changes in the erythema of the skin, considering 
inter- and intra-individual variability, were not indicative of an irritation 
process [60]. The bicelles were found to promote increases in TEWL and 
skin elasticity and harmless decreases in skin hydration.  
 Bicelles act to enhance penetration, causing phase transformations in lipid 
domains that may be relevant to skin permeation [61]. As reported by 
Rodriguez et al. [49], the phase transition of the SC lipid conformation from the 
gel state to the liquid crystalline state, which causes the fluidity of these lipids, 
explains the increase of TEWL in vivo. Compared to other enhancers, bicelles 
would have the additional advantage of not causing skin irritation [62]. 
 Another study reported on the effects of the application of DPPC/DHPC 
bicelles with cL = 20% and q = 2 on the skin of healthy volunteers. The 
results were similar to those obtained with the DMPC/DHPC system, 
although they were more discrete. In a similar way, this system led to an 
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increase in TEWL and a decrease in skin hydration. However, the effects were 
approximately 75% and 50% less intense, respectively, than those obtained 
with the DMPC/DHPC system [63]. This result is not unexpected because the 
DPPC/DHPC system contains less DHPC, so the aggregates formed are 
slightly bigger and have longer bilayer areas, which would exert a protective 
effect on the SC. In addition, as observed in the in vitro studies, this system 
penetrates into the skin SC and reconstitutes its lipids in lipid vesicles inside of 
the skin lamellae, which reinforce the lipid structure of the tissue.  
 
3. Conclusion 
 
 The use of bicelles for skin applications is a scientific novelty. This new 
lipid system represents a unique versatile structure that has different effects 
on the skin depending on the self-assembly adopted. Bicelles are effective 
skin carriers due to their size, structure and composition. Although bicelles 
have no aqueous internal compartment for encapsulating drugs, their 
bilayered structure allows for the encapsulation of lipophilic and amphiphilic 
compounds. Additionally, because of their ability to increase the permeability 
of the SC, these structures enhance the penetration of hydrophilic 
components dissolved in aqueous medium. Further, the conversion of bicelles 
into vesicles inside the SC hinders their migration outside of the tissue and 
allows a lipid reinforcement effect on the skin. By modulating their physical 
and chemical characteristics, bicelles may be useful for a wide range of 
applications. Bicelles are therefore promising nanostructures with the 
potential to become new multifunctional, skin-compatible delivery system. 
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Abstract. Biosurfactants (BS) are a structurally diverse group of 
surface-active substances produced by microorganisms. Interest in 
BS production has markedly increased during the past decade, 
although large-scale production has not been possible because of 
low production yields and high total costs. At present, BS have 
gained importance in environmental applications, while new 
applications in the pharmaceutical, biomedical, cosmetic and food 
industry, with a high added value, are still developing. This article 
describes classical and new BS producer bacteria together with 
their new BS applications. With these specialized and cost-
effective applications, BS can be considered as an interesting 
option for the near future. 
 
1. Introduction 
 
 Surfactants are amphipathic molecules that accumulate at interfaces, 
decrease interfacial tensions and form aggregate structures such as micelles 
[1]. Surface active agents or surfactants are an integral part of our everyday 
life and  are       products  with  a worldwide  production.  The  enormous  market        
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demand for surfactants is currently met by numerous synthetic, mainly 
petroleum-based, chemical surfactants. About 54% of the total surfactant output 
is utilized in household/laundry detergents, with only 32% destined for industrial 
use [2]. Chemical surfactants are available in many forms, and are generally 
classified based on charge as anionic, non-ionic, cationic and amphoteric. 
Cationic surfactants are the most toxic and have historically been used as 
antimicrobials, while anionics are less toxic and are more active against Gram 
positive than Gram negative bacteria, and non-ionics are often considered non-
toxic. Important surfactants include linear alkylbenzene sulfonates (LAS), fatty 
alcohol ethoxylates (FAEO) and lauryl ether sulfate (LES) [3].  
 The growing awareness towards the use of renewable-based products and 
“green products” has stimulated the development of alternatives to these 
chemical surfactants. Biosurfactants (BS) are an example of such 
environmental friendly options [4]. BS can be obtained either by chemical 
synthesis from renewable resources, by microbial fermentation processes or 
by enzymatic syntheses [5].  
 The amphiphilic nature of BS allows the partition at water/air, oil/air or 
the oil/water interfaces where it lowers surface and/or interfacial tension. 
Such characteristics enable emulsifying, foaming, detergency and dispersing 
properties [6]. One important feature of BS is that they have very low critical 
micelle concentrations (CMC). This means that BS are effective at low 
concentrations, lower than many chemically made surfactants. The fact that 
only small amounts of BS are needed to reduce surface tension coupled with 
their known biodegradability makes them excellent candidates for “green” 
detergents and surfactants. 
 Comparing with chemical surfactants, BS have several advantages such 
as lower toxicity, higher biodegradability and diversity, effectiveness at 
extreme temperatures or pH values and widespread applicability. 
Additionally, their unique structures provide new properties that classical 
surfactants may lack. BS occur naturally in soil, which makes them 
acceptable from a social and ecological point of view [2].  
 The most remarkable difficulty for BS commercial application is the BS 
production at low concentrations, which makes product recovery difficult and 
expensive. In order to reduce their production costs and increase their 
competitiveness, various researches have been working in the development of 
new and cheaper processes and/or in the use of low-cost raw materials [4]. 
 
2. Natural Roles of Biosurfactant 
 
 Recent research indicates that there are a number of reasons why 
microorganisms make BS; mainly these reasons relate to the need to change 
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surface or interfacial properties of the cell or local environment. Prokaryotic 
cells communicate with the environment through their envelopes. Smaller 
cells have a higher surface/volume ratio, and thus can have a more efficient 
exchange of nutrients with their surrounding than larger cells. To have an 
effective relationship with the environment, microorganisms need surfactants 
[7]. When considering the natural roles of BS, it is important to emphasize 
that they are produced by a wide variety of diverse microorganisms and have 
very different chemical structures and surface properties. This diversity 
makes difficult to generalize about the natural role of BS [8]. Nevertheless, 
BS appear to play a role whenever a microbe encounters an interface. 
 BS regulate the attachment-detachment of microorganisms to and from 
surfaces. If a BS is excreted, it can modify the interface and enable or inhibit 
bacterial attachment. BS that low interfacial tension are particularly effective 
in mobilizing bound hydrophobic molecules and making them available for 
biodegradation [1,8]. BS may be used as carbon and energy storage 
molecules, as a protective mechanism against high ionic strength, and may 
simply be byproducts released in response to environmental change such as 
extracellular coverings [1]. Surface or interfacial tension changes are needed 
in the complex social responses that control cell development.  
 BS are important for motility (gliding and swarming motility as well as de-
adhesion from surfaces) and cell-cell interactions (biofilm formation, 
maintenance and maturation, quorum sensing, amensalism and pathogenicity). 
In response to certain environmental signals, bacteria will differentiate from an 
independent free-living or to an interdependent surface attached mode of live. 
Surfactants such as rhamnolipids may be able to maintain open channels in 
biofilm formations by affecting cell-cell interactions and the attachment of 
bacterial cells to surfaces. Rhamnolipid synthesis is an active mechanism 
whereby the bacteria exploit intracellular interaction and communication to 
actively maintain these channels [9]. Rhamnolipid production not only 
guarantees the structure, and therefore the nutritional balance of the biofilm, but 
these surfactants also prevent outside invading bacteria from colonizing the 
open spaces in the resident biofilm [10]. 
 Much research has been directed towards determining how 
microorganisms can enhance acces to poorly soluble substrates prior to either 
passive or active uptake into the cell. BS may play a role mediating interactions 
between the hydrophobicity of the cell surface and the substrate surface. It is 
known that exogenously added BS can increase the apparent water solubility of 
organic compounds and alter its bioavailability. BS are used to complex with 
heavy metals. Rhamnolipid eliminated cadmium toxicity when added to the 
medium by a combination of metal complexation and rhamnolipd interaction 
with the cell surface to alter cadmium uptake [8,11,12]. It has been described 
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that di-rhamnolipid removed from artificial contaminated soil, not only the 
leachable or available fraction of Cd and Pb but also the bound metals. 
Additionally, the microbial population of the contaminated soil was increased 
after removal of metals, indicating the decrease of toxicity of heavy metals to 
soil microflora. Heavy metals removal from sediments in a continuous flow 
configuration also was possible whith rhamnolipids [13]. 
 
3. Biosurfactant Classification 
 
 BS are classified based on their chemical structure. A typical BS is 
composed of a hydrophilic component (mainly amino acids, peptides or 
proteins, mono/disaccharides, polysaccharides) and a hydrophobic 
component (mainly saturated or unsaturated fatty acids, hydroxyl fatty acids 
or fatty alcohols) [6]. BS molecular masses generally range from 500 to 1500 
Da and their CMC values range from 1 to 200 mg/L [1]. 
 BS are structurally diverse and can have various chemical structures mainly 
consisting of glycolipids, lipopeptides, phospholipids, neutral lipids, polymeric 
surfactants and particulate BS, depending on the producing microorganism, raw 
matter and process conditions [5,6]. Low molecular weight BS are able to reduce 
the surface tension of water to 25-30 mN/m. The main property of high molecular 
weight BS (polymeric and particulate) is their ability to stabilize oil/water 
emulsions and they are therefore called bioemulsifiers [8,14]. A brief description 
about each class of BS is given below. 
 Glycolipids: Most known BS are glycolipids. They are commonly mono or 
disaccharides acylated with long chain fatty acids or hydroxyl fatty acids. Among 
them, rhamnolipids, trehalose lipids and sophorolipids are the best studied. 
Cellobioselipids and mannosyl erythritol lipids are also included in this group.  
 
• Rhamnolipids are exoproducts of the opportunistic pathogen 
Pseudomonas aeruginosa and were described as a mixture of four 
congeners. Naturally produced rhamnolipids are always found as 
mixtures of different congeners, as observed with various strains of    
P. aeruginosa [15,16,17]. The development of more sensitive 
analytical techniques has lead to the further discovery of a wide 
diversity of rhamnolopid congeners and homologues that are produced 
at different concentrations by various Pseudomonas species. Recently, 
bacteria belonging to other families, classes or even phyla have been 
isolated and described as rhamnolipid producers [18].  
• Different trehalose containing glycolipids are known to be produced 
by several microorganisms belonging to mycolates group, such as 
Mycobacteria, Corynebacteria, Arthrobacter, Nocardia, Gordonia 
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and specially Rhodococcus. Most of the trehalose lipids synthesized 
by this group are bound to the cell envelope and are produced 
mainly when microorganisms are grown on hydrocarbons probably 
as strategy to overcome the low solubility of hydrocarbons and 
enhance their transport. Microbial commercial success of trehalose 
lipids is scarce because its high cost of production related to the fact 
that are bound to the cellular envelope and requires non-renewable 
n-alkane carbon sources [14].  
• Sophorolipids are produced by various yeast species, the most 
intensively studied being Candida bombicola. There are generally 
considered as the most promising glycolipids, because the producing 
microorganism is non-pathogenic and because of the high substrate 
conversion, high productivity and product recovery [3]. 
 
 Lipopeptides: Several types of cyclic lipopeptides with surface active 
properties are produced mainly by members of the Bacillus sp. Up to now, 
lipopeptides are the most effective surfactants with high efficency, that is, 
low BS concentration produces significant reduction of surface tension.  
Antimicrobial activity is a frequent property present in this group. 
 
• Bacillus subtilis produces a cyclic lipopeptid called surfactin, which 
has been reported to be one of the most active BS that has been 
discovered to date [8]. 
• Bacillus licheniformis produced lichenysin, a lipopeptide (1006 to 
1034 Da) with a lipid moiety mixture of 14 linear and branched 
beta-hydroxy fatty acids (C12-C17) and aminoacids such as glutamic 
acid, aparagine, valine, leucine and isoleucine. This BS is a powerful 
surface active agent (surface tension: 28 mN/m; CMC: 12 mg/L) and 
presents good antibacterial activity [19]. 
• The polymyxins are a group of lipopeptides produced by Bacillus 
polymixa and related bacilli. Polimixin B is a decapeptide in which 
amino acids 3-10 form a cyclic octapeptide with a branched-chain 
fatty acid connected to the terminal 2,4-diaminobutyric acid (DAB). 
The hydrophobic side-chain of the fatty acid together with the 
cationic γ-amino groups of the DAB residues give these antibiotics 
the surface-active properties of a catinoc detergent [8]. 
 
 Phospholipids: Kretschmer et al. [20] described in 1982 the lipophilic 
compounds with surfactant properties of the culture suspension containing 
Rhodococcus erythropolis. Thirteen major lipids from organic crude extract 
were isolated. Non polar and polar lipids from which nonionic triglycerides 
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and α,α-trehalose corynomycolates were the most abundant lipids. From 
components described, phosphatidylethanolamines (PE) acted as the most 
powerful surfactants reducing the interfacial tension below 1mN/m.  
 Neutral lipids: The report of the production of surface active bile acids by 
Myroides SM1 bacterial strains was performed by Maneerat et al (2005) [21]. 
These compounds are composed of cholic acid, deoxycholic acid and their 
glycine conjugates. 
 The biosphere offers a vast natural resource of BS. Sampling and 
isolation of bacteria are the basis for screening of BS producing microbe. 
Hydrocarbon-contaminated sites are promising for the isolation of BS 
producing microbes. Mercadé et al. (1996) [22] isolated 5 BS producing 
strains from petroleum-contaminated soil samples by using waste lubricating 
oil as the sole carbon source being Pseudomonas sp. the most frequent 
isolate, followed by Rhodococcus sp. Espuny et al. (1995) [23] and Abalos et 
al. (2001) [15] also described the isolation BS producing strains from vegetal 
oil-contaminated soil sample. Nevertheless, undisturbed soils also can have 
BS producing bacteria. Strain 6.2S, isolated from volcanic soil and identified 
as Sphingobacterium sp., was recently reported as a new BS producer [7]. 
 The exploration of the marine habitat which has been underexplored has 
brought about new microorganisms. This represents a great opportunity to 
discover new bioactive compounds (new functional products). Up to now, 
more than 10,000 metabolites with biological activities have been isolated 
from marine microorganisms, meeting the needs of the industry in the new 
era of the white biotechnology, the “green chemistry”. Beside the well known 
soil microorganisms, BS-yielding marine microbes emerge as a wide source 
of BS producers.  
 A number of new BS has been recently described and accelerated 
advances in molecular and cellular biology are expected to expand our insight 
into the diversity of structures and applications of BS. Inside of glycolipid 
class, of special interest are the first Ochrobactrum sp. (α-Proteobacteria) 
and Brevibacterium sp. (Actinobacteria) isolates which produce a glycolipid 
with surface activity [24]. Some marine γ-proteobacteria as Pseudomonas 
fluorescens, produced a complex BS composed of trehaloselipids link to 
diacyl-monoglyceride-protein [25]. This complex renders the cell capable of 
degrading hydrocarbons. New Halomonas sp. glycoprotein has been 
described with a high emulsifying activity. Other strain of Halomonas sp. 
accumulated glycolipids (oligosaccharide-lipids) and a noteworthy sulfated 
heteropolysaccharie was produced by Halomonas eurithalina [26]. 
Alcanivorax borkumensis, besides to be a good polyhydroxy-alkanoate 
producer, produces an anionic glycolipid containing glycine for the uptake of 
hydrophobic substrates [27]. Other bacteria belonging to the β-proteobacteria 
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such as Alcaligenes sp. [28] produces glycolipids, or Arthrobacter sp. which 
produces a trehalose-lipid, very effective BS [29]. Recently, a marine 
Azotobacter chroochocum has been described as a BS producer [30].  
 From the phylum of the Bacteroidetes, the genus Myriodes (formerly 
Flavobacterium), commonly found in marine habitat especially after oil-
spills, produced ornithine-lipids often cell associated, which allow the cell to 
degrade hydrocarbons, however, surface active properties diminished in 
extreme conditions [31]. In the genus Myroides, recently Myroides odoratus 
has been reported to produce bile acids [21]. Corynebacterium kutscher, a 
glicopeptide-lipid producer, is a new BS producer from sea belonging to 
phylum Actinobacteria [32]. 
 The family of the lipopeptides, a highly effective BS group, has been 
expanded with the description of Bacillus circulans as a new species 
producing a lipopeptide with low toxicity [33] and by a new type of 
lichenysin, produced by B. licheniformis, whose most novel characteristic is 
that the alkyl-chain size ranges between C12 to C17 [33]. Another lipopeptide 
type surfactant is produced by Azotobacter chroococum growing in motor 
lubricant oil. A sponge-associate Actinomyces has been recenly reported. It is 
notewortly to mention that a glycopeptide surfactant has been detected in a 
strain of Bacillus megaterium [34]. 
 The diversity of BS is limited only by biological evolution and suggests 
that only a tiny fraction of BS has been characterized to date. New BS 
discoveries have relied on the employment of advanced analytical methods 
and, often, significant screening efforts [1]. Although the improvements 
obtained from these strategies to successfully compete with synthetic 
surfactants, novel microorganisms must be designed. Data on the genes 
involved on the production of BS are critical to designing organisms with 
improved features and new properties [36].  
 
4. Sphingobacterium sp., a New Biosurfactant Producer 
Bacterium 
 
 Recently, the isolation of a new BS-producing bacterium was carried out 
on a soil sample of the Azores islands. From 10 volcanic earth samples 54 
different isolate colonies were obtained and strain 6.2S was selected on the 
basis of its capacity to decrease surface and interfacial tension. Strain 6.2S 
was identified as a Sphingobacterium sp. and is the first strain in this genus to 
be reported as a BS producer.  
 After 48 h culture of Sphingobacterium sp. 6.2S in G-Mineral Salts Medium 
(G-MSM), of 3.8 mg/mL of protein and 190 mg/L crude extract were obtained. 
Compositional analysis revealed that the crude extract consisted primarily of 
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lipids (71.6%) and a minor fraction of carbohydrate (5.6%) and protein (4.4%). 
When Sphingobacterium sp. grew on G-MSM with n-alkenes the surface tension 
was reduced from 55 mN/m to 32mN/m. The crude extract (BS mixture) strongly 
reduced surface tension (22 mN/m at 10 g/L), producing one of the lowest values 
recorded for a microorganism-produced surfactant [7]. 
 To purify crude extract, a modification of the method described by van 
Echten-Deckert (2000) [37] was used, and two fractions, fraction A and 
fraction B, were obtained (Figure 1), both with superficial activity [7].  
 Fraction A (28.7%, w/w of the total extract) decreased surface tension of 
distilled water to 33.0 mN/m, and presented a CMC of 180 mg/L. Three majority 
spots were visualized in thin layer chromatography with ninhydrin (amine group 
determination) and molybdenum blue (phospholipid determination) (Figure 1). 
These results indicated that the analyzed compounds belong to the family of 
phospholipids and some of them had in their structures nitrogen groups. An 
analysis of each spot with two dimensional-TLC using different standard 
phospholipids showed that fraction A was a mixture of phospholipids, being 
phosphatidyletanolamine  the most abundant.  Finally,         these results were assessed  
 
 
 
Figure 1. Analysis of the extract produced by Sphingobacterium sp. 6.2S. Crude 
extract developed by iodine vapours (lipids), ninhydrin (nitrogen), molish (sugar) and 
molybdenum blue (phospholipids). Fraction A: TLC obtained after purification and 
developed with Ninhydrin. Fraction B: TLC obtained after purification and developed 
with ninhydrin [7]. 
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with a FTIR analysis, confirmating the presence of the functional groups 
characteristic of phospholipids. 
 Further analysis of fraction B (61.3%, w/w of the total extract) revealed 
that it was a mixture of lipopetides and at least one glycolipid. The surface 
tension-concentration curve showed two plateaux, the first of which can be 
attributed to a critical aggregation concentration of the BS with a protein   
(2.7 g/L) and the second to the true CMC in water (6.3 g/L) [7]. 
 Emulsion capacity of supernatant produced by Sphingobacterium sp. was 
studied. At 25º C and pH 5, 70-65% of emulsion was measured and it was 
maintained during 5 days, and only a small decrease was observed (60-65% 
emulsion) after one month. A criterion used to identify bioemulsifiers is their 
ability to maintain at least 50% of the original emulsion volume after 24 h 
formation; therefore, 6.2S BS can be included in this family of compounds. 
 A thermal stability analysis was carried out between 0ºC and 100ºC and 
at pH 5, revealing that surfactant properties were maintained with the 
temperature increase and only a small decrease in interfacial and surface 
tension was observed after a thermal treatment of 121ºC. Nevertheless, it was 
found that after thermal treatment at 121ºC, the emulsification capacity of 
6.2S BS decreased markedly from 65% to 25% (Figure 2). The surface 
activity was affected by pH. At acidic pH (1–5), surface and interfacial 
tension were lower (37 and 10 mN/m, respectively). At pH 7 an increase in 
surface tension and interface tension was observed. This change can be 
related to the pKa, indicating that the ionic form of the surfactant had lower 
surface activity. If developed to higher yields, BS from Sphingobacterium sp. 
6.2S will lead to interesting applications. 
 
 
 
Figure 2. (a) Effect of temperature treatment on the stability of BS produced by 
Sphingobacterium sp., 6.2S grown on G-MSM. (b) Effect of pH on the stability of BS. 
Measurements were conducted on crude supernatant with unknown concentrations of 
BS at 25ºC [7]. 
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5. Applications of Biosurfactants  
 
 Surfactants are an important class of chemical products with a high volume 
of use in a great variety of household and industrial applications. Most of these 
surfactants are petroleum based and are chemically synthesized [6]. BS are the 
natural choice because they are obtained by environmental friendly technologies 
and they possess many advantages over synthetic surfactants, such as lower 
toxicity, effectiveness at a wide range of physical conditions, but they are special 
as consequence of their biodegradability [6]. BS are more effective and efficient 
than many existing synthetic surfactants and they may provide new properties 
that the classical chemical surfactants lack [38,39].  
 BS find applications in an extremely wide variety of industrial processes 
that involve emulsification, foaming, detergency, wetting, dispersion and 
solubilization of hydrophobic compounds [19,40] and, in fact, the demand of 
BS is increasing worldwide in recent years [14,19,39,40,41,42]. At present, 
the main applications are the hydrocarbon bioremediation and oil and 
petroleum industry, in particular for microbial enhanced oil recovery 
(MEOR) due to their biodegradability avoiding environmental accumulation 
and toxicity [14]. In spite of their numerous advantages over the synthetic 
chemical surfactants the problem related with the large scale and cheap 
production still exits and is a major hurdle in economic competitiveness [6].  
 According to Syldatk and Hausmann (2010) [5] and Makkar et al. (2011) 
[6], the reasons for limited use of microbial surfactants in industry are the use 
of expensive substrates, limited product concentrations, low yields and 
formation of product mixtures rather than pure compounds. Nevertheless, 
their higher price is largely compensed by their environmental profile and 
performance benefits. In this regard, discovery of potent BS producing 
microorganisms would enhance their use and hence reduce total dependence 
towards the chemical synthetic surfactant industry [19]. 
 The positive economical outlook can be enhanced by increasing their high 
throughput values or by harnessing other important properties such as 
pharmacological, antifungal and antiviral capabilities. Several BS have recently 
been used or anticipated to use in cost-effective applications in medicine, food 
and cosmetic industries [6]. BS have also potential applications as additives for 
agricultural use, food industry, mining and manufacturing processes, pulp and 
paper industries and as detergents or cosmetics [2,14,19,42,43].  
 
6. Medical and Healthcare Applications  
 
 The biomedical and cosmetics area, in which low amount of high value 
BS is required in a high added value product, opens a large field where the 
Microbial surfactants  161 
research seems to be at its infancy for new applications. Next, possible 
applications of BS in these areas are described. The use of BS in medical 
applications has been proposed, due to several biological properties such as 
antimicrobial ones [14,42]. BS also have potential for use in vaccines and 
gene therapy [42,44]. A judicial and effective combination of these strategies 
might, in the future, lead the way towards large-scale profitable production of 
BS [42].  
 Due to their biological origin, BS are generally considered safer than 
synthetic pharmaceuticals, although, to date there have been very few studies 
carried out to confirm their lack of toxicity [14,36]. In a study of the skin 
potential irritation of trehalose lipids produced by Rhodococcus erythropolis 
51T7 in mouse fibroblast and human keratinocyte lines, results indicated that 
the BS was less irritating than SDS, and could be therefore used in cosmetic 
preparations [39].  
 Trehalose-6,60-dimycolate (TDM), or cord factor, has exhibited a 
number of different biological activities, including antitumor and 
immunomodulating functions [14], although Mycobacterial TDM use is 
limited by the relatively high toxicity of the molecule and the potential 
pathogenicity of producer strains. TDM produced by Rhodococcus sp. 4306 
was demonstrated to exhibit lower toxicity, both in vivo and in vitro, than 
mycobacterial TDM [14].  
 Sophorolipids are other promising modulators of the immune response, 
being able to decrease sepsis related mortality in vivo, adhesion molecules 
levels, cytokine production and IgE levels [42]. Sophorolipids in lactone 
form have also been proposed as anti-ageing agents due to their capacity to 
stimulate skin dermal fibroblast cell metabolism and, more particularly, 
collagen neosynthesis [42].  
 Several BS exhibit antibacterial, antifungal and antiviral activities, which 
make them relevant molecules for applications in combating many diseases 
and infections. BS with known antimicrobial activity include surfactin and 
iturin produced by Bacillus subtilis strains, mannosylerythritol lipids from 
Candida antarctica, and BS isolated from Streptococcus thermophilus A and 
Lactococcus lactis [45]. Cyclic lipopeptides are often found to be 
antimicrobial. For example, the cyclic lipopeptide antibiotic surfactin has 
antibiotic, anticlotting, haemolytic and antiviral properties. In vesicle studies, 
surfactin was found to incorporate into membranes at low concentrations and 
induce slow leakage due to changes in membrane ultrastructure [1,46,47]. 
Two cyclic lipodepsipeptides isolated from Pseudomonas fluorescens have 
also shown antifungal and anti-weed activities [1]. A rhamnolipid mixture 
obtained from P. aeruginosa AT10 has exhibited inhibitory activity against 
the bacteria Escherichia coli, Micrococcus luteus, Alcaligenes faecalis, 
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Serratia marcescens, Mycobacterium phlei and Staphylococcus epidermidis 
and excellent antifungal properties against Aspergillus niger, Chaetonium 
globosum, Penicillium chrysogenum, Aureobasidium pullulans and the 
phytopathogenic Botrytis cinerea and Rhizoctonia solani [15]. Pseudomonas 
aeruginosa 47T2, growing with waste frying oil as a carbon source produces 
a mixture of ramnolipids with wide antimicrobial activity [48]. Rhamnolipids 
are also able to inhibit the growth of harmful bloom algae species, 
Heterosigma akashivo and Protocentrum dentatum. The mannosylerythritol 
lipid (MEL), a glycolipid surfactant from Candida antarctica, has 
demonstrated antimicrobial activity particularly against Gram-positive 
bacteria [42].  
 Infections resulting from microbial adhesion to biomaterial surfaces 
have been observed on nearly al medical devices with severe economic 
and medical consequences. Biofilm infections pose a number of 
challenges. BS have been studied as antiadhesive agents in surgicals, 
representing an interesting approach because it may be possible to modify 
the surface properties to make it simultaneously anti-adhesive and give it 
antimicrobial activity [36, 42]. Lactobacillus paracasei sp. paracasei BS 
showed anti-adhesive activity against Streptococcus sanguis (72.9%), 
Staphylococcus aureus (76.8%), Staphylococcus epidermidis (72.9%) and 
Streptococcus agalactiae (66.6%). This finding is promising to control 
infections in the urinary, vaginal and gastrointestinal tracts, and in the 
skin [45]. 
 Concerning the antiviral properties of BS, inhibition of growth of HIV in 
leukocytes by BS has been cited in the literature [49]. The sophorolipid 
produced by Candida bombicola and its structural analogues have been studied 
for their spermicidal, anti-HIV and cytotoxic activities [42].  
 The succinoyl-trehalose lipid of Rhodococcus erythropolis has been 
reported to inhibit herpes simplex virus and influenza virus and a 1% 
emulsion of rhamnolipids has been shown to be effective for the treatment of 
leaves of Nicotiana glutinosa infected with tobacco mosaic virus and for the 
control of potato virus-x disease [14,40,49]. 
 Moreover, a trehalose lipid BS produced by Rhodococcus spp. has been 
shown to cause hemolysis of human erythrocytes through a colloidosmotic 
mechanism. This pore-type behavior can be explained by the formation of 
enhanced permeability domains in the erythrocyte membrane, as observed in 
model membranes [50,51].  
 Concerning the potential antitumoural activity of BS, first evidences of 
growth arrest, apoptosis and differentiation induced by glycolipids in 
different cancer cell line have been reported [14,42].  
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 Another interesting application of BS could be as pulmonary surfactant 
in cases of deficiency. The isolation of genes for protein molecules of this 
surfactant and cloning in bacteria has made possible its fermentative 
production for medical applications [40,42,49]. 
 BS are also very attractive in the health care and cosmetic industries. A 
large number of compounds for cosmetic applications are prepared by 
enzymatic conversion of hydrophobic molecules by various lipases and 
whole cells. The cosmetic industry demands surfactants with a minimum 
shelf life of three years. Therefore, saturated acyl groups are preferred over 
the unsaturated compounds. Monoglycerides, one of the widely used 
surfactant in the cosmetic industry, has been reported to be produced from 
glycerol-tallow by using Pseudomonas fluorescens lipase treatment [40,49].  
 Finally, BS have several promising applications in the food industry as 
food additives. Bioemulsifiers may stabilize oil-in-water (O/W) and water-in-
oil (W/O) emulsions. The type of emulsion formed by the water and oil 
depends primarily on the nature of the emulsifying agent and, to a certain 
extent, on the process used in preparing the emulsion and the relative 
proportions of oil and water present. Lecithin and its derivatives, fatty acid 
esters containing glycerol, sorbitano, or ethylene glycol, and ethyoxylated 
derivatives of monoglycerides are currently in use as emulsifiers in the food 
industries worldwide [40, 49].  A novel bioemulsifier from Candida utilis has 
shown potential use in salad dressing [49].  Haba et al. [17] tested the ability 
of rhamnolipids to emulsify different oils used in a number of industries 
forming a stable emulsion with liseed oil. Trealose tetraester (THL) produced 
by Rhodococcus erythropolis 51T7, revealed effective emulsification with 
water and paraffin or isopropyl myristate. The composition of 11.3-7.5-81.8 
(isopropyl myristate-THL-W) was stable for at least 3 months. To examine 
the solubilization behaviour of isopropyl myristate and paraffin oil in the 
multicomponent BS solutions, two-phase diagrams of the ternary system 
water–surfactant–oil were developed. Figure 3 shows the zone of 100% 
emulsion phase (shaded area) obtained after mixing different quantities of 
components. When paraffin was used as the oil phase, the diagram revealed a 
wide zone of total emulsion. Out of the shaded area, partial emulsion zones 
with different texture and aspect were observed.  
 Due to its more hydrophilic character, when isopropyl myristate was 
used as the hydrophobic component, the total emulsion zone moved to the 
left vertex, which is the area of higher water proportion. THL proved to be an 
effective emulsifier when there was a low amount of myristate oil in the 
mixture [52]. Apart from their obvious role as emulsifying agents, BS can 
have several other functions in food. For example, to control the 
agglomeration of fat globules,  stabilize aerated systems, improve         texture and 
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Figure 3. Phase diagram illustrating the emulsion area with isopropyl myristate (left) 
and paraffin (right) [39]. 
 
shelf-life of starch-containing products, modify rheological properties of 
wheat dough and improve consistency and texture of fat-based products. 
They are also utilized as fat stabilizers and antispattering agents during 
cooking of oil and fats. Improvement in dough stability, texture, volume and 
conservation of bakery products is obtained by the addition of rhamnolipid 
surfactants [42].  
 The involvement of BS in microbial adhesion and detachment from 
surfaces has also been investigated for food industry application. A surfactant 
released by Streptococcus thermophilus has been used for fouling control of 
heat-exchanger plates in pasteurizers, as it retards the colonization of other 
thermophilic strains of Streptococcus responsible for fouling. The 
preconditioning of stainless steel surfaces with a BS obtained from 
Pseudomonas fluorescens is able to inhibit the adhesion of Listeria 
monocytogenes L028 strain [42]. It is evident that the anti-adherent property 
of BS is very interesting in medicine. The use of plastic material (catether, 
sondes, etc) is a challenge consequence of bacterial adhesion. A BS pre-
treatement on this material can confer anti-adherent and antimicrobial 
properties. 
 
7. Conclusions 
 
 Surfactants are an important class of chemical products in view of the 
volumes sold and their great variety of applications. During the last decades, 
a wide variety of microorganisms have been reported to produce numerous 
types of BS. Their biodegradability and lower toxicity give them an 
advantage over their chemical counterparts. The most important factor 
limiting BS use is the production cost, however, the small amounts of product 
required and the special properties described makes BS high valuable 
molecules. Application of BS as food additives, specialty chemicals, 
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biocontrol agents and as a new generation molecules for health and beauty 
care permits to think in these compunds as the molecules of the future. 
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Abstract. The relevancy of parasites as potential indicators of 
environmental quality has been increasing over the last years, 
mostly due to the variety of ways in which they respond to 
anthropogenic pollution. The use of fish parasites as bioindicators 
of heavy metal pollution in aquatic ecosystems has been widely 
studied. However, little information concerning terrestrial habitats 
is presently available. In fact, in the last two decades several 
studies have been performed worldwide in different habitats and/or 
conditions (theoretically both in polluted and unpolluted terrestrial 
ecosystems, but mainly in aquatic ecosystems) in order to 
investigate heavy metal pollution using parasitological models. 
Different groups of vertebrates (mainly fish, mammals and birds) 
and several parasitological models have been tested involving 
acanthocephalans mostly, but also cestodes and nematodes. It is not 
the aim of this chapter to do a complete revision of the available 
data concerning this subject. Instead, we emphasize some general 
aspects  and     compile  a  mini-review of    the work performed  in this  
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field by our research group. The results obtained until now allow confirming several 
parasitic models as promising bioindicator systems to evaluate environmental cadmium 
and mainly lead pollution in terrestrial non-urban habitats, as it was already demonstrated 
for aquatic ecosystems. The present knowledge also allows confirming that parasites can 
reveal environmental impact. Environmental parasitology is an interdisciplinary field, 
which needs simultaneous expertise from toxicology, environmental chemistry and 
parasitology. Furthermore, environmental parasitology should be taken into account in 
order to increase the efficiency of environmental monitoring programs.  
 
1. Introduction 
 
 Over the last decades parasites have been attracting attention as potential 
indicators of environmental quality due to the variety of ways in which they 
respond to anthropogenic pollution, particularly in aquatic ecosystems. In 
fact, several revision papers have been available for a long time now [1-6]. A 
pioneer study in this field addressed the issue of parasites as indicators of 
water quality as a whole, including the use of helminth transmission in 
marine pollution studies. Among other aspects, the study pointed out that: i) 
levels of infection of certain parasites could be used as early warning 
indicators of deteriorating water quality, ii) laboratory experiments should 
be undertaken to investigate the response of parasite transmission stages 
to selected pollutants, and iii) guidelines for the selection of the most 
appropriate host-parasite systems were needed [1]. Just a few years later, 
the first review on the use of fish parasites as bioindicators of heavy 
metals in aquatic ecosystems [2] presented some conclusions and 
perspectives on parasites as accumulation indicators. Some problems or 
limitations of this kind of studies were also evidenced, such as: i) 
helminth infestations may affect host sensitivity to heavy metals, ii) the 
vitality of fish aqueously exposed to cadmium was markedly reduced 
when they were infested with larval cestodes, and iii) adult parasites may 
have their own detoxification mechanisms or take up metals, which is in 
contrast to the extreme metal sensitivity of certain free-living parasite 
stages like cercariae. It was also pointed out that in order to evaluate the 
relationship between environmental exposure and acanthocephalan metal 
bioconcentration and to validate the role of parasites in environmental 
biomonitoring more laboratory studies on experimentally infected fish are 
needed. These studies should allow determining the bioconcentration 
factors, defined as the ratios of the metal concentration in the parasites to 
those in the host tissues (C [parasite] / C [host tissue]) [7]. 
 Until recently little information was available on the simultaneous effects 
of parasites and pollutants on the physiological homeostasis of organisms. 
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However, today it is possible to assert that: i) parasites influence the 
metabolism of pollutants in infected hosts, ii) parasites interact with 
contaminants in synergistic or antagonistic ways, and iii) parasites induce 
physiological reactions in hosts that are thought to be pollutant-related. In 
addition, there is a close interaction between the effects of pollutants and 
parasites, which seems to be mediated at least partly by the endocrine system, 
which itself is closely related to the immune system of some hosts [8]. In 
fact, since it is well accepted that parasitism and pollution affect the 
physiological homeostasis of aquatic hosts [8], it seems reasonable to 
speculate that the same should occur in terrestrial hosts. The effects of 
pollution on parasitism are variable, i.e. pollution may increase parasitism if 
the pollutant mainly affects the host rather than the parasite (immunotoxic 
chemicals) or it may exercise a negative effect over certain parasites, which 
are more susceptible to the particular pollutant than their hosts. The 
interaction between parasites and pollution can be even more complex. In 
fact, some parasites may even have a "positive" influence on their hosts when 
exposed to environmental pollution or, on the contrary, they may have 
synergistic effects becoming more harmful to the host or modeling gonad 
development of the host [8]. It has been postulated that where hosts face a 
polluted environment parasitism might be advantageous. This hypothesis 
deserves further investigation, as it is unclear if the "negative" effects of 
parasites may be outweighed by the positive impact of reduced pollutant 
levels [5]. Therefore, it would be important to study this effect under realistic 
environmental conditions. 
 Concerning the main goal of this mini-review, it must be said that there 
are several works on the uptake and accumulation of metals by 
acanthocephalans of fish most of which have been summarized elsewhere   
[3, 4]. According to that data the most conspicuous metal accumulation was 
found in Pomporhynchus laevis parasitizing the chub, Leuciscus cephalus, 
which reduce the metal levels in fish host tissues [9]. This fact motivated 
some experimental works that evaluated the kinetics and processes of metal 
uptake by fish tissues and their parasites [10-12]. In fact, a model explaining 
metal uptake by P. laevis and the associated reduction of lead in host tissues 
was developed [10]. In this work the central element of the hypothesis is that 
acanthocephalans take up bile-bound lead in the small intestine. The liver 
expels lead ions by binding them to steroids in the bile and these complexes 
pass down the bile duct into the intestine. In uninfected fish, the intestinal 
wall reabsorbs bile-bound lead, which then runs through the hepatic intestinal 
cycle. This cycle can be interrupted by parasites by taking up bile-bound lead 
thus reducing the available amount of lead that could be reabsorbed by the 
fish host. As a consequence, infection reduces the amount of lead available 
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for accumulation in fish tissues. This fact has been partially analyzed in 
the terrestrial model Rodentolepis microstoma / Mus domesticus in El 
Hierro Island (Canary Archipelago, Spain) considering that this cestode 
inhabits within the duodenum near the bile ducts of this small mammal 
[13]. This uptake has also been described for other elements and even for 
important physiological cations [7,14,15]. For example, it was seen that 
the levels of several essential elements in the liver of Perca fluviatilis 
were negatively correlated with the size of the infrapopulation of 
Acanthocephalus lucii [14]. It appears that acanthocephalans take up 
these essential elements as a by-product when taking up bile salts with 
extreme efficiency, as most intestinal parasites are unable to synthesize 
their own steroids and fatty acids [16,17].      
 Acanthocephalans seem to meet most of the criteria commonly accepted 
for ideal bioindicators, even though their individual age cannot be 
determined. However, it seems unnecessary to specify their exact age, which 
is known to range from 50-140 days; in addition as metal uptake occurs more 
rapidly in the acanthocephalan than in host muscle tissue this ratio could 
provide information on the duration of environmental exposure and a higher 
ratio must be expected after a short-term exposure than in longer exposure 
periods [3, 18-20]. The accumulation capacity of some acanthocephalans 
such as Acanthocephalus lucii from natural infected perch, Perca fluviatilis 
was compared to other established free-living organisms such as the zebra 
mussel Dreissena polymorpha from the same site. The following conclusions 
were obtained: i) the zebra mussel allows to discriminate between gradients 
of pollution most likely due to its immobility as a consequence of being 
attached to the substratum by byssal threads and ii) the bioconcentration 
values of Cd and Pb in A. lucii (despite the high variability of metal burden 
values) were several times greater than those in the zebra mussel. These 
observations suggest that acanthocephalans are even more useful as 
environmental indicators for assessing metal pollution in aquatic habitats than 
other established indicator organisms [21, 22]. In this context we should 
answer and contextualize the question why do we need new accumulation 
indicators especially if we are dealing with endoparasites of vertebrates? 
Among other aspects, it can be said that the use of parasites supposes a 
contribution to the exploration of remote areas, by investigating whether or 
not a specific metal is present in a given habitat at bioavailable 
concentrations [15]. Another interesting possibility is to study the biological 
availability of noble metals such as the platinum group elements (PGE: 
palladium, platinum and rhodium) emitted with exhaust fumes from 
automotive catalytic converters [23].  Around a decade ago it was evident 
that most of the studies performed in this field were made in aquatic habitats 
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and only a few involved terrestrial hosts emphasizing that it would be worthy 
intensifying the research in terrestrial ecosystems [3]. Information using 
terrestrial vertebrates such as rodents is still quite limited even though they 
are thought to be useful in predicting environmental risk and in assessing 
environmental quality [24-26]. There is even less information about models 
involving small mammals and their helminth parasites, which can be 
summarized in only some experimental works [27-29] and in a reduced 
number of field studies [13, 30-32] involving cestodes and acanthocephalans 
as bioindicator models of heavy metal pollution (mainly Pb, Cd and Hg). 
Under natural conditions, there is a very limited amount of research dealing 
with the way parasitism and pollution can interact with each other in 
terrestrial organisms. Nowadays this subject continues to be more studied in 
the aquatic environment despite the increasing awareness that parasitism 
should be investigated in the light of the respective environmental conditions. 
In fact, since pollution can favour or decrease parasitism depending on an 
uncountable number of interacting variables, environmental parasitology is 
an interdisciplinary field which needs simultaneous expertise from 
toxicology, environmental chemistry and parasitology [1, 5, 33].    
 
2. Materials and methods 
 
 Even though such studies have used a wide range of sample types and 
methodologies, there is a common denominator. Samples may include host 
tissues (liver, kidney, muscle, gonads, bone, feathers, etc.) as well as 
parasites (mainly larval and adult stages of several groups of helminths, 
either whole individuals or portions) that must be taken using stainless-steel 
or other non-contaminating instruments.  
 The analytical methodology varies according to different studies. Our 
particular work is performed at the “Centres Científics i Tecnològics de la 
Universitat de Barcelona” (CCiTUB), which holds the ISO 9001:2008 
certifications. At the proper facilities, samples are weighed (if possible 
between 100-200 mg wet weight) and then digested in Teflon vessels with 
suprapure HNO3 (2 mL) and H2O2 (1 mL) in an oven at 90ºC and left 
overnight. All material used in the digestion process is thoroughly acid-
rinsed. After digestion, samples are diluted with Milli-Q water and then 
analyzed for trace elements by inductively coupled plasma-mass 
spectrometry (ICP-MS; Perkin-Elmer Elan 6000).    
 The whole process must be standardized and validated by use of certified 
standards and blanks. In our surveys two standards are mainly used (DORM-
2 and DOLT-3; National Research Council, Canada). The accuracy of all 
results is higher than 90% and very close to 100% for As, Hg, Pb and Cd. 
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Detection limits are very low for each element and are calculated as the mean 
blank value plus three standard deviations of this mean blank.   
 All concentrations are usually presented as ppb (ng g-1) or ppm (μg g-1) 
wet weight. Bioaccumulation factors (BFs) in helminths are calculated as the 
ratios of the metal concentration in the parasite to those in the host tissues   
(C [parasite] / C [host tissue]) [7]. 
 
3. Studies performed  
 
 In the last two decades several studies have been performed worldwide in 
different habitats and/or conditions (theoretically both polluted and 
unpolluted terrestrial and mainly aquatic ecosystems, including freshwater, 
estuarine and marine environments) in order to investigate heavy metal 
pollution using parasitological models. Different host-parasite models using 
several groups of vertebrates (mainly fish, mammals and birds) and parasites 
have been assessed. These models often included acanthocephalans, but also 
cestodes and nematodes were evaluated. Considering the wide diversity 
within this type of research, it is possible to categorize studies according to 
more homogeneous groups. We do not intend this chapter to be a complete 
revision of the available data on this subject. In fact, it emphasizes some 
general aspects and reviews the work performed by our research group. 
 
3.1. Aquatic ecosystems  
 
 Toxic element pollution has been more extensively investigated in 
aquatic environments than in terrestrial habitats. Fish and birds inhabiting 
aquatic ecosystems have been largely used as organisms for monitoring 
environmental pollution. Marine ecosystems are continuously threatened by 
contaminants, including heavy metals, which are frequent products of both 
anthropogenic activities and natural processes. The biomagnification of some 
metals such as mercury along the food chain is a major concern in marine 
environments increasing the potential for human exposure [34-36]. The use 
of bioindicators allows evaluating the risk of exposure, acting as early 
warning systems for environmental deterioration but firstly the selection of 
representative species is required [37]. With respect to the marine 
compartment, seabirds have been intensively used because of their high 
trophic position and bioaccumulation capacities together with their ability to 
process certain inorganic elements [38]. In this context, we have studied the 
concentration of some toxic elements in two seabird species using fresh 
carcasses obtained from beached bird surveys along the central coast of 
Portugal: the Atlantic gannet, Morus bassanus (Sulidae) and the razorbill 
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Alca torda (Alcidae) [39, 40]. In addition we are studying the usefulness of 
the model Tetrabothrius sp. / M. bassanus as a bioindicator of marine toxic 
element pollution. When assessing potentially toxic elements in  M. bassanus 
it was evidenced that: i) mercury was roughly above the minimum level for 
adverse effects in birds, ii) there was a higher accumulation of Se and Cd in 
kidney, of Pb in feathers, and of Mn in liver, and iii) the age of the analyzed 
birds (juveniles, sub-adults and adults) seems to affect the accumulation of 
Cd, Co, Hg, Mn, Se and Zn [39]. Preliminary data concerning the model 
Tetrabothrius sp. / M. bassanus seem to indicate that it could be proposed as 
a good bioindicator system to evaluate environmental Cd and Pb pollution in 
marine environments (personal data). In the similar study involving A. torda 
again it was possible to evidence a possible contamination risk by mercury 
and also by chromium [40]. A higher accumulation of Se and Cd was 
detected in kidney, of Zn and Pb in feathers, and of As and Mn in liver of    
A. torda. Razorbill’s age was also found to affect the accumulation of Cd, Cr, 
Cu, Hg, and Mn, with juveniles presenting higher levels of Cu and Mn than 
older individuals [40].      
 In the polluted estuarine habitat of the Ria de Aveiro (Portugal) we 
analyzed trace element concentrations in Proteocephalus macrocephalus 
(Cestoda) and Anguillicola crassus (Nematoda) in comparison to their fish 
host, the European eel, Anguilla anguilla [41].  Our results confirmed that the 
consumption of eels collected in this study area represents no risk for 
humans, because the values of toxic elements quantified in the edible portion 
of the analyzed eels were below the maximum limits allowed by EU 
regulations. Consequently, the consumption of these fish by humans should 
be safe after removing all viscera, which at times presented higher 
concentrations than those in the edible portion. Nonetheless, since eels are 
prey to birds and carnivores, eels might represent a real contamination risk 
for wildlife. The survey also allowed concluding that the model                
P. macrocephalus / A. anguilla is a promising bioindicator system to evaluate 
environmental Cr, Ni, Pb and Zn exposure in aquatic areas where both 
species are present.  
 
3.2. Terrestrial ecosystems 
 
 As mentioned earlier, most studies dealing with environmental terrestrial 
conditions, using or not parasitic models, have been designed under 
experimental conditions [27-29] or focused either on theoretically polluted 
areas such as floodplains, landfills, dumping sites, mine areas and polluted 
cities, or on areas where major ecological accidents have occurred [e.g. 25, 
26, 30, 32]. Contrarily, insufficient attention is devoted to areas not included 
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in the latter circumstances, where environmental quality is often high because 
they are usually subjected to low disturbances [13, 15]. However, it should be 
taken into account that long-term pollutant activities may disturb the more 
pristine ecosystems. 
 In this sense, we performed an environmental study in an area of high 
ecological interest, the El Hierro Island in the Canary Archipelago, declared a 
reserve of the biosphere by the UNESCO in 2000. Later we compared the 
obtained insular data (El Hierro Island) on Cd and Pb pollution using the 
models Rattus rattus / Moniliformis moniliformis and Mus domesticus / 
Rodentolepis microstoma with those previously reported in NE Spain using 
the model Apodemus sylvaticus / Gallegoides arfaai also obtained under 
natural field conditions. We verified that, although lead values were similar 
in both studies, cadmium tissue levels in the continental area were much 
higher than those found in El Hierro [13, 31]. In the urban dumping site of 
Garraf (located only 32 km away from Barcelona, Spain) concentrations of 
Cd and Pb were also recently tested using another parasitic model (Apodemus 
sylvaticus / Skrjabinotaenia lobata) [32]. The reported levels of lead were 
only slightly higher than those evidenced in El Hierro, but again, cadmium 
concentrations were much higher than those registered in El Hierro [13, 32]. 
In general, it could be stated that pollution in El Hierro is lower than in the 
several areas analyzed in the Iberian Peninsula, corroborating that the 
environmental quality of zones that have partial or complete protection status 
is often high. However, as pointed above, long-term pollutant activities (such 
as tourism-related activities and traffic) might disturb remote or protected 
ecosystems that require a systematic control using suitable species or 
helminthological models as bioindicators of pollution by heavy metals.  
 The model Apodemus sylvaticus / Gallegoides arfaai was the first terrestrial 
host-cestode system evaluated for its potential capacity for accumulating 
cadmium. However, it was found that this model could not be considered an 
effective system for monitoring environmental cadmium pollution [31]. The same 
was found for another rodent / cestode model (A. sylvaticus / Skrjabinotaenia 
lobata), for a lagomorph / cestode model (Oryctolagus cuniculus / Mosgovoyia 
ctenoides), and for a columbiform bird / cestode model (Columba livia / 
Raillietina micracantha) [32, 42, 43]. More recently, the same was found for the 
model M. domesticus / R. microstoma [13].  
 Precedents of terrestrial models involving acanthocephalan parasites of 
vertebrates to study Cd bioaccumulation are scarce. The large 
acanthocephalan pig’s parasite Macracanthorhynchus hirudinaceus was 
considered an important cadmium bioaccumulator on the basis of the study 
performed in Bolivia under naturally conditions [44]. The acanthocephalan 
M. moniliformis was tested under laboratory conditions on infested Rattus 
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norvegicus and it was concluded that M. moniliformis might be used as a 
highly sensitive bioindicator of cadmium pollution in terrestrial and urban 
ecosystems [27]. This presumption has recently been corroborated in the 
above mentioned field study reported from El Hierro although it is necessary 
to note that natural conditions are much more heterogeneous than 
experimental premises [13].  
 As indicated for cadmium, again a reduced number of terrestrial systems 
involving acanthocephalans parasites of vertebrates were evaluated in respect to 
their potential for lead bioaccumulation. The species M. hirudinaceus was able to 
bioaccumulate lead at least under the above mentioned conditions in which the 
study was performed in Bolivia and it was pointed out that M. hirudinaceus 
might be used as an important lead bioaccumulator in terrestrial biotopes 
especially as it is a very abundant parasite of domestic and wild pigs throughout 
the world [44]. The model R. norvegicus / M. moniliformis was tested under 
experimental conditions and it was considered a useful and promising 
bioindicator system for lead in urban ecosystems in temperate regions [28]. 
Despite the variability of natural conditions in contrast to experimental controlled 
variables, the bioaccumulation factors reported from El Hierro show little 
difference from those obtained experimentally, and confirm the suitability of this 
system as a useful and promising tool in environmental monitoring [13, 28].   
 The first terrestrial model involving a cestode parasite of rodents 
studied for the possible capacity of lead accumulation was Rattus 
norvegicus / Hymenolepis diminuta, probably because the host is widely 
distributed and easily accessible, meeting some of the criteria set for a 
good bioindicator [18], either under experimental conditions or in the 
field [29, 30]. The survey performed in the city of El Cairo (Egypt) 
allowed considering this model as a promising bioindicator for lead in 
urban ecosystems [30]. In the same study from El Cairo, the 
bioaccumulation capacity of the larval stage of Taenia taeniaeformis 
located in cysts in liver tissue of the same rats parasitized by H. diminuta 
was also tested. It was observed that the level of lead in T. taeniaeformis 
was similar to those of the different evaluated tissues. This observation 
allowed postulating that the cestodes’ ability to take up lead is related 
with the parasite’s microhabitat within the host and/or its developmental 
stage [30]. Furthermore, it was pointed out that heavy metals are not 
distributed evenly in the cestodes being concentrated especially in the 
gravid proglottids of the strobila. Thus it was suggested that those parts of 
strobilae, which are similar in size and have gravid proglottids should be 
preferred when assessing heavy metals in cestodes [30]. 
 Other studies have also been performed in terrestrial habitats from Spain 
and Portugal to evaluate the relationship between bioaccumulation in 
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cestodes of vertebrates and environmental lead exposure. Similar models 
were used involving rodents, but also lagomorphs and even urban birds (A. 
sylvaticus / G. arfaai and S. lobata, O. cuniculus / M. ctenoides and C. livia / 
R. micracantha) [13, 31, 32, 42, 43]. The need to use the above mentioned 
portions of cestodes is easy to fulfill when trying to test entire cestodes 
smaller than H. diminuta such as R. microstoma, G. arfaai and S. lobata. 
 
Table 1 Mean lead bioaccumulation factors [7] calculated for diverse cestode 
parasitic models in respect to several terrestrial vertebrate tissues. 
 
Model Parasite Family Liver Kidney Muscle Ref.
 
A. sylvaticus 
G. arfaai 
Anoplocephalidae 
 
20 6 24 [31]
 
A. sylvaticus 
S. lobata 
Catenotaeniidae 
 
33 – 53 6 – 8 52 -81 [32]
 
R. rattus 
H. diminuta 
Hymenolepidiidae 
 
29 – 87 6 – 11  [30]
 
M. domesticus 
R. microstoma 
Hymenolepidiidae 
 
18 26 28 [13]
 
O. cuniculus 
M. ctenoides 
Anoplocephalidae 
 
1.5 2  [42]
 
C. livia 
R. micracantha 
Davaneidae 
 
10 15 80 [43]
 
 Table 1 presents the lead BFs for models involving cestodes belonging to 
several families and their vertebrate hosts in terrestrial ecosystems. The       
A. sylvaticus / G. arfaai model was proposed as an alternative to evaluate 
environmental lead exposure, especially outside urban areas where the wood 
mouse may be readily available [31]. Similarly, the model A. sylvaticus /      
S. lobata was tested and proven to be a useful tool for biomonitoring lead 
pollution in terrestrial habitats [32]. In addition, the BFs reported in the 
model M. domesticus / R. microstoma are in agreement with the hypothesis 
that cestodes with a relatively large tegumental surface in respect to its 
weight should reach high bioaccumulation factors and therefore they could be 
considered potentially good bioindicators [13, 43]. It is well-known that 
cestodes inside the intestine are very efficient taking up bile salts produced in 
the liver through the hepatic intestinal cycle [10]. This capacity should be 
increased in the case of R. microstoma due to its hepatic (inside the bile 
ducts) and duodenal location. In fact the BFs reported for this cestode are quite 
high (see table 1) particularly if we consider that the sample was obtained from 
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El Hierro Island, an area with very low lead pollution [13]. With respect to 
models involving parasites of terrestrial birds, only a few have been assessed as 
bioindicators of environmental pollution. The model Columba livia / Raillietina 
micracantha from the city of Santa Cruz de Tenerife (Canary Islands, Spain) 
was proposed as another promising bioindicator to evaluate environmental 
toxic element exposure, particularly Pb and Mn, in areas where pollution levels 
are still relatively low and where both common species are present [43]. The 
concentration of some toxic elements was also studied in a cestode parasite of 
lagomorphs, concretely in the model Oryctolagus cuniculus / Mosgovoyia 
ctenoides collected from Portugal. Unlike the above mentioned models, the 
obtained results from M. ctenoides and wild-rabbits disproved this model as a 
promising bioindicator system [42]. The contrasting results obtained in the 
different models might be due to the large size of M. ctenoides in comparison 
to the other evaluated cestodes and/or due to differences in the tegumental 
absorption processes between cestode families.  
 
4. Conclusions 
 
 The information available to date confirms that several parasitic models 
are promising bioindicator systems to evaluate environmental cadmium and 
mainly lead pollution in terrestrial non-urban habitats as it has been widely 
demonstrated in aquatic environments. In addition, the present knowledge 
gives a positive answer to the question on whether or not parasites can really 
reveal environmental impact. In the future, some recommendations for the design 
of monitoring studies should be taken into question in order to increase the 
efficiency of environmental monitoring programs. 
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Abstract. Mycophenolate mofetil (MMF), an ester prodrug of the 
immunosuppressant mycophenolic acid (MPA), is widely used for 
maintenance immunosuppressive therapy and prevention of renal 
allograft rejection in renal transplant recipients. 
      MPA inhibits inosine monophosphate dehydrogenase (IMPDH), 
an enzyme involved in the “de novo” synthesis of purine 
nucleotides, thus suppressing both T-cell and B-cell proliferation. 
MPA shows a complex pharmacokinetics with considerable inter- 
and intra- patient by between- and within patient variabilities 
associated to MPA exposure. Several factors may contribute to it. 
The pharmacokinetic modeling according to the population 
pharmacokinetic   approach   with          the   non-linear   mixed   effects  
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models has     shown to be a powerful tool to describe the relationships between MMF 
doses and the MPA exposures and also to identify potential predictive patients’ 
demographic and clinical characteristics for dose tailoring during the post-transplant 
immunosuppresive treatment.  
 
Introduction 
 
 Mycophenolic acid based therapies are widely used in combination 
with calcineurin inhibitors (cyclosporine, tacrolimus, sirolimus) as 
maintenance immunosuppression in renal transplantation. Mycophenolate 
mofetil (MMF, brand name cellCept®, Hoffmann-La Roche, Basel, 
Switzerland) is one of the therapies currently used. In this context, there 
has been considerable interest in immunosuppressive regimens which 
permit reduction or elimination of calcineurin inhibitor (CNI)-associated 
and other chronic toxicities while maintaining adequate immune-
suppresion [1]. MPA exposure values show a high variability partly 
attributable to its complex pharmacokinetics [2,3]. Several factors as 
albumin concentrations, renal function, co-medication and genetic 
polymorphism, may contribute to it [2-6]. Recent literature supports the 
notion that therapeutic drug monitoring (TDM) of MPA improves 
monitoring of kidney transplant patients on high risk of acute rejection or 
on calcineurin inhibitor minimization protocols [7,8]. The current review 
discusses the pharmacokinetics of MPA and its conjugated metabolites as 
well as the population pharmacokinetic models developed to describe it. 
Results of an integrated model recently developed by our group including 
the MPA protein binding, the pharmacokinetics (PK) of both metabolites 
(7-O-MPA glucuronide (MPAG) and acyl-glucuronide (AcMPAG) and 
the influence of co-medication and of multidrug resistance associated 
protein 2 (MRP2) polymorphism on the PK of MPA and its metabolites 
are also presented. 
 
1. Chemistry of mycophenolic acid and its metabolites 
 
 Mycophenolic acid (MPA) is an antibiotic substance derived from 
Penicillium stoloniferum. Mycophenolate mofetil (MMF) is the 2,4-
morpholinoethyl esther of MPA [9]. It was developed as a prodrug 
because the low oral bioavailability of MPA. Molecular structures of  
mycophenolic acid and its conjugated metabolites, i.e. the phenolic MPA 
7-O-glucuronide (MPAG) and the acyl-glucuronide (AcMPAG) are 
summarized in Fig. 1. 
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Figure 1. Molecular structures of mycophenolate mofetil (MMF), mycophenolic acid 
(MPA) and its metabolites, i.e. phenolic MPA 7-O-glucuronide (MPAG) and  acyl-
glucuronide (AcMPAG). 
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Figure 2. Purine biosynthetic pathways and mycophenolic acid activity. 
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2. Pharmacodynamics of mycophenolic acid 
 
 MPA blocks the “de novo” biosynthesis of purine nucleotides by 
inhibition of the enzyme inosine monophosphate dehydrogenase [10-12]. 
Mycophenolic acid is important because of its selective effects on the 
immune system. As displayed in Fig. 2, it prevents the proliferation of T-
cells, lymphocytes, and the formation of antibodies from B-cells. It also may 
inhibit recruitment of leukocytes to inflammatory sites.  
 
3. Pharmacokinetics of mycophenolic acid 
 
 The pharmacokinetic processes that take place when MMF is given 
orally are summarized in Fig. 3. After its oral administration, MMF is rapidly 
and essentially, completely absorbed, and then completely hydrolised to 
MPA, by estearases in the gut wall, blood, liver and tissue [2]. Oral 
bioavailability of MPA, after MMF administration ranges from 80.7% to 
94% [3]. MPA is mainly metabolized by glucuronidation by several uridine 
diphosphate glucuronosyltransferases (UGTs) in the liver, gastrointestinal 
tract and kidneys into its inactive MPA 7-O-glucuronide (MPAG) and the 
pharmacologically active acyl-glucuronide (AcMPAG) [13]. Renal clearance 
of unchanged MPA is negligible [3] while MPAG and AcMPAG are mainly 
excreted into urine via active tubular secretion mediated by MRP2 (multidrug 
resistance-associated protein 2). In the liver MPA is taken up into 
hepatocytes, glucuronidated to MPAG which is then excreted into bile 
through MRP2  and then de-conjugated back to MPA by gut bacteria [14]. 
The formed MPA is then reabsorbed in the colon. Biliary secretion of 
MPAG, leading to this enterohepatic recirculation (EHC), contributes 
approximately 40% to the area under the plasma concentration-time curve 
(AUC) and  is considered as the major cause of the secondary peak (observed 
from 6 to 12 h after oral administration) of MPA in plasma [15]. The EHC is 
also assumed to occur for the conjugated metabolite AcMPAG [16]. 
Ciclosporin causes a decrease in the biliary secretion of MPAG and thereby 
decreases MPA plasma levels and its exposure [14,17,18]. This interaction 
has been associated with MRP2 inhibition of biliary secretion of MPAG and 
MPA by ciclosporin [19,20]. On the other hand, MPA is extensively bound to 
serum albumin [21] and a protein binding ranging from 97% to 99%  has 
been reported in patients with normal renal and liver functions [2]. Although 
lower, MPAG also displays a high albumin protein binding (82%) in stable 
patients [3]. Therefore, competition between MPA and MPAG by albumin 
binding may exist. The interplay between all the processes above described 
leads to large between-patient and within–patient variabilities associated to 
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the exposure of MPA and its metabolites in renal transplant patients, as it has 
been previously reported [2,3]. 
 
4. Pharmacokinetic variability 
 
 Renal function, serum albumin concentrations, haemoglobin levels, 
delayed graft function and immunosuppressive co-medication have been 
described as factors contributing to the variability and time-dependent 
pharmacokinetics described for MPA [6,22-27]. Previous studies [28] 
demonstrated that decreased albumin plasma concentrations lead to increased 
free fractions both of MPA and MPAG. As consequence, relatively more free 
MPA (fMPA) is available for elimination resulting in decreased total MPA 
(tMPA) exposure. However, the fMPA exposure is unaffected. This often 
happens with drugs of low extraction rate [29] as it is the case of MPA [30] 
and it implies that, in these cases, tMPA exposure could drop below the 
therapeutic values, so that MMF dose should be increased in order to avoid 
acute   rejection.  The influence of  renal  function on the  pharmacokinetics  of  
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Figure 3. Pharmacokinetics of mycophenolic acid (MPA) and its metabolites, 
phenolic MPA 7-O-glucuronide (MPAG) and acyl-glucuronide (AcMPAG) after 
mycophenolate mofetil (MMF) oral administration. 
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MPA and its conjugates has also been widely reported [22,28]. As it should 
be expected, a very poor renal allograft function (i.e. CLCR values around    
10 mL/min), mainly occurring in the earliest phases after transplantation, 
have major effects on both MPAG and AcMPAG exposures than on 
exposures to tMPA or fMPA. According to De Winter et al. [28], depending 
on the calcineurin inhibitor (CNI) given to patients with impaired renal 
function, differential effects on tMPA and fMPA exposures can be observed. 
In the case of ciclosporin tMPA exposure decreases and fMPA exposure 
remains the same. In patients under tacrolimus an increased exposure to 
tMPA and a small increase in fMPA exposure are observed. 
 The justification of this is that under tacrolimus, accumulation of MPAG, 
as consequence of low renal function, results in increased transport of MPAG 
to the gallbladder leading to increased recirculation of MPAG to MPA. 
Because the extra-recirculation, MPAG does not accumulate to an extent 
where it can displace MPA from its protein binding sites. It results in 
increased tMPA and fMPA due to extra-recirculation and no change in 
unbound fraction of MPA. By contrast, in patients under ciclosporin the 
accumulated MPAG following renal impairment cannot be compensated by 
increased recirculation because MRP2 transport is inhibited by ciclosporin. 
As a result MPAG displaces MPA from its protein binding sites, leading to 
an increased fraction of fMPA. The increased fMPA exposure is immediately 
compensated for by an increase in MPA glucuronidation according to the 
theory of restrictively cleared drugs. Therefore, in this case the result is 
decreased tMPA exposure, unchanged fMPA exposure and an increased 
fMPA fraction. The genetic factors controlling the level of UGT-mediated 
MPA metabolism [31-34] and the MRP2-mediated conjugated metabolites 
transport [35] can also partly explain the observed variability in MPA 
exposure. The large variability and the MPA narrow therapeutic index lead to 
optimization of the immunosuppressive regimen in order to avoid the risk of 
acute rejection (AR), and to prevent adverse-effects associated with long-
term immunosuppressive treatment.  
 
5. Relationship between MPA exposure and clinical outcome 
 
 In vitro studies have suggested that the fMPA concentrations may more 
accurately reflect the degree of immunosuppressive action of the drug than 
does the concentrations of tMPA [21]. The fMPA concentrations have been 
shown to correlate with the risk of leukopenia and infection [24]. However, 
although a relationship between fMPA exposure and the risk for acute 
rejection should be expected, it has not been demonstrated yet. More 
information is needed about the relationship between fMPA exposure and the 
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risk for acute rejection and side effects to interpret the clinical effect of 
changes in protein binding of MPA. Alterations in both albumin 
concentrations and renal function have little effect on fMPA exposure and 
thereby little clinical relevance. However special attention must be paid on 
patients under tacrolimus with very poor renal function, as the increased 
fMPAG can cause elevated exposure to both tMPA and fMPA. Regarding to 
tMPA, a correlation between tMPA exposure and the risk of acute rejection 
has been reported [36]. The proper tMPA exposure (AUC) range to avoid 
acute rejection has been recommended to be 30-60 μg·h/mL when combined with 
ciclosporin [36-39]. Under this co-medication there is no further reduction in 
acute rejection at AUC values >60 (mg/L)·h [36]. Therefore, avoidance of higher 
exposure would seem prudent on the basis of these results. For patients under 
tacrolimus, the range of 30-60 μg·h/mL has also been suggested for MPA 
exposure [39]. Regarding to patients with low albumin concentrations or poor 
renal function, accompanied by low tMPA exposures, candidates to increased 
doses of MMF to avoid acute rejection, the dose increase will also increase the 
fMPA exposure. Therefore, the neutrofil count in these patients should be 
accurately monitored, as there may be a potential increased risk of leucopenia and 
infections. In that sense it should be noted that fMPA exposures > 0.14 (mg/L)·h, 
are expected to increase the risk of adverse events. This cut-off has been 
established in a pediatric study in the early post-transplant phase [24]. On the 
other hand, measurement of the pharmacologically active metabolite AcMPAG 
could also provide information about proper exposures to it in order to avoid the 
risk for adverse events. The population approach has shown to be a powerful tool 
for these purposes. The characteristics of this approach are reviewed below. 
  
6. Population pharmacokinetic approach: Non linear mixed 
effects modeling 
 
 According to the FDA Guidance [40], population pharmacokinetics, is 
the study of the sources and correlates of variability in drug concentrations 
among individuals who are the target patient population receiving clinically 
relevant doses of a drug of interest. It allows to identify the determinants of 
pharmacokinetic variability, explaining between-patient differences in drug 
exposure and can provide clinically applicable models for dose tailoring. 
With this approach, the description of the pharmacokinetics of a given drug 
in the target population can be performed by determining a) what is the mean 
population pharmacokinetic behaviour, b) which factors influence the mean 
population PK behaviour and, c) what is the uncertainty degree associated to 
the mean population PK behaviour, i.e. the magnitude of between-patient 
variability and residual error can be quantified. Its advantages when compared 
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to the classical approach are numerous such as being able to analyze 
concentration-time data of parent compound and metabolites, data from several 
doses or plasmatic and urine data, simultaneously. Moreover, apart from 
analyzing dense data (intensive sampling in each individual) it allows to 
analyze unbalanced data and sparse data (few samples per individual) coming 
from observational studies, phase II/III/IV clinical studies or from special 
populations (neonates, children, elderly, transplantation, HIV) or from 
therapeutic drug monitoring (TDM).  
 Non linear mixed effects models implemented in several softwares are the 
most widely used for these purposes [41]. Once validated, the models developed 
with this approach will allow, a) description and a better knowledge of the  
pharmacokinetic profile of a given drug in the target population, b) simulations of 
new scenarios to predict exposures to different dosing regimens, to evaluate 
consequences of alternative sampling designs, or to evaluate the impact of 
changes in patients’ characteristics, and c) calculation of the first dose and dose 
tailoring during the therapeutic drug monitoring, in order to achieve the target 
value of a given PK parameter (in general, AUC or area under the curve, peak or 
through concentrations) demonstrated to be the best marker of efficacy. 
Regarding to the last point, it should be noted that computer programs designed 
for dose optimisation for individual patients to be used as a part of routine clinical 
care, exist [42]. These programs require the implementation of the PK parameters 
estimated through the non linear mixed effects modeling.  
 In the mixed-effects modeling context [41], the collection of population 
characteristics is composed of population mean values (derived from fixed-
effects parameters) and their variability within the population (generally the 
variance-covariance values derived from random-effects parameters). This 
approach allows to estimate directly the parameters of the population from 
the full set of individual concentration values. The individuality of each 
subject is maintained and accounted for, even when data are sparse. Fig. 4 
summarizes the relationship between fixed and random effects in a 
population PK model. According to this and taking into account one of the 
PK parameters, i.e. clearance (CL), it is assumed that the deviations of 
individual plasmatic clearances of subject 1 (CL1) or 2 (CL2) from the mean 
population value ( CL ) are given by η1CL and η2CL, respectively (left panel). 
The set of values of etas (ηi) of all individuals in the target population is 
assumed to follow a normal distribution of mean equal to zero and variance 
ω2.  Moreover, the set of deviations of the observed concentrations in each 
individual at a given sampling time j (open circles), from the individual 
predictions by the model (continuous lines or f(CL1), f(CL2), or f(CLi) for the 
i subject), given by εij, in general (i denoting the individual, i.e. i=1,2,..n; and 
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j the sampling time, i.e.,j=1,2,…t) are also assumed to follow a normal 
distribution of mean equal to zero and variance σ2 (right panel). f( CL ) 
represents the concentrations predicted for an individual of the target 
population showing the typical clearance value equal to the mean population 
value, CL . In summary, the population parameters estimated by the non 
linear mixed approach are the following: 
 
a) the fixed effects, i.e. the mean population pharmacokinetic 
parameters as CL or the corresponding regression parameters when 
there is a stististically significant relationship between the PK 
parameters and continuous (age, body weight, creatinine clearance, 
doses or exposure parameters corresponding to  co-medication…) or 
discontinuous (gender…) covariates.  
b) the variances of the η and  ε distributions, that is ω2 and  σ2, 
respectively..  
 
 During the estimation process the η and  ε values for each individual will 
be calculated and thus the individual PK parameter values obtained to be 
used for dose tailoring during the TDM. However, before that, the validation 
or evaluation of the predictability of the model developed is required. Internal 
or external validation techniques can be applied for this purpose [40]. 
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Figure 4. Relationship between fixed effects and random effects in the non linear 
mixed effects approach. 
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7. Population pharmacokinetic modeling of mycophenolic acid 
and its metabolites 
 
 Several MPA population pharmacokinetic models have been previously 
developed trying to identify the sources of variability of MPA 
pharmacokinetics after MMF oral administration [4,6,28,34,43-48]. Some of 
them have allowed to describe the second MPA plasma peak by including the 
EHC in the modeling process [34, 49], as the influence either of changes of 
protein binding [28,47], or of genetic polymorphism in UGT on MPA 
exposure [34]. Recently our group has addressed its work on the 
simultaneous modeling of total and free MPA as total MPAG and AcMPAG 
concentration vs time data proceeding from the PK sub-study of the 
Symphony study [50]. In the Symphony PK sub-study the effect of four 
different immunosuppressive therapies on the PK of MPA was evaluated. 
Briefly, patients randomized in four groups were given fixed doses of MMF 
(1 g twice daily) together with either standard doses of ciclosporin (group A), 
low doses of ciclosporin (group B) or low doses of the immunosuppressive 
macrolides that is to say tacrolimus (group C) or sirolimus (group D). PK 
sampling was performed on 5 occasions (on day 7 and at 1, 3, 6 and 12 
months after transplantation) during the first year after transplantation and 
each time tMPA, fMPA, tMPAG and tAcMPAG exposures were measured. 
Results corresponding to the non-compartmental analysis of this study [50] 
indicated that tMPA and fMPA exposures were lower in patients receiving 
ciclosporin compared to those that were given macrolides. In contrast, 
exposures to the metabolites MPAG and acylMPAG were higher in patients 
treated with ciclosporin compared to the others (Fig. 5). 
 Moreover, in general, a trend to increased tMPA and fMPA exposures 
and decreased tMPAG and tAcMPAG exposures with post-transplant time 
was observed (Fig. 5). This was attributable to the decreasing and increasing 
of MPA and MPAG/AcMPAG clearances, respectively, with post-transplant 
time. On the other hand, Lloberas et al. [35], reported statistically lower 
tMPA and fMPA exposures in patients treated with macrolides being 
homozygous (TT) or heterozygous (CT) carriers of the MRP2 C24T single 
nucleotide polymorphism (SNP) vs non carriers (CC), after having 
investigated the influence of genetic polymorphism of MRP2-mediated 
transport on the MPA exposures in all groups of treatment. It should be noted 
that this effect could not be observed in the group of patients treated with 
ciclosporin. The time-dependent clearance found in this study was in 
agreement with results of  previous studies [4,6,45]. As previously reported, 
ciclosporin dose tapering and  improvement of the renal function along the 
post-transplant  period  can be among others,    some  of the  causes of it.  Since 
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Figure 5. Normalized by dose exposure values given by AUCs (area under the the 
curve) observed for tMPA, fMPA, tMPAG and tAcMPAG, during the first three post-
transplant months of the PK sub-study of the Symphony study [40]. 
 
MPA is a low extraction rate drug, the low albumin concentrations associated 
to a delayed graft function during the early post-transplant stages can also 
lead to higher MPA clearances values at the early stages vs the late. On the 
other hand, inhibition of MRP2 transport by ciclosporin, in patients treated 
with it, leads to decreased MPAG biliar excretion that in turns results in 
decreased EHC, increased MPAG and AcMPAG exposures and decreased 
MPA exposures  when compared to the others. Regarding to the influence of 
C24T SNP, results of this study suggested a lower activity of transport of 
MPAG or AcMPAG through MRP2 in presence of C24T SNP that led to a 
decreased EHC, followed by lower MPA exposure and subsequently lower 
MPAG or AcMPAG exposures caused by its decreased formation, when 
compared to the non carrier (CC) genotype. This was only evidenced under 
macrolides when the effect of ciclosporin was not masking that of the SNP. 
Prompted by these results, a population pharmacokinetic model to allow the 
description of all these processes was developed (Fig. 6) (submitted for 
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publication). The pharmacokinetics of fMPA, tMPA, tMPAG and tAcMPAG 
were best described by an integrated model consisting on three linked 
compartment models; i.e.  two two-compartment models for fMPA and 
tMPAG and a one-compartment model for tAcMPAG (Fig. 6). The model 
was parameterized in terms of volumes of distribution (V) and plasmatic 
(CL) and distributional (CLD)clearances. An albumin compartment was also 
linked directly to the central compartment of fMPA to describe its binding to 
this plasmatic protein (KB=binding rate constant). EHC could not be 
successfully modeled. 
 According to this model, after oral administration, MMF was transformed 
to and absorbed as MPA according to a time lagged first order kinetic process. 
Once in the systemic circulation MPA was simultaneously bound to albumin 
(bMPA) and the free fraction (fMPA) distributed and eliminated.  
 
CLf AcMPAG=CLMPA·(1-fm)CLf MPAG=CLMPA·fm
MPAG
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VC MPAG
CLD MPAG
CLMPAG
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Figure 6. Schematic representation of the final pharmacokinetic model to 
simultaneously describe the protein binding of free mycophenolic acid (fMPA) and its 
conversion to its phenolic 7-O-glucuronide (MPAG) and acyl-glucuronide 
(AcMPAG) conjugates by first order processes, after oral administration of 
mycophenolate mofetil. Dashed lines correspond to the part that could not be 
successfully modeled. bMPA: MPA bound to albumin. 
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 The fMPA protein binding was best described by a linear model 
(bMPA=KB·fMPA) as previously reported by Van Hest et al [46]. This might 
be due to the fact that the fMPA concentrations found in the current study 
(from 0.000019 to 0.005573 mmol/L) were far below the median plasma 
albumin concentrations of the studied population (42 g/L or 0.6087 mmol/L) 
and no saturation of the binding sites could be achieved. Obviously, taking 
into account at least one binding site to albumin, the protein binding would 
be hardly saturated with the current fMPA concentrations. It should be noted 
that fMPA and tMPA concentrations found in our study were around twice 
those observed by Van Hest et al [46] in which higher ciclosporin doses were 
given (around twice those of our study), and nevertheless the linear protein 
binding still described correctly our data. Effectively, unlike our results, Van 
Hest et al. [46], found statistically significant correlations between individual 
KB values and albumin plasma levels and MPAG concentrations. This could 
be attributed to the fact that most of the patients included in the current study 
showed albumin plasma concentrations within the expected range of normal 
healthy adults (43 g/L, ranging from 35 to 53 g/L), even on day 7 of the study 
when delayed graft function should be expected to be more likely.  Only 8 
out of 56 patients and 2 out of 56 patients showed albumin plasma levels less 
than 35 and greater than 53 g/L, respectively; the albumin concentrations of 
the remaining patients were around the study population median level (42 
g/L). Regarding to MPAG concentrations, these were lower in our study than 
those found by Van Hest el al. [46]. The stable renal function of patients and 
also the lower doses of ciclosporin in patients under this co-medication, 
might be the contributing factors to this fact. According to Bullingham et al. 
[3], MPA free fractions (fu) can increase as the MPAG concentrations 
increase to 475 mg/L (957 mmol/L). In our study peak MPAG concentrations 
were lower than 236 mg/L (479 mmol/L) in most patients, so that no 
displacement of bound MPA (bMPA) by MPAG should be expected.  
 Regarding to the elimination process of fMPA it took place by first-order 
kinetic processes as did the metabolites. According to the fm value obtained 
(0.874), MPAG was the major metabolite, while only a 0.126 (1-fm) of fMPA 
present in the blood stream was transformed to AcMPAG. These values were 
in agreement with that reported by Shipkova et al [16], The total clearance 
value of fMPA was the contribution of the clearance of formation MPAG 
(fm·CLMPA) and the clearance of formation AcMPAG ((1-fm)·CLMPA). 
Although EHC modeling could not be included, it does not seem to have a 
relevant impact from a clinical point of view, since the covariates that could 
affect the recycling rate constant (KS) could be incorporated in both the MPA 
and its metabolites clearances. In effect, in agreement with results of the non-
compartmental analysis, an statistically significant relationship was found 
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between CLMPA and ciclosporin through concentrations in patients under 
ciclosporin, in such a way that CLMPA increased with it and was higher in C24 
SNP homozygous (TT) or heterozygous (CT) carriers vs non carriers (CC), in 
patients under macrolides. The time-dependent clearance of MPA in the 
target population was also confirmed by the model that suggested that CLMPA 
on day 7 was higher than at the remaining monitoring days; however, gradual 
tapering of ciclosporin through concentrations along the post-transplant 
period was not sufficient to describe these changes over time nor other 
covariates whose significance could not be demonstrated as low graft 
function or acidosis or uremia associated to it and consequently low levels of 
albumin.  
 Regarding the metabolites, AcMPAG showed around a ten times faster 
elimination than MPAG, probably due to the highest hydrophilicity of the 
former. Plasmatic clearances of both metabolites were influenced by renal 
function through the estimated CLCR according to the Cockcroft-Gault 
formula, as it should be expected, due to its elimination major pathway by 
urinary excretion [3, 16, 22].  Explicitly, both CLMPAG and CLAcMPAG were 
estimated to increase with renal function. Moreover, CLMPAG decreased in a 
significant statistically way with increasing ciclosporin trough concentrations 
in patients under ciclosporin and similarly to CLMPA, it was higher in C24 
SNP homozygous (TT) or heterozygous (CT) carriers vs non carriers (CC), in 
patients under macrolides. Regarding the influence of C24T SNP in 
CLAcMPAG, it was statistically significant, but only in patients under 
macrolides. By contrast, no statistically significant effect of ciclosporin 
through concentrations on CLAcMPAG could be evidenced.  
 Simulations performed once the model had been evaluated (Fig. 7), 
showed that after multiple fixed doses of MMF (1 g), at one month of the 
post-transplant period, both fMPA and tMPA exposures decreased 
significantly with increasing ciclosporin through concentrations from 100 to 
300 ng/mL. In patients co-treated with macrolides (sirolimus or tacrolimus), 
fMPA and tMPA were significantly lower in homozygous and heterozygous 
variants of the C24T SNP vs wild-type. Among all patients, the highest 
exposure would be observed in wild-type or no variant alleles co-treated with 
sirolimus or tacrolimus while the lowest exposure would be found in patients 
co-treated with standard doses of ciclosporin. Regarding MPAG, exposures 
increased significantly with increasing ciclosporin through concentrations 
(from 100 to 300 ng/mL) and in patients co-treated with macrolides, they 
were significantly lower in homozygous and heterozygous variants of the 
C24T SNP vs wild-type. In the case of ACMPAG, significantly lower 
exposures were observed in homozygous and heterozygous variants of the 
C24T SNP vs wild-type in       patients co-treated with macrolides and also vs the  
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Figure 7. Median values of simulated exposures of fMPA, tMPA and MPAG and 
AcMPAG, after 1 g MMF given orally to patients under ciclosporin with trough 
concentrations of either 100 or 300 ng/mL and to patients under macrolides whether 
non carriers or CT/TT carriers of the C24T SNP of MRP2. The impact of renal 
function given by CLCR estimated according to cockroft-Gault is also shown for 
MPAG and AcMPAG. 
 
remaining patients.  On the other hand, as expected, the major effects on both 
tMPAG and tAcMPAG exposures were due to changes in renal function 
given by CLCR (estimated according to Crokroft-Gault). In effect, 
independently of the co-medication group, exposures significantly decreased 
with increasing CLCR values, the effect was higher for MPAG (around 55% 
from 25 mL/min to 60 mL/min and around 47% from 60 mL/min to 120 
mL/min) than for AcMPAG (around 26% from 25 mL/min to 60 mL/min and 
around 42% from 60 mL/min to 120 mL/min). Then, renal function is the 
most influential covariate in both cases (CLMPAG and CLAcMPAG) followed by 
ciclosporin through concentrations and C24T SNP in the case of MPAG. The 
effect of C24T SNP is more relevant in CLAcMPAG than in CLMAPG. 
Unfortunately, the developed model did not allow the evaluation of the 
impact of changes in renal function on tMPA or fMPA exposures. Regarding 
changes in MPAG exposure with renal function observed in the current work, 
they are comparable to those found by De Winter et al. [28]. In summary we 
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built a population PK model to adequately describe plasma data of tMPA, 
fMPA and its currently known metabolites as a function of co-medication, 
C24T SNP of Mrp2 and renal function. According to it, patients under 
macrolides and non carriers of C24T SNP would require lower doses of 
MMF (around 40% less) than those under standard doses of ciclosporin with 
the same renal function. Since the model development does not allow 
evaluation of the impact of changes in albumin plasma levels and renal 
function on tMPA and fMPA it should be applied to patients with median 
albumin plasma levels of 42 g/L and median CLCR values of 60 mL/min , as 
the median of the population of the current study. 
 
8. Conclusion 
  
 In the present chapter we summarize the relevance of modeling by using 
the population approach in order to describe the pharmacokinetics of 
mycophenolic acid and its metabolites. It allows, not only increasing our 
knowledge to better understand the clinical PK of this drug, but also it may 
prove useful in predicting the PK of MPA and all the characterized 
metabolites after various administration regimens of MMF.  
 Moreover, based on the protein binding model developed, precise 
predictions of fMPA concentrations can be made. This can be useful in at 
least two situations: a) for historical data were only tMPA concentrations are 
available, fMPA concentrations can be predicted and used in developing 
PK/PD relationships, and b) as the tMPA assay is considerably simpler than 
the fMPA assay, measuring only tMPA concentrations may be an alternative 
to measuring fMPA. 
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 Abstract. Conjugated linoleic acid (CLA) has been reported to 
exert beneficial physiological effects on body composition and the 
immune system. However, little information is available on the 
influence of CLA on immune function during early life periods. 
The present study evaluates the effect of feeding an 80:20 mixture 
of cis-9,trans-11- and trans-10,cis-12-CLA isomers during 
gestation, suckling and early infancy on the systemic and mucosal 
immune responses of Wistar rats at three different time points: at 
the end of the suckling period (21-day-old rats), in early infancy 
(28-day-old rats), and later in life (adulthood). Cis-9,trans-11- and 
trans-10,cis-12-CLA isomers were detected in the milk of CLA-fed 
dams and in the plasma of all CLA-supplemented pups, and the 
highest content was achieved in those rats supplemented over the 
longest period. Dietary supplementation with that CLA mix 
enhances the systemic  production  of  the main in vivo and ex vivo 
immunoglobulin (Ig) isotypes in 21- and 28-day-old rats. 
Moreover, CLA supplementation during suckling and early infancy 
also enhances the humoral immune defenses at intestinal level, by 
means of mucosal IgA increase, whereas down-regulates the 
systemic   lymphoproliferative   response.   Finally,          we   described  
 
Correspondence/Reprint request: Dr. Àngels Franch, Department of Physiology, Faculty of Pharmacy 
University of Barcelona, 08028 Barcelona, Spain. E-mail: angelsfranch@ub.edu 
Francisco J. Pérez Cano et al. 204 
herein how feeding a diet enriched with the same isomer mix of cis9,trans11- and 
trans10,cis12-CLA from gestation to adulthood improves the capacity of adult rats to 
achieve a specific systemic and mucosal immune responses. All these data support the 
immunomodulatory effects of dietary supplementation of CLA, particularly of the 
cis9,trans11-CLA isomer, during early stages of life on immune system development, 
as well as the long-term effects on the specific immune response in adult age. 
  
Introduction 
 
 Birth is for the newborn a transition from a sterile environment to a 
world full of bacteria and viruses, where protection is crucial. During the first 
stages of life, antibodies from the mother are transferred to the foetus and the 
child decrease the number of infectious episodes caused by microorganisms 
to which exist maternal immunological memory [1,2]. The immune system is 
in constant evolution, and their function is profoundly influenced by 
maternal, environmental, dietary, and behavioural factors. Although the 
impact of these factors is greatest during the prenatal and immediate postnatal 
periods, their influence extends beyond this period. Patterns of development 
in postnatal life determine many of the immune outcomes in later life [3].  
 Over the last years, the effect of nutrition on the development of the 
immune system has acquired great interest and has led to adoption of the term 
“immunonutrition”. Because breast milk is the only natural food for 
newborns, and dietary contact has a pivotal role in the development of their 
immune system, significant progress has been made in the characterisation of 
milk components affecting growth, development and functions of the 
gastrointestinal tract and the immune system [4]. In this sense, breast milk is 
rich in, among others, immunoglobulins (Ig) that can bind and neutralise 
pathogens in the intestinal tract; bactericidal factors such as lactoferrin, 
lactoperoxidase and lysozyme and growth factors, nucleotides and cytokines 
that improve immune defence and gut-barrier function [5]. Besides these 
compounds, the dietary lipids present in breast milk have been studied with 
special attention. In this sense, it has been suggested that polyunsaturated 
fatty acids (PUFA), specifically docosahexaenoic acid and arachidonic acid, 
which constitute a relatively low fraction of the total fatty acids in human 
breast milk, participate in neonate immune development [6]. 
 Human milk contains measurable quantities of conjugated linoleic acid 
(CLA), a class of positional and geometric conjugated dienoic isomers of 
linoleic acid. The predominant CLA isomer in milk and dairy products is    
cis-9,trans-11 (c9,t11)-CLA, also called rumenic acid, which ranges in 
human milk from 83 to 100% of total CLA [7,8]. The trans-10,cis-12 
(t10,c12)-CLA isomer is also found in dairy products, although in lower 
proportion than rumenic acid [8,9], but even very low doses of the t10,c12-
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CLA isomer seem to have large biological effects [10]. The concentration of 
CLA in milk is influenced by the intake of food of ruminant origin [8].  
 CLA has been reported to exert beneficial physiological effects on body 
composition and inhibition of carcinogenesis, atherosclerosis, and diabetes 
[11-14]. Moreover, CLA isomer mixtures have been shown to modulate 
immune function in vitro and in vivo [15-19]. Results from these studies 
show great variability, partly because of differences in the experimental 
animal species used and the length of the studies, but also because of 
differences in the isomer mixtures used for supplementation. However, little 
work has been done on the immunomodulatory effects of CLA during the 
early postnatal periods (lactation or infancy), and even less during the 
prenatal period (gestation).  
 The present study evaluates the influence of dietary supplementation 
during gestation, suckling, and early infancy with an 80:20 isomer mix of 
c9,t11- and t10,c12-CLA on the systemic and mucosal immunity in Wistar 
rats at the end of the suckling period (21-day-old rats), in early infancy     
(28-day-old rats), and later in life (adulthood). 
  
1. Dietary supplementation with CLA during early life on the 
development of the immune system in rats   
 
 The aim of this part of the study was to evaluate the effect of dietary 
supplementation during early life with an 80:20 isomer mixture of c9,t11- 
and t10,c12-CLA on the development of the immune system in Wistar rats. 
CLA supplementation was performed during three life periods: gestation, 
suckling, and early infancy. For that purpose, the immunomodulatory effects 
of dietary CLA during gestation and suckling were evaluated in 21-day-old 
rats (at the end of the suckling period) [20]. And, on the other hand, the 
influence of CLA supplementation limited to suckling period and to early 
infancy was evaluated in 28-day-old rats (early infant rats, 1 wk after 
weaning) [21]. Moreover, as it has been suggested that CLA intake during 
early stages of development may have effects later in life [22,23], we have 
also studied whether CLA supplementation limited to suckling produces 
effects which can last until early infancy  [21]. 
 At both ages, their immune system is still in maturation (i.e., antibody 
production), however, in 28-day-old rats some immune functions are similar 
to those of adult animals (i.e., lymphoproliferative response). To investigate 
the immunomodulatory ability of CLA supplementation on the immune 
system of 21- and 28-day-old rats, both systemic and mucosal immune 
responses were evaluated [20,21,24]. 
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1.1. Experimental design           
 
 Animals were distributed in eight experimental groups according to the 
total period of CLA supplementation, administration route used, and age at 
the time immune status was assessed (21- or 28-day-old) (Fig. 1).   
 
 Day 21 assessment: Pregnant Wistar rats at 7 days’ gestation were 
randomly assigned to one of the following four dietary groups, and pups from 
these groups were sacrificed at the end of the suckling period (21- day-old):  
 
- 21/5* group: Pups from dams fed a 1% CLA diet during the last 2 
weeks of gestation and throughout the suckling period. During 
suckling, the pups received CLA through the dams’ milk. The total 
period of supplementation was 5 wk.  
- 21/5 group: Pups from dams fed a 1% CLA diet during gestation and 
a standard diet during suckling. During suckling, pups were CLA-
supplemented daily by oral (p.o.) administration. The total period of 
supplementation was 5 wk.  
- 21/3 group: Pups from dams fed the standard diet during gestation and 
suckling. Pups received CLA daily by p.o. administration throughout 
the suckling period. The total period of supplementation was 3 wk.  
- 21/0 group (Ref): Pups from dams fed the standard diet throughout 
the study. These animals constitute the reference diet group. The 
total period of supplementation was 0 wk.  
 
 Day 28 assessment: On the day of birth, pups from dams fed standard diet 
during gestation were randomly assigned to one of the following four dietary 
groups. All dams were fed standard diet throughout the period of study. Pups 
from these groups were sacrificed 1 week after weaning (28- day-old).  
 
- 28/4 group. Pups received CLA daily by p.o. administration during 
 suckling; after weaning, animals were fed 1% CLA diet from day 21 
 to 28 (early infancy). The total period of supplementation was 4 wk. 
- 28/3 group. Pups received CLA daily by p.o. administration during 
 suckling; after weaning, animals were fed standard diet up to day 28. 
 The total period of supplementation was 3 wk. 
- 28/1 group.  Pups received 1%  CLA diet  exclusively for one week 
 after weaning (days 21–28). The total period of supplementation was 
 1 wk. 
 - 28/0 group (Ref). Pups fed standard diet during suckling and early 
  infancy. These animals constitute the reference diet group. The total 
  period of supplementation was 0 wk.  
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Figure 1. Diagram of the experimental design beginning on day 7 of gestation until 
day 21 of suckling or day 28 of life. 1 CLA arrives at the foetus by transplacental 
transfer. 2 CLA arrives at  pups through the dams’ milk. 3 Total period of CLA 
supplementation from gestation until the end of suckling. 4 Total period of CLA 
supplementation from the day of birth until 1 wk after weaning.   
 
1.2. Dietary CLA supplementation      
 
 The standard diet used in this study corresponded to the American 
Institute of Nutrition (AIN)-93G formulation, containing 7% soybean oil. The 
1% CLA diet was obtained from modified standard flour AIN-513 (Harlan) 
containing 10 g CLA/kg [20]. Thus, the supplemented diet contained 6% 
soybean oil plus 1% CLA oil. The CLA isomer mixture was approximately 
80% c9,t11 and 20% t10,c12 from the total CLA isomers in oil. This 
proportion has been chosen due to its resemblance to that one present in 
breast milk [7]. CLA oil was kindly supplied by Loders Croklaan (Lipid 
Nutrition, Wormerveer, The Netherlands). The 1% CLA diet in suckling 
animals corresponded to a daily administration of 1.5 mg CLA oil provided/g 
of rat body weight from day 1 to 21. 
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1.3. Relative CLA concentration in dams’ milk   
 
 In order to confirm the CLA transfer from dams to pups through milk, we 
collected milk from dams on day 21 post-partum [20] and evaluated the 
content of c9,t11- and t10,c12-CLA isomers by fast gas chromatography, as 
previously described [25] (Table 1). The results showed that, at the end of 
suckling (day 21), milk from dams fed the CLA diet during gestation and 
suckling showed higher concentrations of the c9,t11- and t10,c12-CLA 
isomers than rats fed the standard diet. Moreover, the presence of a small 
quantity of c9,t11- and not of t10,c12-CLA in the milk of non-supplemented 
rats supports the concept that rats produce rumenic acid (c9,t11-CLA), as has 
been suggested by other authors, by conversion of free linoleic acid by the 
intestinal bacterial flora [26] or by the endogenous conversion of trans-
vaccenic acid, present in vegetable oils contained in standard diets [27]. 
 On the other hand, the proportion of these two isomers in milk, 86:14, 
varied from that supplemented to dams, 80:20 (Table 1). The lower 
proportion of t10,c12-CLA than that initially supplemented is probably due to 
the faster metabolism of this isomer. It has been reported that t10,c12-CLA 
activates the β-oxidation system more strongly than c9,t11-CLA in rats; 
therefore, the former could easily become oxidised [28]. 
 
Table 1. Relative content of c9,t11- and t10,c12-CLA isomers in dams’ milk and in 
the plasma of  21- and 28-day-old pups (% total fatty acids).  
 
 c9,t11-CLA1 t10,c12-CLA1 
Dams milk: standard diet 0.02 ± 0.00 0.00 ± 0.00 
Dams milk: CLA diet 2.93 ± 0.11** 0.46 ± 0.02** 
Plasma: 21/5* group 1.34 ± 0.01*σϖ 0.21 ± 0.01*σϖ 
Plasma: 21/5   group 1.78 ± 0.05*σ 0.13 ± 0.01*σ 
Plasma: 21/3   group 0.90 ± 0.01* 0.05 ± 0.00* 
Plasma: 21/0   group 0.15 ± 0.01 N.D. 
Plasma: 28/4  group 1.31 ± 0.03*φΨ 0.13 ± 0.01*φΨ 
Plasma: 28/3   group 0.44 ± 0.03*φ 0.05 ± 0.00*φ 
Plasma: 28/1   group 1.23 ± 0.03* 0.08 ± 0.00* 
Plasma: 28/0   group 0.15 ± 0.01 N.D. 
 
 
1 Values are expressed as mean ± SEM (n= 4-7 dams/group; n= 10 
pups/group). N.D., non-detectable. Significant differences: **P<0.001 vs. 
standard diet group; *P<0.05 vs. age-matched reference group (21/0 or 28/0); 
σP<0.05 vs. 21/3; ϖP<0.05 vs. 21/5; φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. 
Modified of Ramírez-Santana et al. [20,21].  
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1.4. Relative CLA concentration in rat plasma     
 
 Once confirmed that the CLA from the dams’ diet was able to be 
transferred through dams’ milk to pups, the efficiency in the incorporation of 
such PUFA from milk or directly by p.o. was also evaluated in the pups 
[20,21]. Therefore, the content of c9,t11- and t10,c12-CLA isomers in the 
plasma of 21- and 28-day-old pups was quantified by fast gas 
chromatography (Table 1). Regarding the concentration of CLA in the 
plasma of pups determined on the day of weaning, pups from group 21/0 
(Ref) showed a low plasma content of c9,t11-CLA and no t10,c12-CLA. 
Groups 21/5*, 21/5 and 21/3 had approximately nine, twelve and six times 
higher levels of c9,t11-CLA than group 21/0, respectively. Moreover, the 
plasma CLA content in the groups supplemented with the 80:20 CLA mix 
during gestation and suckling (21/5* and 21/5 groups; 5 wk) was ∼ 1.5 and 2 
times higher, respectively, than that of animals supplemented only during 
suckling (21/3 group; 3 wk) (Table 1).  
 These results demonstrate that CLA was absorbed by all the supplemented 
animals since c9,t11- and t10,c12-CLA isomers were detected in the plasma of 
all 21-day-old rats fed CLA. They also indicate that CLA, besides being 
incorporated after CLA p.o. supplementation, was also able to be transferred 
from dams to pups during suckling. However, these results cannot demonstrate 
that CLA transfers through the placenta, since the plasma of newborns was not 
analysed. Nevertheless, Chin et al. [29] found a 20-fold increase of CLA in the 
liver of foetuses (at day 20 of gestation) from dams fed a 0.5% CLA diet during 
gestation than in foetal livers coming from dams fed a control diet. This, 
together with our findings of a higher content of c9,t11- and t10,c12-CLA in 
the milk of rats fed CLA than in those fed the standard diet and the higher 
content of this isomer in 21/5 group plasma than in 21/3 group, confirms that 
CLA is transferred through the placenta to the foetus, as well as through the 
milk to the pup. The highest plasma CLA values in pups from 21/5 group may 
be due to CLA transfer during suckling from the maternal stores accumulated 
during gestation, besides supplementation by p.o. administration.  
 Similarly to that occurred in dams’ milk after CLA intake, the 
supplemented proportion of c9,t11- and t10,c12-CLA (80:20) changed in all 
the groups (Table 1). The proportion of CLA isomers was 86:14, 93:7 and 
94:6 for groups 21/5*, 21/5 and 21/3, respectively. Hence, group 21/5 
presented a higher content of c9,t11-CLA, but a lower content of t10,c12-
CLA than group 21/5*. Moreover, differences between 21/5* and 21/5 
groups in the proportion of CLA isomers in pups’ plasma may be due to the 
influence of the food matrix in 21/5* group, as milk is one of the major 
factors that affect PUFA bioavailability [30]. 
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 Regarding the concentration of CLA isomers quantified in plasma from 
28-day-old animals (Table 1), plasma from reference rats (28/0 group) had 
no t10,c12-CLA and a low content of c9,t11-CLA, which were lower than 
those found in the rest of the groups. The animals who received CLA 
supplementation continuously during suckling and early infancy (28/4 group; 
4 wk) showed the highest content of both CLA isomers among the groups. 
However, rats from the 28/3 group (3 wk) presented lower content of both 
CLA isomers in plasma than rats from the 28/1 group (1 wk). And, again, as 
showed for dams’ milk and 21-day-old pups’ plasma, the relative proportion 
between c9,t11- and t10,c12-CLA was higher in all CLA-supplemented 
groups (28/4, 91:9; 28/3, 90:10; 28/1, 94:6) than that of the original mixture 
(80:20).  
 These results match with the above data concerning 21-day-old animals 
and with other PUFA studies using similar experimental designs [31]. The 
highest content of CLA in plasma was achieved in the longest and continuous 
CLA supplementation (28/4 group), whereas the group that received CLA for 
3 wk and then nothing for 1 wk (28/3 group) exhibited lower CLA plasma 
content than the 28/1 group which only received CLA for the last week. 
Previous interventional studies have shown that the proportion of fatty acids 
in the dietary supplement is highly correlated to that one found in plasma and 
membrane [32]. Therefore, we can suggest that in our study, just finishing the 
supplementation period, CLA plasma levels are an indicative measure of the 
CLA incorporated in the cell membranes, in our case for 28/4 and 28/1 
groups. But this is not the case for the 28/3 group due to the time lapse 
between the last CLA intake and the day of quantification of CLA plasma 
content. The CLA membrane incorporation suggested here agrees with the 
study of Subbaiah et al. [33], which demonstrates that CLA is incorporated 
into cell membranes to varying extent, depending upon the experimental 
conditions.  
 On the other hand, the relative proportion of c9,t11/t10,c12 in the plasma 
of CLA-supplemented animals (∼90:10) is higher than in the original isomer 
mixture (80:20) administered to the animals. These changes in proportions 
could be attributed to the isomer-differentially β-oxidation induction above 
commented (see section 1.3). However, although it has been described that 
both isomers have similar absorption rates in adult rat intestine [34], it is 
possible that young rodents preferentially absorb the c9,t11-CLA isomer. 
Additionally, although no t10,c12-CLA was found in the plasma of reference 
animals (28/0), small quantities of c9,t11-CLA isomer were detected, which 
would indicate an endogenous production of c9,t11-CLA, as previously 
described [26], and, therefore, its influence on the c9,t11/t10,c12 ratio 
observed in plasma. 
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1.5. Immunoglobulin concentration in dams’ milk  
 
 One of our objectives was to evaluate the modulation on the Ig response 
in pups due to CLA, either coming through the milk or directly by p.o. 
administration. However, it has been described that IgA and IgG have a local 
mammary gland production [35], and are absorbed by pups from the ingested 
milk through the intestinal mucosa and extended beyond this compartment. 
Therefore, to better dissect the direct effect of CLA on Ig production by pups, 
we first evaluated the CLA influence on IgA, IgG and IgM concentrations in 
dam’s milk whey at the end of the suckling period [20].  
 As can be shown in Figure 2, the predominant Ig present in rat milk was 
IgG (~280 μg/mL), followed by IgA (~30 μg/mL) and finally IgM (~5 
μg/mL). Dams had a milk concentration pattern of IgG > IgA > IgM, which 
agrees with that described by Dahlgren et al. [35]. This pattern was 
maintained in dams fed the CLA diet, although IgG and IgA concentrations, 
the main Ig isotypes in rat milk, were much higher in these rats. Specifically, 
dams fed the CLA diet during gestation and suckling increased the 
concentration of IgG and IgA, about 6- and 2-fold, respectively. Thus, rat 
milk from CLA fed dams not only transfers CLA to pups, but also high 
concentrations of antibodies.  
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Figure 2. CLA effects on IgA (A), IgG (B) and IgM (C) of rat milk collected on day 
21 of the suckling period. IgA, IgG and IgM concentrations were quantified by 
ELISA in milk whey supernatant fractions after centrifugation and fat layer 
discarding. Values are expressed as mean ± SEM (n= 4-7). Significant differences: 
*P<0.05 vs. standard diet. Modified of Ramírez-Santana et al. [20]. 
 
1.6. Effect of CLA on the development of the systemic immunity in rats 
 
 As had been mentioned before, this study evaluated the effect of CLA on 
the systemic immune response in Wistar rats. For that purpose, we quantified 
serum Ig concentrations, spleen cell proliferation and cytokine secretion 
ability and ex vivo splenocyte Ig production as biomarkers of systemic 
immune development [20,21]. 
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1.6.1. Serum immunoglobulin concentration     
 
 This study evaluated the effect of feeding an 80:20 CLA isomer 
mixture during gestation and/or suckling and/or early infancy in the 
incipient antibody production of suckling and early infant rats. For that, 
serum IgG, IgM and IgA concentrations were quantified in 21- and 28-
day-old animals from all the groups included in the exhaustive 
experimental design (Fig. 3).  
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Figure 3. CLA effects on serum IgG, IgM and IgA from 21- and 28-day-old animals. 
Serum IgG (A, B), IgM (C, D) and IgA (E, F) concentrations were quantified by 
ELISA at the end of the suckling period (day 21; A, C, E) and 1 week after weaning 
(day 28; B, D, F). Values are expressed as mean ± SEM (n= 15-20). Significant 
differences: *P<0.05 vs. age-matched reference group (21/0 or 28/0); σP<0.05 vs. 
21/3; ϖP<0.05 vs. 21/5; φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Ramírez-
Santana et al. [20,21].  
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 Regarding the results obtained from the 21-day-old animals, those from 
the group 21/0 (Ref) showed ∼5 mg/mL of IgG (Fig. 3A), ∼95 μg/mL of IgM 
(Fig. 3C) and ∼2.7 μg/mL of IgA (Fig. 3E). CLA supplementation for 5 wk, 
2 wk during gestation and 3 wk during suckling through the dams’ milk 
(21/5* group), increased the total Ig serum concentration almost 4-fold, 
mainly by enhancement of IgG. At this age, there were no differences in 
serum IgM concentration among the groups. However, 21/5* group exhibited 
a lower IgA serum concentration than those of the other groups.  
 With respect to 28-day-old animals, rats from the 28/0 group (Ref) had 
∼2 mg/mL of IgG (Fig. 3B), ∼80 μg/mL of IgM (Fig. 3D) and ∼8 μg/mL of 
IgA (Fig. 3F). Similarly to that observed in younger animals, those that 
received CLA diet during and after suckling (28/4 group) showed higher 
serum IgG, IgM and IgA concentrations than those receiving CLA only for   
1 week after suckling (28/1) and rats from the 28/0 group. Moreover, rats 
from the 28/3 group, i.e., those receiving CLA diet only during suckling, 
showed 3 times the IgG concentration than those from the 28/1 and 28/0 
groups. Considering total serum Ig, CLA supplementation during suckling 
(28/4 and 28/3 groups) increased the Ig concentration 4-fold compared to the 
28/1 and 28/0 groups, mainly by increasing IgG.  
  All  these  results show the enhancing properties of CLA on the main      
in vivo serum Ig isotype, IgG. However, this effect was not observed in all 
the supplemented groups, a fact that underlines the importance of continuous 
CLA supplementation during gestation and suckling (21 day assessment), or 
during suckling and early infancy (28 day assessment). This immuno-
enhancing effect has already been reported in older animals, as by Sugano et 
al. [15] in 7-week-old rats receiving 1% CLA (50:50 isomer mix), showing 
an increase in serum IgA, IgG and IgM concentrations and a decrease in IgE. 
Song et al. [36] reported a similar effect in human subjects following 
supplementation with a 50:50 isomer mixture for 12 wk. Nevertheless, 
Yamasaki et al. [37] found no significant effect on serum IgA, IgG or IgM 
concentrations after feeding 5-week-old rats for 3 wk with a 50:50 CLA 
isomer mixture at doses ranging from 0.05 to 0.5%. Discrepancies with the 
study reported by Yamasaki et al. [37] might be due to the low doses of CLA 
tested in that study. Studies carried out in other species during gestation and 
lactation periods have also reported serum IgG increases [38,39], in keeping 
with the present results.  
 With respect to the serum IgA decrease observed in the present study 
after CLA supplementation during gestation and suckling, Turpeinen et al. 
[40]
 
also detected an IgA reduction in subjects with birch pollen allergy 
supplemented for 12 wk with a CLA mixture containing 63,5% of c9,t11. 
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Yamasaki et al. [37] found a slightly lower concentration of serum IgA after 
feeding the 0.5% CLA dose, although the reduction was not significant. 
Considering that IgA is the main Ig in the gut surface (80–90%) and the fact 
that systemic IgA-plasma cells continuously migrate to the intestinal wall 
[41], the serum IgA decrease should not be interpreted as harmful. In fact, 
this serum IgA decrease is accompanied by an increase in intestinal IgA in 
CLA-supplemented weaned rats [24; see section 1.7.1.]. We also have 
reported an increase in mucosal IgA after a specific challenge in adult rats 
following this CLA diet through life [42; see section 2.3.].   
 
1.6.2. Ex vivo spleen immunoglobulin production        
 
 The CLA immunoenhancing effects on antibody synthesis, observed 
upon the supplementation of c9,t11-  and t10,c12-CLA isomers at 80:20 ratio 
in vivo in suckling and infant rats, were also studied ex vivo. With this 
purpose, IgM and IgG production by unstimulated spleen cells, from animals 
corresponding of all groups, were quantified after 7 days of culture [20,21].  
 The spontaneous IgM and IgG production by splenocytes from 21-day-
old rats showed that IgM was the main isotype found in supernatant fractions 
(Fig. 4A), being forty times higher than IgG (Fig. 4B). Regarding CLA 
supplementation, IgM production from both groups supplemented for 5 wk 
(21/5* and 21/5 groups, ∼900–1200 ng/mL) was higher than that of the 
groups supplemented for 3 wk (21/3 group) and 0 wk (21/0 group) (both 
∼500 ng/mL). However, this increase was only significant when pups 
received CLA during gestation and suckling by p.o. administration (21/5 
group) (Fig. 4A). Otherwise, IgG production was very low (∼10 ng/mL) and 
no differences were found among groups (Fig. 4B). Thus, continuous CLA 
supplementation during gestation and suckling enhances splenocyte IgM 
production, increasing total Ig concentration by almost 2-fold that of non-
supplemented animals.  
 With respect to 28-day-old assessment, IgM was also the predominant 
isotype found in supernatants (Fig. 4C), being ∼100 times higher than IgG 
production (Fig. 4D). The groups supplemented with CLA during suckling 
(28/4 and 28/3 groups) synthesised higher IgM and IgG levels than the 
reference group (28/0), but it was only significant in the 28/3 group. This fact 
indicates the lasting of the CLA effect on the Ig synthesis later in life, or at 
least 1 week after finishing the CLA intake. Spleen Ig production from the 
28/1 and 28/0 groups was similar.  
 Overall, in the present study, CLA supplementation in early life 
enhanced spleen IgM production. These results agree with other studies 
carried   out  in  older  rats,   which  reported       enhancement  of  splenocyte  Ig 
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Figure 4. CLA effects on spleen cell Ig production from 21- and 28-day-old animals. 
IgM (A, C) and IgG (B, D) concentrations in supernatants after 7 days of spleen cell 
culture were quantified by ELISA at the end of the suckling period (day 21; A, C) and 
1 week after weaning (day 28; B, D). Values are expressed as mean ± SEM (n= 15-
20). Significant differences: *P<0.05 vs. age-matched reference group (21/0 or 28/0); 
σP<0.05 vs. 21/3. Modified of Ramírez-Santana et al. [20,21].  
 
production after feeding 50:50 CLA isomer mixtures [15,37]. In addition, 
some authors have reported this increase in old mice after feeding the pure 
t10,c12-CLA isomer [43]. Although the present results confirmed the 
immunoenhancing effect of the c9,t11 isomer, we cannot rule out immune 
functions for t10,c12-CLA.  
 
1.6.3. Spleen lymphocyte functionality: Proliferation and cytokine secretion   
                                                                        
 Besides the capacity of in vivo Ig production, the influence of dietary CLA 
supplementation on the functionality of ex vivo isolated spleen lymphocytes was 
also evaluated by their ability to proliferate and to produce cytokines.  
 At the end of suckling (21-day-old assessment), the CLA diet did not 
modify the lymphoproliferative capacity in any group (21/5*, 21/5, 21/3), 
measured 72 h after mitogen-stimulation when compared to reference 
animals (21/0) (Fig. 5A). However, in the assessment of older animals (1 wk 
after weaning), CLA supplementation during suckling (28/4 and 28/3 groups) 
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reduced ex vivo spleen lymphoproliferative ability compared to that in the 28/1 
and 28/0 groups, but it was only significant for the 28/4 group (Fig. 5B). Cell 
viability was slightly reduced after mitogen-stimulation, but, this decrease did 
not differ among groups in 21-day-old evaluation, indicating that CLA dietary 
supplementation had no effect on splenocyte viability. On the other hand, CLA 
supplementation effect on 28-day-old animals conferred more resistance to the 
mitogen toxic effects, as is demonstrated by the lowest mortality of 28/4 group 
among the groups. Thus, the decrease in the proliferation rate cannot be 
attributed to a lower viability caused by CLA diet.  
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Figure 5. CLA effects on proliferation rate in mitogen-stimulated spleen cells from 
21- and 28-day-old animals. Lymphoproliferative response was determined after 
stimulating with phorbol myristate acetate (PMA) plus ionomycin (Io) for 72 h at the 
end of the suckling period (day 21; A) and 1 week after weaning (day 28; B). The 
proliferation rate (%) are expressed relative to the age-matched reference group (21/0 
or 28/0), which was set at 100%. Values are expressed as mean ± SEM (n= 15-20). 
Significant differences: *P<0.05 vs. age-matched reference group (21/0 or 28/0); 
φP<0.05 vs. 28/1. Modified of Ramírez-Santana et al. [20,21].  
 
 Moreover, interleukin (IL)-2 production, the main proliferative signal for 
lymphocytes, was measured in supernatant fractions obtained after 24 h of 
spleen cell stimulation and was not modified by CLA supplementation either 
in 21- or 28-day-old assessment (Table 2).  
 The lack of CLA dietary effect on lymphocyte proliferation found in 21-
day-old rats is in agreement with the results reported by Kelley et al. [16] in 
8-week-old mice after feeding pure isomers of CLA for 56 days, and in 
human subjects either by ingestion of pure isomers [44]
 
or 50:50 and 80:20 
isomer mixtures [16,45]. Since IL-2 plays a central role in the cell-mediated 
immune response by regulating proliferative abilities, it could be expected 
that if CLA does not modify splenocyte proliferation, it will not affect IL-2 
production. The present results are consistent with most other studies in 
animals and human subjects, which have found no significant effects on IL-2 
splenocyte secretion among the dietary groups [43,44,46].  
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Table 2. Content of cytokines in 24 h splenocyte supernatants after mitogen (PMA/Io) 
stimulation1. 
 
Cytokines (day 21) 21/5* group      21/5 group 21/3 group 21/0 group 
 
IL-2 (ng/mL) 4.1 ± 1.1 4.1 ± 1.0 5.6 ± 0.9 4.1 ± 0.8 
IFNγ (ng/mL) 4.6 ± 0.8 5.9 ± 1.0 6.4 ± 1.4 3.7 ± 0.8 
IL-4 (pg/mL) 29.3 ± 7.9 32.4 ± 6.0 (*) 15.9 ± 1.3 12.4 ± 1.8 
IL-10 (pg/mL) 181.7 ± 47.2 176.3 ± 43.8 90.6 ± 8.5 108.0 ± 19.6 
Cytokines (day 28) 28/4 group 28/3 group 28/1 group 28/0 group 
 
IL-2 (ng/mL) 6.2 ± 0.8 6.1 ± 0.8 7.2 ± 1.1 6.8 ± 1.2 
IFNγ (ng/mL) 10.9 ± 1.4 7.1 ± 0.9 7.3 ± 0.8 6.0 ± 1.3 
IL-4 (pg/mL) 27.8 ± 4.0 18.8 ± 2.8 28.7 ± 7.4 17.3 ± 2.4 
IL-10 (pg/mL) 244.4 ± 41.0 224.9 ± 29.2 222.4 ± 34.5 191.6 ± 24.2 
IL-6 (pg/mL) 219.0 ± 38.0*φΨ 40.1 ± 12.9 45.7 ± 15.1 N.D.  
 
1  Values are expressed as mean ± SEM (n= 10). N.D., non-detectable. Significant 
differences: (*) P=0.06 vs. reference group (21/0); *P<0.05 vs. reference group (28/0); 
φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Ramírez-Santana et al. [20,21].  
 
 Despite the above results, a wide range of PUFA, including CLA, have 
been found to reduce the mitogen-stimulated proliferation of lymphocytes 
isolated from several species [47,48]. Thus, the lack of effect observed in   
21-day-old animals, may be probably due to the immaturity of this function 
(which is acquired later in life) at a very early age [49]. In contrast, the 
mitogen-induced splenocyte proliferation on 28-day-old animals was down-
modulated in the longer-lasting CLA supplementation, similarly to that 
described in adults [42,50,51]. Thus, the age of 28 days is optimal to evaluate 
CLA effects, since at this age CLA still increases antibody production and is 
also able to down-modulate lymphoproliferation. Calder and Newsholme [52] 
reported that some PUFA inhibited lymphocyte proliferation without 
decreasing IL-2 concentration, a fact that is consistent with the present results 
showing that CLA supplementation did not modify IL-2 production. In this 
sense, many studies have described conformation changes in IL-2 receptors 
by PUFA, specifically modifying lipid rafts [53,54]. Thus, CLA, even with 
trans double bonds, could potentially alter membrane structure, including 
lipid rafts, by preventing IL-2Rα migration to soluble membranes, where   
IL-2 signalling occurs and T-cell activation and proliferation are 
consequently induced [53,55,56]. In addition, the anti-proliferative 
lymphocyte effect exhibited by dietary CLA in the present study could be 
mediated by the nuclear peroxisome proliferator-activated receptor (PPAR)γ, 
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because intestinal PPARγ gene expression has been found up-regulated after 
CLA supplementation (see section 1.7.2.) [24]. The PPARγ-dependent CLA 
effect was first described by Bassaganya-Riera and Hontecillas [57] in a pig--
inflammatory bowel disease model, where dietary CLA resulted in intestinal 
disease amelioration and PPARγ gene expression up-regulation.  
 Besides IL-2 quantification, in the present study other cytokines were 
also analyzed in splenocyte supernatants after mitogen-stimulation (Table 2). 
Interferon (IFN)-γ, a T helper 1 (Th1) cytokine, was also secreted in similar 
amounts in all experimental groups. T helper 2 (Th2) cytokines, IL-4 and   
IL-10, were also quantified in the same splenocyte supernatant fractions and 
although no statistical differences were found among groups, due to the large 
intra-group variability, rats from 21/5* and 21/5 groups showed almost 2-fold 
higher values than those observed in 21/3 and 21/0 groups (Table 2). This 
IL-10 increase is in line with studies showing higher IL-10 production by 
dendritic cells incubated with c9,t11-CLA after stimulating with 
lipopolysaccharide [58]. This effect may be related to the anti-inflammatory 
properties attributed to CLA [22,59].  Moreover, by increasing IL-4, CLA 
might be promoting T helper 2 (Th2) responses, such as modulating antibody 
production and inhibiting several cellular functions, which is in agreement 
with the present results regarding CLA enhancement of the principal in vivo 
and in vitro Ig.  
 However, in 28-day-old animals, the concentration of IL-6, which was 
also included in the study, was increased in the 28/4 group compared to the 
28/3 and 28/1 groups, while IL-6 was not detected in the 28/0 group (Table 
2). This result is of interest because IL-6 is clearly defined as a prominent 
regulator of T-cell proliferation and differentiation of Ig-secreting B cells 
[60]. Therefore, it might be suggested that the effects on proliferation -in 
early infant rats- and antibody production -in both suckling and early infant 
rats- induced by CLA could be due to an up-regulation of IL-6 production. 
Further studies should confirm this hypothesis and ascertain the mechanism 
involved.  
 
1.7. Effect of CLA on the development of the mucosal immunity in rats  
   
 As it had been mentioned before, this study also evaluated the effect of 
CLA-supplementation during gestation, suckling, and/or early infancy on 
mucosal immunity (small intestine and colon) in Wistar rats. In these periods, 
their mucosal immune response is still in development. In fact, the mucosal 
immune system of the rat continues developing during the suckling period 
and early infancy, and, as occurs in humans, mucosal Ig production is poor. 
Previous studies have shown that IgM production by lamina propia cells 
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begins during the second week of life in parallel to the phenotypic 
development of B cells in rat intestine, and later, weaker production of IgA 
initiates [61]. For that reason, in this study we quantified intestinal IgA at 
both the gene and protein levels as a biomarker of mucosal immune 
development, and TGFβ and PPARγ gene expression as possible mediators of 
CLA’s immunomodulatory effects [24]. Finally, a broad array of genes was 
studied in that compartment to elucidate other mediators in CLA action.  
 
1.7.1. Effect of CLA on IgA gene expression and IgA protein secretion in 
intestinal mucosa   
  
 IgA gene expression in small intestine and colon was assessed in 21- and 
28-day-old animals from all experimental groups. Dietary CLA did not 
modify IgA gene expression in small intestine or colon at the end of the 
suckling period. However, IgA gene expression in animals continuously 
CLA-supplemented during suckling and early infancy (28/4 group; 4 wk) was 
up-regulated almost 5-fold (Fig. 6A, 6B). This increase was seen in both 
tissues analyzed as compared with the reference group (28/0). 
Supplementation limited to the suckling or early infancy periods failed to 
produce this immunoenhancing effect (Fig. 6A, 6B). 
 In addition to detection of changes in gene expression, IgA protein 
concentration was quantified in intestinal washes of 28-day-old animals (Fig. 
7). IgA content was statistically higher in animals CLA-supplemented for 4 
weeks (28/4 group) than in animals in the 28/3, 28/1 or 28/0. These results 
demonstrate that continuous CLA dietary supplementation for a longer 
period,       during  suckling  and  early  infancy,  increases  expression of the IgA  
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Figure 6. Effect of CLA on IgA gene expression in 28-day-old animals. Gene 
expression was evaluated in small intestine (A) and colon (B) by Real Time PCR. IgA 
gene expression was normalized using β-actin and are showed as percentage relative 
to values in age-matched reference animals (21/0 or 28/0). Values are expressed as 
mean ± SEM (n= 5). Significant differences: *P<0.05 vs. reference group (28/0); 
φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Pérez-Cano et al. [24].  
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Figure 7.  Effect of CLA on IgA in intestinal washes from 28-day-old rats. Secretory 
IgA was quantified in intestinal washes of small intestine by ELISA. Results are 
expressed as IgA protein (ng) referred to intestinal weight (g) used for the wash. 
Values are expressed as mean ± SEM (n= 9-10). Significant differences: *P<0.05 vs. 
28/0; φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Pérez-Cano et al. [24].  
 
gene and protein, thereby enhancing development of the rat’s mucosal 
defense system. This is the first in vivo report, to our knowledge, showing an 
increase of mucosal IgA after feeding CLA during early life [24]. In line with 
our data, Sugano et al. [15] reported an increase in IgA secretion from 
cultured mesenteric lymph nodes of 7-week-old rats, fed a 1% CLA 50:50 
isomer mix. 
 The specific mechanism by which CLA enhances IgA levels at mucosal 
sites remains unknown. But since CLA has been shown to suppress IL-4 
production in vitro [62], attenuate Th2 responses in challenged animals [63], 
and regulate the number and effectors functions of several lymphocytes [64], 
further studies should be addressed to elucidate whether it exist a direct 
enhancer mechanism of CLA on IgA-producing cells. 
 
1.7.2. Effect of CLA on TGF-β and PPARγ gene expression in small intestine  
and colon   
 
 Because IgA gene expression and intestinal production were increased 
after feeding CLA, we also studied molecules which could have a role in this 
process. In this sense, transforming growth factor (TGF)β gene expression 
was a candidate due to its involvement in the isotype switching process from 
IgM to IgA [65,66]. However, intestinal TGFβ gene expression was not 
modified in any of the CLA-supplemented groups during gestation, suckling 
and/or early infancy. Nonetheless, an influence of CLA on TGFβ cannot be 
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ruled out. If CLA is modulating the effects of TGFβ on IgA production, it is 
probably due to posttranscriptional and/or translational regulation, which are 
important in this cytokine, because it has been suggested that TGFβ mRNA 
levels do not completely correlate with the quantity of protein produced [67]. 
On the other hand, the increase of IgA as result of CLA supplementation 
might be independent of the isotype switching mechanism produced by 
TGFβ, which has been described, but is not completely defined [68].  
 On the other hand, two main mechanistic theories have been proposed to 
explain the immunoenhancing effects of dietary CLA: a PPARγ-dependent 
and a PPARγ-independent pathway [69]. The present study investigates 
PPARγ gene expression in the small intestine and colon of 21- and 28-day-
old animals fed standard and CLA-supplemented diets (Fig. 8). At both ages, 
there were no differences in PPARγ gene expression in small intestine between 
CLA and non-supplemented groups. However, PPARγ was up-regulated in 
colon tissue, particularly in 21-day-old animals fed CLA (21/5*, 21/5, and 21/3 
groups), when compared with reference animals (21/0) (Fig. 8A). This 2-fold 
up-regulation was only significant in the 21/5* group. Similar to the results 
found in 21-day-old animals, colon PPARγ gene expression was also up-
regulated in 28-day-old animals fed CLA (28/4, 28/3, and 28/1), when 
compared with reference animals (28/0) (Fig. 8B). Nevertheless, only the 28/3 
and 28/1 groups showed statistical differences, since 28/4 group had a great 
variability. Overall, CLA-supplemented rats showed higher PPARγ expression 
than non-supplemented animals.                       Specifically, the effects seem to be related to a  
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Figure 8.  Effect of CLA on colon PPARγ gene expression in 21- and 28-day-old 
animals. Gene expression was evaluated by Real Time PCR at the end of the suckling 
period (day 21; A) and 1 week after weaning (day 28; B). PPARγ gene levels were 
normalized using the β-actin gene and are expressed as percentage relative to values 
from age-matched reference animals (21/0 or 28/0). Values are expressed as mean      
± SEM (n= 5). Significant differences: *P<0.05 vs. age-matched reference group (21/0 
or 28/0). Modified of Pérez-Cano et al. [24].  
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dose-dependent manner that was proportional to the duration of 
supplementation over gestation, suckling, or early infancy. Thus, CLA 
modulated PPARγ expression in all the dietary conditions examined, even 
when animals were supplemented for only 1 week. 
 These results concur with findings from studies showing an increase of 
PPARγ mRNA expression associated with CLA supplementation in colon of 
healthy and ill mice and pigs [22,57,63,69]. Moreover, PPARγ up-regulation 
by CLA is in line with the results of Takamura et al. [70], who showed that 
specific natural or synthetic ligands of PPARγ can induce a mean 2- to 3-fold 
expression of this receptor in a positive feedback loop. In vitro studies have 
also indicated that the PPARγ activating capabilities of CLA are cell type-
dependent and isomer specific [69].  
 PPARγ comprises two isoforms, PPARγ1 and PPARγ2. Both are 
expressed in adipocytes, but PPARγ1 is expressed in T and B cells, 
monocytes, dendritic cells, and epithelial cells [71,72]. Hence, the effects of 
CLA found in the present study may be due to the interaction of CLA with 
PPARγ1. There are several possible options through which CLA might act. 
First, although a direct relationship between PPARγ increase and IgA gene 
expression has not been described, Ponferrada et al. [73] reported that PPARγ 
agonists can revert stress-induced decrease of IgA production in the colon 
mucosa, even beyond the IgA-controlled basal concentration. Moreover, it 
seems that this nuclear receptor acts through modulation of transcriptional 
factors such as NF-κB, AP1, and STAT1 [74,75], which are involved in      
B-cell regulatory processes. Second, recent research has also indicated close 
links between intestinal-microbial interactions and regulation of PPARγ 
expression by epithelial cells of colon tissue [76], suggesting that CLA may 
influence the natural mechanisms involved in intestinal homeostasis 
regulation. Lastly, it has been demonstrated that PPARγ regulates the 
epithelial differentiation process [77]. Thus, CLA may be modulating the 
entry of luminal antigen, the capacity for direct antigenic presentation, or 
even the transmission of antigen to dendritic cells from the intestinal mucosa. 
These hypotheses are supported by the fact that dendritic cell 
immunogenicity is regulated by PPARγ [78].  
 
1.7.3. Effect of CLA on rat mesenteric lymph nodes gene expression profiles      
 
 The data reported in above sections 1.7.1. and 1.7.2. provide scientific 
evidence of the impact of lipid nutrition, particularly the influence of the 
c9,t11-CLA isomer, on mucosal immunomodulation. On the other hand, it is 
known that food components play a role in influencing, either directly or 
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indirectly (through hormonal regulation), the expression of genes involved in 
immune responses [79]. Thus, further studies were developed to define the 
mechanism of action CLA at genic level in the intestinal compartment [80].  
 For that purpose, the gene expression profile in animals supplemented 
with CLA during gestation and suckling of mesenteric lymph nodes, sites of 
activation and proliferation of lymphocytes coming from the intestinal tissue 
(i.e. an inductor site), was determined. The specific GeneChip® Rat Genome 
230 2.0 (Affymettrix) and bioinformatic analyses (GeneSpring GX software) 
were used. It led to the identification of 123 genes differentially expressed in 
all CLA dietary approaches with respect to the reference group. Generation of 
a biological association network evidenced several genes, such as connective 
tissue growth factor (Ctgf), tissue inhibitor of metalloproteinase 1 (Timp1), 
galanin (Gal), synaptotagmin 1 (Syt1), growth factor receptor bound protein 
2 (Grb2), actin gamma 2 (Actg2) and smooth muscle alpha actin (Acta2), as 
highly interconnected nodes of the resulting network [80]. All these genes 
modulated by CLA supplementation may have a role on lymphoproliferation 
and mucosal immune responses in early life. 
 
2. Long-term feeding of CLA from gestation to adulthood: Effect 
on the immune system in adult rats       
 
 As previous studies have suggested that CLA intake during 
developmental phases may have effects later in life [22,23], this second part 
of the study was performed from gestation to adulthood. The aim was to 
ascertain whether the capacity to produce a specific immune response in 
ovalbumin (OVA)-sensitized adult rats is influenced by long-term feeding of 
an enriched diet containing an 80:20 CLA isomer mix of c9,t11- and t10,c12-
CLA, respectively [42].    
 
2.1. Experimental design                                             
 
 Pregnant Wistar rats at 7 days’ gestation were assigned to 1 of the 2 
dietary groups and after delivery, litters were kept with their dams until 
weaning (day 21). Thereafter, pups consumed the same diet as their mothers. 
The 2 dietary groups were the CLA group and the reference (REF) group 
(Fig. 9). The CLA group was constituted by rats whose dams were fed a 1% 
CLA diet (see section 1.2.) during gestation (2 wk) and suckling (3 wk); pups 
received CLA through the placenta and milk, respectively. From weaning 
until the end of the study (15-wk-old rats), animals were also fed 1% CLA 
diet. The total period of supplementation was 17 wk. Rats from the reference 
group were fed a standard diet throughout the 17 wk of study.          Nine-week-old  
Francisco J. Pérez Cano et al. 224 
Week 15Day 7 of gestation Birth day (1) Day 21
Gestation (2 wk) Suckling (3 wk) Infancy (6 wk)
CLA supplemented animals Non-supplemented animals
CLA Diet                   
Dams’ Milk2
CLA Diet1                                                
Pups (17 wk)3:
Dams:
CLA diet                                        
Adult age (6 wk)
Week 9
Standard Diet                  
Dams’ MilkPups (0 wk):
Dams:
Standard diet                                    
Standard Diet
CLA group
REF group
ovalbumin
immunization4
 
 
Figure 9. Diagram of the experimental design beginning on day 7 of gestation until 
week 15 of life. 1 CLA arrives at the foetus by transplacental transfer. 2 CLA arrives at 
pups through the dams’ milk of dams. 3 Total period of CLA supplementation from 
gestation until 15 weeks of age. 4 Ovalbumin immunization by i.p. injection to           
9-week-old rats.    
 
rats from both groups were immunized with ovalbumin (OVA) emulsified with 
alum adjuvant by intraperitoneal (i.p.) injection. Six weeks after immunization, 
15-wk-old rats were sacrificed and immune status was assessed (Fig. 9). 
 
2.2. Effect of CLA on the polyclonal and antigen-specific cell immune 
response                                                                                                                                                                               
 
 Although the main goal was to examine whether a long-term CLA diet 
was able to modulate the capacity to generate an antigen (Ag)-specific cell 
immune response, the ex vivo capacity to generate a mitogen-induced 
immune response was also evaluated in isolated spleen lymphocytes by 
means of their ability to proliferate and to secrete IL-2 [42]. The Figure 10A 
shows that spleen cells from rats fed CLA throughout the study (17 wk) had a 
∼10% lower proliferative response than reference rats after mitogen-
stimulation. This down-regulatory effect by dietary CLA was not due to cell 
viability loss, because viability from the CLA after mitogen addition was 
comparable to that of reference cells. Secretion of IL-2 was also lower in cell 
cultures of CLA-fed rats than in those of rats fed the standard diet (Fig. 10B). 
These results agree with those found in the 28-day-old assessment (see 
section 1.6.3.) and those of Tricon et al. [44], who showed that peripheral 
blood mononuclear cells from subjects fed either c9,t11- or t10,c12-CLA 
isomers, after mitogen-stimulation, decreased CD69 expression, which 
strongly correlates with lymphocyte proliferation. However, there are other 
studies using diverse CLA isomer mixtures that described either increased 
splenocyte proliferation or no effect after stimulus addition [45,47,81].  
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 Regarding the long-term effects of dietary CLA supplementation on Ag-
specific immune response, the lymphoproliferative capacity after OVA 
addition was evaluated. Reference and CLA groups had a higher (2- to 3--
fold) splenocyte proliferation after OVA stimulation than unstimulated cells 
and after control protein addition (Fig. 11). In terms of specific proliferative 
response,  splenocytes  recovered  from  OVA-immunized  rats  fed    CLA       had  
 
REF (US) 
REF (S)
CLA (US)
CLA (S)
0.0
0.5
1.0
1.5
2.0
*φ
*
A
Pr
ol
ife
ra
tio
n
(O
D
 u
ni
ts
)
0
1000
2000
3000
4000
*φ
*
B
IL
-2
 (p
g/
m
L)
Pr
ol
ife
ra
tio
n
(O
D
 u
ni
ts
)
IL
-2
 (p
g/
m
L)
 
 
Figure 10.  Proliferative response (A), and IL-2 production (B) of unstimulated (US) 
and mitogen-stimulated (S) spleen cells from rats fed a CLA or standard diet (CLA or 
REF groups). Polyclonal proliferative response was determined after stimulating with 
PMA/Io for 72 h. IL-2 was quantified by ELISA in 24-h supernatant cultures. Data are 
means ± SEM (n= 20). Significant differences: *P<0.05 vs. US cells within the same 
dietary group; φP<0.05 vs. reference group. Modified of Ramírez-Santana et al. [42].  
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Figure 11.  OVA-specific proliferative response of spleen cells from rats fed the CLA 
or the standard diet (CLA or REF groups). Specific response was determined after 
OVA stimulation for 96 h. Control protein (casein, CAS) and only medium 
(unstimulated cells, US) were used as negative reference controls. Data are means ± 
SEM (n= 20). Significant differences: *P<0.05 vs. US cells within a diet group; 
δP<0.05 vs. CAS-stimulated cells within a diet group. φP<0.05 vs. reference group. 
Modified of Ramírez-Santana et al. [42].  
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higher (∼275%) lymphoproliferative response to OVA than splenocytes 
recovered from OVA-immunized rats fed the standard diet (∼165%). The 
OVA-specific splenocyte proliferation enhancement by CLA found here 
agrees with that reporting a higher specific proliferative response of T CD8+ 
lymphocytes from pigs fed a CLA diet (∼50:50 isomers mix) [50,51]. In 
addition, following hepatitis B vaccination, specific lymphocyte proliferation 
was higher in humans fed CLA 50:50 than in the control group [45]. 
Conversely, Kelley et al. [82] showed no effect on influenza-specific 
proliferation in humans after feeding CLA, but in this case, the two main 
isomers used contributed only 40% of total CLA isomers, whereas in most of 
the studies affecting proliferative response, the main isomers made up ∼80% 
of all CLA isomers. 
 
2.3. Effect of CLA on the Ag-specific systemic and mucosal humoral 
immune responses  
 
 To ascertain long-term CLA diet effects on systemic humoral immune 
response, we have quantified serum OVA-specific antibody concentration, 
ex vivo spleen anti-OVA antibody production, and spleen anti-OVA-
antibody-secreting cells (SC) number. Long-term dietary CLA did not 
modify the humoral immune response against the OVA-specific challenge 
either in serum or in splenocyte supernatants. However, using enzyme-
linked immunosorbent spot technique (ELISPOT) we counted spontaneous 
anti-OVA IgG-, IgM-, and IgA-SC in spleens and we found that OVA-
immunized rats had more spleen anti-OVA IgA-SC in CLA-fed rats (15.6 ± 
3.5; mean ± SEM) than in reference group (11.9 ± 1.9). These results show 
overall that, although OVA-primed spleen B cells produced specific anti-
OVA antibodies after later OVA contact, rats fed a CLA diet did not 
generate a higher systemic (serum and spleen) humoral response against 
OVA. This might suggest that the presence of 1% CLA in the diet increased 
neither the number of primed memory B cells nor their ability to produce 
specific antibodies. Our results agree with others carried out in humans and 
animals fed CLA [51,82,83], although Albers et al. [45] showed a higher 
concentration of anti-B hepatitis antibodies in subjects consuming CLA 
50:50 capsules. On the other hand, CLA feeding did not modify total serum 
Ig concentrations. This result agrees with many others [16,81,82] but 
disagrees with a human study that reported increased IgM and IgA plasma 
concentrations after consuming CLA [36]. Nevertheless, better humoral 
enhancing effects were observed in developing states (see section 1.6.), 
although specific adaptive responses were not addressed in such studies 
[20,21].  
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 Regarding mucosal sites, we found interesting CLA results in this 
particular immune compartment: the dietary CLA modulated mucosal IgA 
production. Long-term dietary CLA increased the anti-OVA IgA synthesis in 
the intestinal mucosa ∼75% (Fig. 12), although CLA did not modify total gut 
IgA. These data suggest that the CLA diet had a restricted enhancement 
effect on OVA-specific IgA intestinal production but not a general effect on 
humoral immunity.  
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Figure 12.  OVA-specific IgA in intestinal washes from rats fed the CLA or the 
standard diet (CLA or REF groups). Six weeks after immunization, secretory IgA was 
quantified in intestinal washes of small intestine by ELISA. Results are expressed 
relative to the reference group, which was set at 100%. Data are means ± SEM (n= 
20). Significant differences: *P<0.05 vs. reference group. Modified of Ramírez-
Santana et al. [42].  
 
 The boost of specific intestinal IgA is of great importance, because this 
Ig is the main isotype present in all mucosa and confers high protection 
against foreign substances and microbe entry through the intestine, as well as 
by other mucosal compartments, due to specific secretory IgA homing among 
mucosal sites [84]. Thus, to our knowledge, this is the first time that a CLA 
supplementation enhancement of Ag-specific mucosal responses has been 
reported.  
 Because the CLA diet increased only intestinal-specific IgA, but not 
spleen or serum antibodies, it is plausible to suggest that CLA may be 
enhancing B cells present in the lamina propria or even promoting the IgA-
secreting cell migration to the intestine from other immune compartments. 
This particular type of immunoenhancement induced by CLA, acting on a 
specific cell subset, is likely, because Bassaganya-Riera et al. [64] reported a 
higher percentage of a particular immune cell subset, but not of others, in 
swine fed CLA.  
Francisco J. Pérez Cano et al. 228 
3. Conclusions 
 
 The data reported in this chapter contribute to the scientific evidence pointing 
to the potential impact of lipid nutrition on immune system development during 
early life, particularly the effect of the c9,t11-CLA isomer, the main CLA isomer 
present in breast milk. Although further studies should be carried out to elucidate 
CLA signalling mechanisms, the results presented herein by the dietary 
supplementation with an 80:20 c9,t11:t10,c12 CLA mix demonstrate that: 
 
 - CLA is transferred from the dams’ diet to breast milk and later is 
  efficiently incorporated by their pups. This supplementation also 
  increases dam’s milk IgG and IgA concentrations. 
 - The capacity of immune cells to synthesise antibodies, i.e. humoral 
  immune response, is enhanced by CLA during gestation, suckling 
  and/or early infancy. It is demonstrated, in vivo and ex vivo, by the 
  increase of serum IgG concentration and spleen IgM production, 
  respectively, in CLA fed animals.  
 - CLA supplementation during suckling and early infancy down-
  regulates the systemic lymphoproliferative response and increases 
  the secretion of some Th2 cytokines during early age.   
 - CLA increases the intestinal immune defenses of rats during the first 
  stages of life. CLA-dependent enhancement of humoral mucosal 
  immune response was demonstrated by the striking increase of 
  intestinal IgA expression in early infant rats fed CLA along life. 
  Moreover, PPARγ gene expression levels were up-regulated in a 
  supplementation period-dependent manner. 
 - It is clearly shown that the effects of CLA are more pronounced the 
  earlier  and  more long-lasting CLA  dietary  supplementation. 
  Specifically, the importance of the continuous supplementation 
  during gestation-suckling or suckling-early infancy is evidenced by 
  the observation of some immunomodulatory effects only produced 
  when CLA is received during these periods.  
 - CLA diet  administered from  gestation to  adulthood enhances 
  specific systemic cell-mediated immunity as well as the mucosal 
  IgA immune response, whereas it down-regulates the polyclonal 
  activation of the immune system. These data support the long-term 
  effects of dietary CLA on the immune system. 
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